{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "NomicEmbeddings\n",
    "\n",
    "Rag with metadata\n",
    "\n",
    "Human in the loop\n",
    "\n",
    "--------------------"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "patients identity hidden from llm\n",
    "\n",
    "using python Relp for relative month in profile or policy comply\n",
    "\n",
    "add database to google api\n",
    "\n",
    "utilities:   \n",
    "- patients DB creator\n",
    "\n",
    "steps:\n",
    "- Create Agents\n",
    "- Define tools\n",
    "- Create graph\n",
    "- Define Agent Nodes\n",
    "- Define Tool Node\n",
    "- Define Edge Logic\n",
    "- Define the Graph\n",
    "- show the graph\n",
    "- Invoke\n",
    "  \n",
    "- Human in the loop\n",
    "- Maximum number of steps\n",
    "- Helper Utilities"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# LLM Agents for Clinical Trial Management\n",
    "\n",
    "In this notebook, we develop an agent-based system to automate the management and analysis of clinical trial data, ensuring compliance with regulatory standards, and providing comprehensive reports for stakeholders. This pipeline also incorporate human-in-the-loop (HITL) and memory mechanisms to enhance functionality and accuracy."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Steps and Plan\n",
    "\n",
    "1. Define the Problem:\n",
    "\n",
    "Objective: Automate clinical trial data management, analysis, compliance checks, and reporting.\n",
    "\n",
    "Key Components: Data collection, data analysis, compliance verification, reporting, and human-in-the-loop interventions.\n",
    "\n",
    "2. Design the Architecture:\n",
    "**Agents:**\n",
    "Data Collection Agent: Gathers patient data, trial results, and other relevant information.\n",
    "\n",
    "Data Analysis Agent: Analyzes the collected data to generate reports on trial outcomes.\n",
    "\n",
    "Compliance Agent: Ensures all data and processes adhere to regulatory standards.\n",
    "\n",
    "Reporting Agent: Compiles and presents the analysis findings in comprehensive reports.\n",
    "\n",
    "Human-in-the-Loop: Integrate a review phase where human experts validate data analysis and compliance checks before final reporting.\n",
    "\n",
    "Memory: Utilize LangGraph’s memory capabilities to track the progress and history of each trial."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The Clinical Trial Matching Agent is designed to match patients wit\th suitable clinical trials based on their medical history, symptoms, and ongoing treatments. This application helps patients find relevant clinical trials they may be eligible for, improving their chances of accessing new treatments and contributing to medical research.\n",
    "\n",
    "\n",
    "1. Database Setup\n",
    "- SQLite Database: Create two databases:\n",
    "- Patients DB: Stores patient medical history, previous trials, and other relevant data.\n",
    "- Clinical Trials DB: Contains information about ongoing and upcoming clinical trials, including eligibility criteria.\n",
    "2. Agents and Tools\n",
    "- Patient Data Ingestion Agent: Retrieves patient data from the SQLite database or prompts the user to provide missing data.\n",
    "- Data Validation and Collection Loop: Ensures all required fields are collected using persistence.\n",
    "- Policy Compliance Agent: Cross-checks patient data with institutional policies.\n",
    "- Trial Vectorization Agent: Extracts and vectorizes recruiting trials for efficient search.\n",
    "- Trial Matching Agent: Forms prompts from patient data to search the vector database for potential trial matches.\n",
    "- Human-in-the-Loop (HIL) Agent: Presents top trial matches to the user for selection.\n",
    "- Persistence Mechanism: Allows the application to save and resume states, especially useful for collecting patient data and searching trials."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "import getpass\n",
    "import os\n",
    "\n",
    "\n",
    "def _set_if_undefined(var: str):\n",
    "    if not os.environ.get(var):\n",
    "        os.environ[var] = getpass.getpass(f\"Please provide your {var}\")\n",
    "\n",
    "\n",
    "_set_if_undefined(\"OPENAI_API_KEY\")\n",
    "_set_if_undefined(\"LANGCHAIN_API_KEY\")\n",
    "# _set_if_undefined(\"TAVILY_API_KEY\")\n",
    "\n",
    "# Optional, add tracing in LangSmith\n",
    "os.environ[\"LANGCHAIN_TRACING_V2\"] = \"true\"\n",
    "os.environ[\"LANGCHAIN_PROJECT\"] = \"Clinical Trial Management\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Parameters"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "\n",
    "policy_vstore_created = False\n",
    "trials_vstore_created = False\n",
    "trials_db_downloaded = False\n",
    "chromadb_path = \"../../chroma_db\"\n",
    "policy_collection = \"policy-chroma\"\n",
    "trial_collection = \"trial-chroma\"\n",
    "\n",
    "modelID = \"gpt-3.5-turbo\"\n",
    "n_retrieved_policies = 6\n",
    "# n_retries = 6\n",
    "n_retrieved_trials = 6\n",
    "\n",
    "\n",
    "\n",
    "model = ChatOpenAI(temperature = 0.0, model=modelID)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# import os\n",
    "\n",
    "# from dotenv import load_dotenv, find_dotenv\n",
    "# _ = load_dotenv(find_dotenv()) # read local .env file\n",
    "\n",
    "import warnings\n",
    "warnings.filterwarnings(\"ignore\")\n",
    "\n",
    "import pprint\n",
    "# A function for printing nicely\n",
    "def nprint(text, indent=2):\n",
    "    pp = pprint.PrettyPrinter(indent=indent)\n",
    "    pp.pprint(text)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Creating the sample datasets"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Patients database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Jane Thomas</td>\n",
       "      <td>37</td>\n",
       "      <td>peritoneal cancer</td>\n",
       "      <td>NCT03710197</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Sophia Thomas</td>\n",
       "      <td>56</td>\n",
       "      <td>Obesity</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Michael Thomas</td>\n",
       "      <td>40</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Daniel Doe</td>\n",
       "      <td>44</td>\n",
       "      <td>suicidal ideation</td>\n",
       "      <td>NCT08404176</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-07-31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Sophia Johnson</td>\n",
       "      <td>64</td>\n",
       "      <td>lung cancer</td>\n",
       "      <td>NCT08487833</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-08-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Daniel Thomas</td>\n",
       "      <td>66</td>\n",
       "      <td>solid tumors</td>\n",
       "      <td>NCT04103469</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Jane Wilson</td>\n",
       "      <td>74</td>\n",
       "      <td>liposarcoma</td>\n",
       "      <td>NCT04959533</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-08-02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>James Smith</td>\n",
       "      <td>60</td>\n",
       "      <td>anxiety disorder</td>\n",
       "      <td>NCT01052103</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-12-12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Jane Brown</td>\n",
       "      <td>62</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>NCT05825583</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-12-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Jane Brown</td>\n",
       "      <td>44</td>\n",
       "      <td>Depression</td>\n",
       "      <td>NCT08548726</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>Michael Garcia</td>\n",
       "      <td>27</td>\n",
       "      <td>Arthritis</td>\n",
       "      <td>NCT01878576</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>Oliver Garcia</td>\n",
       "      <td>62</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>NCT02417705</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2022-11-04</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>Sophia Thomas</td>\n",
       "      <td>72</td>\n",
       "      <td>myelomonocytic leukemia</td>\n",
       "      <td>NCT01624834</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2024-04-23</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>Michael Martinez</td>\n",
       "      <td>50</td>\n",
       "      <td>prostate cancer</td>\n",
       "      <td>NCT03206553</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2024-02-22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>Alice Smith</td>\n",
       "      <td>56</td>\n",
       "      <td>rectal cancer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>Sophia Anderson</td>\n",
       "      <td>52</td>\n",
       "      <td>Hypertension</td>\n",
       "      <td>NCT08961304</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2024-01-27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>Emily Wilson</td>\n",
       "      <td>59</td>\n",
       "      <td>depressive disorder</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>Jane Brown</td>\n",
       "      <td>47</td>\n",
       "      <td>prostate cancer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>Emily Wilson</td>\n",
       "      <td>31</td>\n",
       "      <td>myeloid leukemia</td>\n",
       "      <td>NCT09167628</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>Emma Smith</td>\n",
       "      <td>40</td>\n",
       "      <td>rectal cancer</td>\n",
       "      <td>NCT07510504</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-10-18</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    patient_id              name  age          medical_history  \\\n",
       "0            1       Jane Thomas   37        peritoneal cancer   \n",
       "1            2     Sophia Thomas   56                  Obesity   \n",
       "2            3    Michael Thomas   40                 Diabetes   \n",
       "3            4        Daniel Doe   44        suicidal ideation   \n",
       "4            5    Sophia Johnson   64              lung cancer   \n",
       "5            6     Daniel Thomas   66             solid tumors   \n",
       "6            7       Jane Wilson   74              liposarcoma   \n",
       "7            8       James Smith   60         anxiety disorder   \n",
       "8            9        Jane Brown   62        colorectal cancer   \n",
       "9           10        Jane Brown   44               Depression   \n",
       "10          11    Michael Garcia   27                Arthritis   \n",
       "11          12     Oliver Garcia   62                 Diabetes   \n",
       "12          13     Sophia Thomas   72  myelomonocytic leukemia   \n",
       "13          14  Michael Martinez   50          prostate cancer   \n",
       "14          15       Alice Smith   56            rectal cancer   \n",
       "15          16   Sophia Anderson   52             Hypertension   \n",
       "16          17      Emily Wilson   59      depressive disorder   \n",
       "17          18        Jane Brown   47          prostate cancer   \n",
       "18          19      Emily Wilson   31         myeloid leukemia   \n",
       "19          20        Emma Smith   40            rectal cancer   \n",
       "\n",
       "   previous_trials trial_status trial_completion_date  \n",
       "0      NCT03710197      Ongoing                        \n",
       "1                                                      \n",
       "2                                                      \n",
       "3      NCT08404176    Withdrawn            2023-07-31  \n",
       "4      NCT08487833    Withdrawn            2023-08-05  \n",
       "5      NCT04103469      Ongoing                        \n",
       "6      NCT04959533    Completed            2023-08-02  \n",
       "7      NCT01052103    Completed            2023-12-12  \n",
       "8      NCT05825583    Withdrawn            2023-12-03  \n",
       "9      NCT08548726      Ongoing                        \n",
       "10     NCT01878576      Ongoing                        \n",
       "11     NCT02417705    Completed            2022-11-04  \n",
       "12     NCT01624834    Completed            2024-04-23  \n",
       "13     NCT03206553    Withdrawn            2024-02-22  \n",
       "14                                                     \n",
       "15     NCT08961304    Withdrawn            2024-01-27  \n",
       "16                                                     \n",
       "17                                                     \n",
       "18     NCT09167628      Ongoing                        \n",
       "19     NCT07510504    Completed            2023-10-18  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from datetime import datetime, timedelta\n",
    "import numpy as np\n",
    "import json\n",
    "import random\n",
    "\n",
    "# Generate the sample data again for display\n",
    "columns = [\"patient_id\", \"name\", \"age\", \"medical_history\", \"previous_trials\", \"trial_status\", \"trial_completion_date\"]\n",
    "data = []\n",
    "\n",
    "# Given names and surnames\n",
    "names = [\"John\", \"Jane\", \"Alice\", \"Michael\", \"Emily\", \"Daniel\", \"Sophia\", \"James\", \"Emma\", \"Oliver\"]\n",
    "surnames = [\"Doe\", \"Smith\", \"Johnson\", \"Brown\", \"Davis\", \"Garcia\", \"Martinez\", \"Anderson\", \"Thomas\", \"Wilson\"]\n",
    "\n",
    "# Generate all possible unique combinations of names and surnames\n",
    "combinations = [(name, surname) for name in names for surname in surnames]\n",
    "\n",
    "# Shuffle the combinations to ensure randomness\n",
    "random.shuffle(combinations)\n",
    "\n",
    "# Select the first 100 unique combinations\n",
    "unique_names = combinations[:100]\n",
    "\n",
    "# Generate the full names\n",
    "full_names = [f\"{name} {surname}\" for name, surname in unique_names]\n",
    "\n",
    "with open('../../source_data/diseases_list.json', 'r') as file:\n",
    "        trial_diseases =  json.load(file)\n",
    "\n",
    "list_trial_diseases = list({disease for diseases in trial_diseases.values() for disease in diseases})\n",
    "\n",
    "other_medical_conditions = [\"Hypertension\", \"Diabetes\", \"Asthma\", \"Heart Disease\", \"Arthritis\",\n",
    "                      \"Chronic Pain\", \"Anxiety\", \"Depression\", \"Obesity\"]\n",
    "\n",
    "all_conditions = list(set(list_trial_diseases + other_medical_conditions))\n",
    "\n",
    "trial_statuses = [\"Completed\", \"Ongoing\", \"Withdrawn\"]\n",
    "\n",
    "def random_date(start, end):\n",
    "    return start + timedelta(days=random.randint(0, int((end - start).days)))\n",
    "\n",
    "# start_date must be 2 years before now\n",
    "start_date = datetime.now() - timedelta(days=365 * 2)\n",
    "# start_date = datetime(2020, 1, 1)\n",
    "\n",
    "# end_date must be a month before now\n",
    "end_date = datetime.now() - timedelta(days=10)\n",
    "# end_date = datetime(2023, 1, 1)\n",
    "\n",
    "for i in range(1, 101):\n",
    "    name = random.choice(full_names)\n",
    "    age = random.randint(20, 80)\n",
    "    medical_history = random.choice(all_conditions)\n",
    "    \n",
    "    if random.choice([True, False]):\n",
    "        previous_trials = f\"NCT0{random.randint(1000000, 9999999)}\"\n",
    "        trial_status = random.choice(trial_statuses)\n",
    "        trial_completion_date = random_date(start_date, end_date).strftime('%Y-%m-%d')\n",
    "    else:\n",
    "        previous_trials = \"\"\n",
    "        trial_status = \"\"\n",
    "        trial_completion_date = \"\"\n",
    "    if trial_status == \"Ongoing\":\n",
    "        trial_completion_date = \"\"\n",
    "\n",
    "    data.append((i, name, age, medical_history, previous_trials, trial_status, trial_completion_date))\n",
    "\n",
    "df = pd.DataFrame(data, columns=columns)\n",
    "# save df to csv\n",
    "df.to_csv(\"patients.csv\", index=False)\n",
    "df.head(20)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "100\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Jane Thomas</td>\n",
       "      <td>37</td>\n",
       "      <td>peritoneal cancer</td>\n",
       "      <td>NCT03710197</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Sophia Thomas</td>\n",
       "      <td>56</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Michael Thomas</td>\n",
       "      <td>40</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Daniel Doe</td>\n",
       "      <td>44</td>\n",
       "      <td>suicidal ideation</td>\n",
       "      <td>NCT08404176</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-07-31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Sophia Johnson</td>\n",
       "      <td>64</td>\n",
       "      <td>lung cancer</td>\n",
       "      <td>NCT08487833</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-08-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Daniel Thomas</td>\n",
       "      <td>66</td>\n",
       "      <td>solid tumors</td>\n",
       "      <td>NCT04103469</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Jane Wilson</td>\n",
       "      <td>74</td>\n",
       "      <td>liposarcoma</td>\n",
       "      <td>NCT04959533</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-08-02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>James Smith</td>\n",
       "      <td>60</td>\n",
       "      <td>anxiety disorder</td>\n",
       "      <td>NCT01052103</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-12-12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Jane Brown</td>\n",
       "      <td>62</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td>NCT05825583</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-12-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Jane Brown</td>\n",
       "      <td>44</td>\n",
       "      <td>Depression</td>\n",
       "      <td>NCT08548726</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   patient_id            name  age    medical_history previous_trials  \\\n",
       "0           1     Jane Thomas   37  peritoneal cancer     NCT03710197   \n",
       "1           2   Sophia Thomas   56            Obesity            None   \n",
       "2           3  Michael Thomas   40           Diabetes            None   \n",
       "3           4      Daniel Doe   44  suicidal ideation     NCT08404176   \n",
       "4           5  Sophia Johnson   64        lung cancer     NCT08487833   \n",
       "5           6   Daniel Thomas   66       solid tumors     NCT04103469   \n",
       "6           7     Jane Wilson   74        liposarcoma     NCT04959533   \n",
       "7           8     James Smith   60   anxiety disorder     NCT01052103   \n",
       "8           9      Jane Brown   62  colorectal cancer     NCT05825583   \n",
       "9          10      Jane Brown   44         Depression     NCT08548726   \n",
       "\n",
       "  trial_status trial_completion_date  \n",
       "0      Ongoing                  None  \n",
       "1         None                  None  \n",
       "2         None                  None  \n",
       "3    Withdrawn            2023-07-31  \n",
       "4    Withdrawn            2023-08-05  \n",
       "5      Ongoing                  None  \n",
       "6    Completed            2023-08-02  \n",
       "7    Completed            2023-12-12  \n",
       "8    Withdrawn            2023-12-03  \n",
       "9      Ongoing                  None  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import os\n",
    "import sqlite3\n",
    "import pandas as pd\n",
    "\n",
    "overwrite = True\n",
    "\n",
    "database_file = 'patients_database.db'\n",
    "df = pd.read_csv('patients.csv')\n",
    "if overwrite or not os.path.exists(database_file):\n",
    "    if os.path.exists(database_file):\n",
    "        os.remove(database_file)\n",
    "    conn = sqlite3.connect(database_file)\n",
    "    cursor = conn.cursor()\n",
    "    cursor.execute('''\n",
    "    CREATE TABLE IF NOT EXISTS patients (\n",
    "        patient_id INTEGER PRIMARY KEY,\n",
    "        name TEXT,\n",
    "        age INTEGER,\n",
    "        medical_history TEXT,\n",
    "        previous_trials TEXT,\n",
    "        trial_status TEXT,\n",
    "        trial_completion_date TEXT\n",
    "    )\n",
    "    ''')\n",
    "\n",
    "    # Insert DataFrame into SQLite table\n",
    "    df.to_sql('patients', conn, if_exists='append', index=False)\n",
    "\n",
    "    # Commit and close the connection\n",
    "    conn.commit()\n",
    "else:\n",
    "    conn = sqlite3.connect(database_file)\n",
    "    cursor = conn.cursor()\n",
    "\n",
    "query = 'SELECT * FROM patients'\n",
    "\n",
    "# Execute the query and fetch all results\n",
    "cursor.execute(query)\n",
    "rows = cursor.fetchall()\n",
    "\n",
    "# Optionally, you can get the column names\n",
    "column_names = [description[0] for description in cursor.description]\n",
    "\n",
    "# Convert the results to a Pandas DataFrame for better readability\n",
    "df = pd.DataFrame(rows, columns=column_names)\n",
    "print(len(df))\n",
    "\n",
    "# Display the DataFrame\n",
    "conn.close()\n",
    "\n",
    "db = database_file\n",
    "df.head(10)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Clinical Trials database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Only trials with status recruiting are selected.\n",
      "The database for trials is saved to ../../data/trials_data.csv \n",
      " It has 30 rows.\n",
      "---- Sample 1 ----\n",
      "\n",
      "        Key Inclusion Criteria:\n",
      "\n",
      "          -  Subject must be ≥18 years of age.\n",
      "\n",
      "          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\n",
      "             based on local or central evaluation.\n",
      "\n",
      "          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\n",
      "             and urine sampling during the study.\n",
      "\n",
      "          -  Subjects must have ECOG PS of 0 to 2.\n",
      "\n",
      "          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\n",
      "\n",
      "          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\n",
      "             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\n",
      "             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\n",
      "             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\n",
      "             disease\n",
      "\n",
      "          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\n",
      "             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\n",
      "             rate (GFR)\n",
      "\n",
      "          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\n",
      "             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\n",
      "\n",
      "          -  Female subjects with reproductive potential must have a negative serum pregnancy test\n",
      "             within 7 days prior to the start of therapy and on the first day of study drug\n",
      "             administration.\n",
      "\n",
      "        Key Exclusion Criteria:\n",
      "\n",
      "          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\n",
      "             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\n",
      "             time of screening, or with clinically significant graft-versus-host disease (GVHD).\n",
      "             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\n",
      "             GVHD is permitted.)\n",
      "\n",
      "          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\n",
      "             their first day of study drug administration. (Hydroxyurea is allowed prior to\n",
      "             enrollment and after the start of AG-120).\n",
      "\n",
      "          -  Subjects who received an investigational agent <14 days prior to their first day of\n",
      "             study drug administration.\n",
      "\n",
      "          -  Subjects who are pregnant or breastfeeding.\n",
      "\n",
      "          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\n",
      "             screening visits or on their first day of study drug administration (at the discretion\n",
      "             of the Investigator, subjects with tumor fever may be enrolled).\n",
      "\n",
      "          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\n",
      "             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\n",
      "             within approximately 28 days of C1D1.\n",
      "\n",
      "          -  Subjects with a history of myocardial infarction within the last 6 months of\n",
      "             screening.\n",
      "\n",
      "          -  Subjects with a known unstable or uncontrolled angina pectoris.\n",
      "\n",
      "          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\n",
      "\n",
      "          -  Subjects with known unstable or uncontrolled angina pectoris.\n",
      "\n",
      "          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\n",
      "             increase the risk of QT prolongation or arrhythmic events.\n",
      "\n",
      "          -  Patients taking medications that are known to prolong the QT interval\n",
      "\n",
      "          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\n",
      "             hepatitis B or C.\n",
      "\n",
      "          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\n",
      "             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\n",
      "             there is a clinical suspicion of CNS involvement by leukemia during screening.\n",
      "\n",
      "          -  Subjects with immediately life-threatening, severe complications of leukemia such as\n",
      "             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\n",
      "             intravascular coagulation.\n",
      "      \n",
      "---- Sample 2 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma\n",
      "             (Islet cell neoplasms or neuroendocrine carcinomas are excluded)\n",
      "\n",
      "          2. ≥ 18 years of age at the time of signing the informed consent document\n",
      "\n",
      "          3. ECOG 0-1\n",
      "\n",
      "          4. At least one measurable lesion according to recist v1.1\n",
      "\n",
      "          5. No prior palliative chemotherapy for the treatment of metastatic pancreatic cancer\n",
      "             (Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in\n",
      "             the adjuvant setting is allowed if the treatment had been received at least 6 months\n",
      "             before enroll).\n",
      "\n",
      "          6. Adequate BM function: ANC ≥1.5 × 109/L; Platelet count ≥100,000/mm2 (100 × 109/L); Hb\n",
      "             (Hb) ≥9 g/dL.\n",
      "\n",
      "          7. Adequate liver and renal function (obtained ≤14 days prior to enroll): AST (SGOT), ALT\n",
      "             (SGPT) ≤2.5 × upper limit of normal range (ULN), unless liver metastases are clearly\n",
      "             present, then ≤5 × ULN is allowed; Total bilirubin 1.5 ≤ ULN; Serum creatinine within\n",
      "             normal limits or calculated clearance ≥ 60 mL/min/1.73 m2\n",
      "\n",
      "          8. Albumin level ≥ 3 g/dl\n",
      "\n",
      "          9. Subjects should be asymptomatic for jaundice prior to Cycle 1 Day 1\n",
      "\n",
      "         10. Subject with signed the Informed Consent Form (ICF) prior to participation in any\n",
      "             study-related activities.\n",
      "\n",
      "         11. Female of childbearing potential (FCBP) (defined as a sexually mature woman who (1)\n",
      "             has not undergone hysterectomy [the surgical removal of the uterus] or bilateral\n",
      "             oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally\n",
      "             postmenopausal for at least 24 consecutive months [ie, has had menses at any time\n",
      "             during the preceding 24 consecutive months]) must:\n",
      "\n",
      "               -  Either commit to true abstinence or agree to the use of 2 physician-approved\n",
      "                  contraceptive methods (oral, injectable, or implantable hormonal contraceptive;\n",
      "                  tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or\n",
      "                  vasectomized partner) while on IP; and for 3 months following the last dose of\n",
      "                  IP; and\n",
      "\n",
      "               -  Has a negative serum pregnancy test (β-hCG) result at screening\n",
      "\n",
      "         12. Male subjects must practice true abstinence or agree to use a condom during sexual\n",
      "             contact with a pregnant female or a female of childbearing potential while\n",
      "             participating in the study, during dose interruptions, and for 6 months following IP\n",
      "             discontinuation, even if he has undergone a successful vasectomy\n",
      "\n",
      "         13. Subject able to adhere to the study visit schedule and other protocol requirements.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Subject has known symptomatic brain metastases.\n",
      "\n",
      "          2. History of malignancy in the last 5 years.\n",
      "\n",
      "          3. Breast-feeding or pregnant female\n",
      "\n",
      "          4. Patients with plastic biliary stent (Metal biliary stents are allowed.)\n",
      "\n",
      "          5. Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring\n",
      "             systemic therapy.\n",
      "\n",
      "          6. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\n",
      "             C.\n",
      "\n",
      "          7. Subject has undergone major surgery within 4 weeks prior to Cycle 1 Day 1 of treatment\n",
      "             in this study.\n",
      "\n",
      "          8. Subject who experienced a recent myocardial infarction, including severe/unstable\n",
      "             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\n",
      "             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\n",
      "             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\n",
      "             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\n",
      "             year.\n",
      "\n",
      "          9. Subject has a history of allergy or hypersensitivity to any of the study drugs\n",
      "\n",
      "         10. Subjects with history of connective tissue disorders (eg, lupus, scleroderma,\n",
      "             arteritis nodosa).\n",
      "\n",
      "         11. Subjects with a history of interstitial lung disease\n",
      "\n",
      "         12. Any other malignancy within 5 years prior to enrollment, with the exception of\n",
      "             adequately treated in-situ carcinoma of the prostate (Gleason score ≤ 7), cervix,\n",
      "             uteri, or nonmelanomatous skin cancer (all treatment of which should have been\n",
      "             completed 6 months prior to enrollment).\n",
      "\n",
      "         13. Patients has > Grade 1 pre-existing peripheral neuropathy (per CTCAE)\n",
      "\n",
      "         14. Subject has serious medical risk factors involving any of the major organ systems, or\n",
      "             serious psychiatric disorders, which could compromise the subject's safety or the\n",
      "             study data integrity.\n",
      "\n",
      "         15. Subject is enrolled in any other clinical protocol or investigational trial with an\n",
      "             interventional agent or assessments that may interfere with study procedures.\n",
      "\n",
      "         16. Subject is unwilling or unable to comply with study procedures\n",
      "\n",
      "         17. Any significant medical condition, laboratory abnormality, or psychiatric illness that\n",
      "             would prevent the subject from participating in the study.\n",
      "      \n",
      "---- Sample 3 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Diagnosis of adenocarcinoma of the rectum\n",
      "\n",
      "          -  Age: 18-70 years old\n",
      "\n",
      "          -  Signed informed consent; able to comply with study and/or follow- up procedures\n",
      "\n",
      "          -  Stage of the primary tumor may be determined by ultrasound or MRI\n",
      "\n",
      "          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\n",
      "             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\n",
      "             1.0 cm]\n",
      "\n",
      "          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\n",
      "\n",
      "          -  Distal border of the tumor must be located < 12 cm from the anal verge\n",
      "\n",
      "          -  Tumor amenable to curative resection\n",
      "\n",
      "          -  Adequate bone marrow, hepatic and renal function as assessed by the following\n",
      "             laboratory requirements conducted within 7 days of starting study treatment:\n",
      "\n",
      "          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\n",
      "             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\n",
      "\n",
      "          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\n",
      "\n",
      "          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\n",
      "\n",
      "          -  Alkaline phosphatase limit ≤ 5x ULN.\n",
      "\n",
      "          -  Amylase and lipase ≤ 1.5 x the ULN.\n",
      "\n",
      "          -  Serum creatinine ≤ 1.5 x the ULN.\n",
      "\n",
      "          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\n",
      "\n",
      "          -  No renal disease that would preclude study treatment or follow-up\n",
      "\n",
      "          -  ECOG status: 0～1\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\n",
      "\n",
      "          -  No More than 4 weeks since prior participation in any investigational drug study\n",
      "\n",
      "          -  More than 4 weeks since prior participation in any investigational drug study\n",
      "\n",
      "          -  Clear indication of involvement of the pelvic side walls by imaging\n",
      "\n",
      "          -  With distant metastasis\n",
      "\n",
      "          -  History of invasive rectal malignancy, regardless of disease-free interval\n",
      "\n",
      "          -  Fertile patients must use effective contraception\n",
      "\n",
      "          -  Uncontrolled hypertension\n",
      "\n",
      "          -  Cardiovascular disease that would preclude study treatment or follow-up\n",
      "\n",
      "          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\n",
      "             gastrointestinal tract bleeding\n",
      "\n",
      "          -  Synchronous colon cancer\n",
      "\n",
      "          -  Pregnant or nursing, Fertile patients do not use effective contraception\n",
      "\n",
      "          -  Other malignancy within the past 5 years except effectively treated squamous cell or\n",
      "             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\n",
      "             carcinoma in situ of the colon or rectum\n",
      "\n",
      "          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\n",
      "             investigator, would preclude study participation\n",
      "\n",
      "          -  patients refused to signed informed consent.\n",
      "      \n",
      "---- Sample 4 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed locally advanced gastric (primary endpoint includes proximal\n",
      "             and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral)\n",
      "             adenocarcinomas are eligible for enrolment but will not be included in the primary\n",
      "             analysis\n",
      "\n",
      "          -  Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary\n",
      "             tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)\n",
      "\n",
      "          -  All patients must have diagnostic laparoscopy with diagnostic washings for cytology;\n",
      "             both cytology positive and negative patients are eligible for enrolment, but only\n",
      "             cytology negative patients will be included in the primary analyses; gross peritoneal\n",
      "             disease is not eligible\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1\n",
      "\n",
      "          -  Eligible for surgery with curative intent\n",
      "\n",
      "          -  Absolute neutrophil count (ANC) >= 1250/ul\n",
      "\n",
      "          -  Hemoglobin >= 9 g/dL\n",
      "\n",
      "          -  Platelets >= 100,000/ul\n",
      "\n",
      "          -  Total bilirubin < 1.5 x upper limit of normal\n",
      "\n",
      "          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\n",
      "             transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver\n",
      "             metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver\n",
      "             metastases\n",
      "\n",
      "          -  Creatinine =< 1.5 x upper limit of normal\n",
      "\n",
      "          -  Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor\n",
      "             (RECIST) 1.1 will be allowed\n",
      "\n",
      "          -  Women of child-bearing potential and men must agree to use adequate contraception\n",
      "             (hormonal or barrier method of birth control; abstinence) prior to study entry and for\n",
      "             the duration of study participation, up until 30 days after final study treatment;\n",
      "             should a woman become pregnant or suspect that she is pregnant while participating in\n",
      "             this study, she should inform her treating physician immediately\n",
      "\n",
      "          -  Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3,\n",
      "             subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative\n",
      "             drugs whenever possible, given the potential for drug-drug interactions with\n",
      "             irinotecan\n",
      "\n",
      "          -  Signed informed consent\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Previous or concurrent malignancy, except for adequately treated basal cell or\n",
      "             squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the\n",
      "             patient has been previously treated and the lifetime recurrence risk is less than 30%\n",
      "\n",
      "          -  Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's\n",
      "             disease, ulcerative colitis)\n",
      "\n",
      "          -  Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology\n",
      "             Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)\n",
      "\n",
      "          -  Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0\n",
      "\n",
      "          -  Serious underlying medical or psychiatric illnesses that would, in the opinion of the\n",
      "             treating physician, substantially increase the risk for complications related to\n",
      "             treatment\n",
      "\n",
      "          -  Active uncontrolled bleeding\n",
      "\n",
      "          -  Pregnancy or breastfeeding\n",
      "\n",
      "          -  Major surgery within 4 weeks\n",
      "\n",
      "          -  Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be\n",
      "             allowed and treated as in the *28/*28 dosing group\n",
      "      \n"
     ]
    }
   ],
   "source": [
    "import sys\n",
    "module_dir = os.path.abspath('../../src')  # Gets the absolute path to the src directory\n",
    "sys.path.append(module_dir)\n",
    "from helper_functions import dataset_create_trials\n",
    "\n",
    "overwrite = False\n",
    "if trials_db_downloaded and not overwrite:\n",
    "    print(f'Trials database already downloaded and stored in {trials_path}')\n",
    "    df_trials = pd.read_csv(trials_path)\n",
    "else:\n",
    "    df_trials, trials_path = dataset_create_trials(status='recruiting')\n",
    "    trials_db_downloaded = True\n",
    "\n",
    "# print the ctriteria column value froom 4 random rows of the dataferam. use a for loop\n",
    "df_samples = df_trials.sample(4).reset_index(drop=True)\n",
    "for i in range(4):\n",
    "    print(f'---- Sample {i+1} ----')\n",
    "    print(df_samples.iloc[i]['criteria'])\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Creating Vectore Stores"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## vectorstore for policy database\n",
    "\n",
    "local embedding via NomicEmbeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:root:USER_AGENT environment variable not set, consider setting it to identify your requests.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "12\n",
      "Vectore store loaded from existing chromadb\n",
      "12\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 7. **Emergency Contact and Support**\\n   - **Emergency Contact**: Patients must provide emergency contact information.\\n   - **Support Systems**: Patients must have access to appropriate support systems (e.g., caregiver, family member) to assist them throughout the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 9. **Dietary and Lifestyle Restrictions**\\n   - **Dietary Compliance**: Patients must adhere to any dietary restrictions or requirements specified by the trial protocol.\\n   - **Lifestyle Modifications**: Patients must be willing to comply with lifestyle modifications required by the trial protocol, such as exercise regimens or smoking cessation.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 10. **Allergies and Sensitivities**\\n   - **Allergy Disclosure**: Patients must disclose any known allergies or sensitivities, particularly to medications, foods, or environmental factors.\\n   - **Medication Sensitivity**: Patients with known sensitivities to medications being tested in the trial are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 11. **Cognitive and Communication Abilities**\\n   - **Cognitive Assessment**: Patients must have the cognitive ability to understand and comply with the trial protocol and instructions.\\n   - **Communication Abilities**: Patients must be able to effectively communicate with the research team and understand instructions, either directly or with the assistance of a caregiver.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 12. **Employment and Daily Responsibilities**\\n   - **Employment Impact**: Patients must disclose if participation in the trial could impact their employment or daily responsibilities significantly.\\n   - **Availability**: Patients must be available for all scheduled trial visits and assessments as required by the protocol, with minimal risk of missing appointments.', metadata={'source': '../../source_data/instut_trials_policy.md'})]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import re\n",
    "\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.document_loaders import WebBaseLoader\n",
    "from langchain_community.vectorstores import Chroma\n",
    "from langchain_nomic.embeddings import NomicEmbeddings\n",
    "from langchain_community.document_loaders import UnstructuredMarkdownLoader\n",
    "from langchain_core.documents import Document\n",
    "import chromadb\n",
    "\n",
    "# vstore_delete = False\n",
    "vstore_load = True\n",
    "markdown_path = \"../../source_data/instut_trials_policy.md\"\n",
    "\n",
    "with open(markdown_path, \"r\") as f:\n",
    "    policy_text = f.read()\n",
    "\n",
    "\n",
    "doc_splits = [\n",
    "    Document(page_content= txt, metadata={\"source\": markdown_path}) for txt in re.split(r\"(?=\\n###)\", policy_text)\n",
    "    ]\n",
    "\n",
    "# the title of markdown is not required in the split\n",
    "doc_splits = doc_splits[1:]    \n",
    "\n",
    "print(len(doc_splits))\n",
    "doc_splits\n",
    "\n",
    "persistent_client = chromadb.PersistentClient(path = chromadb_path)\n",
    "\n",
    "if vstore_load == False:\n",
    "    vectorstore.delete_collection()\n",
    "\n",
    "\n",
    "# if chromadb_path exists\n",
    "if os.path.exists(chromadb_path) and vstore_load:\n",
    "    vectorstore = Chroma(\n",
    "        client=persistent_client,\n",
    "        collection_name=policy_collection,\n",
    "        embedding_function=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                                inference_mode='local'),\n",
    "    )\n",
    "    print('Vectore store loaded from existing chromadb')\n",
    "    # vectorstore._collection.count()\n",
    "else:\n",
    "    vectorstore = Chroma.from_documents(\n",
    "        documents=doc_splits,\n",
    "        client=persistent_client,\n",
    "        collection_name=policy_collection,\n",
    "        # persist_directory=chromadb_path,\n",
    "        embedding=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                                inference_mode='local'),\n",
    "    )\n",
    "    print('Vectore store created and stored in persistent chromadb client')\n",
    "print(vectorstore._collection.count())\n",
    "doc_splits\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.path.exists(chromadb_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "6\n",
      "\n",
      "#### 3. **Previous Trial Participation**   \n",
      "   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\n",
      "   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\n",
      "   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\n",
      "   - **Trial Outcomes**:\n",
      "     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\n",
      "     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 12. **Employment and Daily Responsibilities**\\n   - **Employment Impact**: Patients must disclose if participation in the trial could impact their employment or daily responsibilities significantly.\\n   - **Availability**: Patients must be available for all scheduled trial visits and assessments as required by the protocol, with minimal risk of missing appointments.', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever_policy = vectorstore.as_retriever(search_kwargs={\"k\": n_retrieved_policies})\n",
    "# question = \"policy about patient's past trials\"\n",
    "question = \"\\ntrial_completion_date: 2024-04-01\"\n",
    "docs_retrieved = retriever_policy.get_relevant_documents(question)\n",
    "print(len(docs_retrieved))\n",
    "doc_txt = docs_retrieved[0].page_content\n",
    "print(doc_txt)\n",
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Vstore for trials"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "we just work on 3 main categories of cancer, lukemia, and mental health problems as a demo application.\n",
    "\n",
    "For a more proper application, this must be done with the help of domain specialists."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'nctid': 'NCT00715611', 'status': 'recruiting', 'diseases': \"['mesothelioma']\", 'disease_category': 'cancer', 'drugs': \"['pemetrexed and cisplatin or carboplatin']\"}\n",
      "Loading the vectorstore from persistent client\n",
      "18\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Provide written informed consent to participate on the study\\r\\n\\r\\n          -  Patients must have a pathologically confirmed diagnosis either at MSKCC or at the\\r\\n             participating site of stage I-III malignant pleural mesothelioma\\r\\n\\r\\n          -  Epithelioid or biphasic histology subtype (Note: patients with biphasic histology can\\r\\n             have < 10% sarcomatoid)\\r\\n\\r\\n          -  No evidence of metastatic disease.\\r\\n\\r\\n          -  Patient age ≥ 18 years but ≤ 80 years at the time of consent.\\r\\n\\r\\n          -  Karnofsky performance status ≥ 80%\\r\\n\\r\\n          -  Pulmonary Function Tests:\\r\\n\\r\\n               1. For all patients: DLCO > 40% predicted (corrected for Hgb)\\r\\n\\r\\n               2. For patients enrolled post-P/D, only: FEV1 >/= 35% (corrected for Hgb) (Note:\\r\\n                  patients enrolled prior to P/D will have PFTs repeated pre-IMRT. If this criteria\\r\\n                  is not met, they will be removed from study)\\r\\n\\r\\n          -  In cases of concern about decreased renal function and potential high radiation dose\\r\\n             to the kidneys, an optional nuclear medicine kidney function scan may be performed\\r\\n             prior to radiation therapy to determine the functional contribution of each kidney.\\r\\n\\r\\n          -  Patient enrolled prior to chemotherapy must have adequate organ function as indicated\\r\\n             by the following laboratory values:\\r\\n\\r\\n               1. Absolute neutrophil count ≥1.5 K/mcL\\r\\n\\r\\n               2. Platelets ≥100 K/mcL\\r\\n\\r\\n               3. Serum total bilirubin ≤ 1.5 X ULN\\r\\n\\r\\n               4. AST (SGOT) or ALT (SGPT) ≤ 3.0 X ULN Note: patients enrolled after chemotherapy\\r\\n                  do not have to meet the above criteria\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  > 10% Sarcomatoid or desmoplastic histology\\r\\n\\r\\n          -  Continuous oxygen use\\r\\n\\r\\n          -  Prior nephrectomy on the contralateral side of MPM\\r\\n\\r\\n          -  Prior intrapleural therapy (except pleurodesis) or intrapleural therapy at the time of\\r\\n             P/D (i.e.: intrapleural chemotherapy, photodynamic therapy, intrapleural betadine)\\r\\n\\r\\n          -  Prior thoracic radiation therapy preventing hemithoracic pleural IMRT\\r\\n\\r\\n          -  Bulky disease in the fissure preventing lung-sparing pleural IMRT\\r\\n\\r\\n          -  Patients undergoing extrapleural pneumonectomy\\r\\n\\r\\n          -  Patients with an active infection that require systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a concurrent active malignancy (except squamous or basal cell carcinoma\\r\\n             of the skin)\\r\\n\\r\\n          -  Patients with serious unstable medical illness\\r\\n\\r\\n          -  Presence of third space fluid that cannot be controlled by drainage\\r\\n\\r\\n          -  For patients who develop or have baseline clinically significant pleural effusions\\r\\n             before or during initiation of pemetrexed therapy; consideration should be given to\\r\\n             drain the effusion prior to chemotherapy administration\\r\\n\\r\\n          -  No acute congestive heart failure\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Men or women not using effective contraception\\r\\n\\r\\n        Reproductive risks Patients should not become pregnant or father a baby while on this study\\r\\n        because the drugs in this study can affect an unborn baby. Women should not breast-feed a\\r\\n        baby while on this study. Women of childbearing age will be counseled to use birth control\\r\\n        while on this study.\\r\\n      ', metadata={'nctid': 'NCT00715611', 'status': 'recruiting', 'diseases': \"['mesothelioma']\", 'disease_category': 'cancer', 'drugs': \"['pemetrexed and cisplatin or carboplatin']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients with a confirmed diagnosis of symptomatic multiple myeloma stage I to III\\r\\n             according to the International Staging System ISS (see appendix A), i.e. at least one\\r\\n             of the CRAB criteria should be present;\\r\\n\\r\\n          -  Measurable disease as defined by the presence of M-protein in serum or urine (serum\\r\\n             M-protein> 10 g/l or urine M-protein > 200 mg/24 hours), or abnormal free light chain\\r\\n             ratio;\\r\\n\\r\\n          -  Age 18-65 years inclusive;\\r\\n\\r\\n          -  WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by\\r\\n             comorbid conditions);\\r\\n\\r\\n          -  Negative pregnancy test at inclusion if applicable;\\r\\n\\r\\n          -  Written informed consent.\\r\\n\\r\\n        Inclusion for randomisation 1:\\r\\n\\r\\n          -  WHO performance 0-2;\\r\\n\\r\\n          -  Bilirubin and transaminases < 2.5 times the upper limit of normal values;\\r\\n\\r\\n          -  A suitable stem cell graft containing at least 4 x 106 CD34+ cells/kg (or according to\\r\\n             national guidelines).\\r\\n\\r\\n        Inclusion for randomisation 2:\\r\\n\\r\\n          -  Bilirubin and transaminases < 2.5 times the upper limit of normal values;\\r\\n\\r\\n          -  ANC >= 0.5 x 109/l and platelets > 20 x 10^9/l;\\r\\n\\r\\n          -  Patient is able to adhere to the requirements of the Lenalidomide Pregnancy Prevention\\r\\n             Risk Management Plan.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Known intolerance of Boron;\\r\\n\\r\\n          -  Systemic AL amyloidosis;\\r\\n\\r\\n          -  Primary Plasmacell Leukemia;\\r\\n\\r\\n          -  Non-secretory MM;\\r\\n\\r\\n          -  Previous chemotherapy or radiotherapy except local radiotherapy in case of local\\r\\n             myeloma progression or corticosteroids maximum 5 days for symptom control;\\r\\n\\r\\n          -  Severe cardiac dysfunction (NYHA classification II-IV);\\r\\n\\r\\n          -  Significant hepatic dysfunction, unless related to myeloma;\\r\\n\\r\\n          -  Patients with GFR <15 ml/min,\\r\\n\\r\\n          -  Patients known to be HIV-positive;\\r\\n\\r\\n          -  Patients with active, uncontrolled infections;\\r\\n\\r\\n          -  Patients with neuropathy, CTC grade 2 or higher;\\r\\n\\r\\n          -  Patients with a history of active malignancy during the past 5 years with the\\r\\n             exception of basal carcinoma of the skin or stage 0 cervical carcinoma;\\r\\n\\r\\n          -  Patients who are not willing or capable to use adequate contraception during the\\r\\n             therapy (all men, all pre-menopausal women);\\r\\n\\r\\n          -  Lactating women.\\r\\n\\r\\n        Exclusion for randomisation 1:\\r\\n\\r\\n          -  Severe pulmonary, neurologic, or psychiatric disease;\\r\\n\\r\\n          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment;\\r\\n\\r\\n          -  Allogeneic Stem Cell Transplantation (Allo SCT) planned;\\r\\n\\r\\n          -  Progressive disease.'\\r\\n\\r\\n        Exclusion for randomisation 2:\\r\\n\\r\\n          -  Progressive disease;\\r\\n\\r\\n          -  Neuropathy, except CTCAE grade 1;\\r\\n\\r\\n          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment.\\r\\n      \", metadata={'nctid': 'NCT01208766', 'status': 'recruiting', 'diseases': \"['multiple myeloma']\", 'disease_category': 'cancer', 'drugs': \"['bortezomib, melphalan, prednisone (vmp)', '1 or 2 cycle(s) hdm (high dose melphalan)', '2 cycles of bortezomib, lenalidomide, dexamethasone (vrd)']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\\r\\n             previously treated with docetaxel-based therapy and has progressed during treatment of\\r\\n             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\\r\\n\\r\\n          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\\r\\n             or radiographic evidence of disease progression in soft tissue or bone\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\\r\\n\\r\\n          -  Adequate hematologic and organ function\\r\\n\\r\\n          -  Documented willingness to use an effective means of contraception\\r\\n\\r\\n          -  Safety cohort only: agreement to use CGM for first cycle of treatment\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\\r\\n             patients who are receiving any pharmacologic treatment for diabetes are not eligible\\r\\n\\r\\n          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\\r\\n             fraction < 50% or ventricular arrhythmia requiring medication\\r\\n\\r\\n          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\\r\\n             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\\r\\n             within 6 months prior to Day 1\\r\\n\\r\\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\\r\\n             drugs or active inflammatory disease which requires immunosuppressive therapy\\r\\n\\r\\n          -  Clinically significant history of liver disease\\r\\n\\r\\n          -  History of adrenal insufficiency or hyperaldosteronism\\r\\n\\r\\n          -  Phase II only: Previous therapy for prostate cancer with 17\\r\\n             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\\r\\n\\r\\n          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\\r\\n             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\\r\\n\\r\\n          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\\r\\n             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\\r\\n      ', metadata={'nctid': 'NCT01485861', 'status': 'recruiting', 'diseases': \"['prostate cancer']\", 'disease_category': 'cancer', 'drugs': \"['abiraterone', 'apitolisib', 'ipatasertib', 'placebo', 'prednisone', 'prednisolone']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'nctid': 'NCT02028806', 'status': 'recruiting', 'diseases': \"['metastatic pancreatic cancer']\", 'disease_category': 'cancer', 'drugs': \"['mfolfirinox']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n        Suicidal Ideation group:\\r\\n\\r\\n          1. Any person admitted to the emergency room department after a suicide attempt , defined\\r\\n             as requiring medical intervention - not just a psychiatrist ( surgical or\\r\\n             pharmacological treatment but also the need for observation ) .\\r\\n\\r\\n          2. The need for medical intervention will be defined by the ER ED physician\\r\\n\\r\\n          3. Ages 18-65\\r\\n\\r\\n        For the depression group:\\r\\n\\r\\n          1. Diagnosed with major depression according to DSM VI.\\r\\n\\r\\n          2. Ongoing depression (according to DSM criteria) despite treatment with at least two\\r\\n             antidepressants in adequate dosages and for longer than three weeks.\\r\\n\\r\\n          3. Ages 18-65\\r\\n\\r\\n        For the romantic relationship breakup:\\r\\n\\r\\n        1. Participants that have experienced a meaningful romantic relationship break-up within\\r\\n        the past 12 months\\r\\n\\r\\n        -\\r\\n\\r\\n        Exclusion Criteria for all groups:\\r\\n\\r\\n          1. Psychotic state instate in the examination\\r\\n\\r\\n          2. Diagnosis of schizophrenia / schizoaffective disorder\\r\\n\\r\\n          3. Drug or alcohol abuse as is revealed in by blood/urine tests\\r\\n\\r\\n          4. Patient in which, according to the examiner, there is primary or secondary gain.\\r\\n\\r\\n          5. Patient , which, at the time of his admission , is without any pharmacological\\r\\n             treatment.\\r\\n      ', metadata={'nctid': 'NCT02037503', 'status': 'recruiting', 'diseases': \"['suicidal ideation', 'major depressive disorder', 'healthy participants']\", 'disease_category': 'mental_health', 'drugs': \"['ketamine', 'saline']\"}),\n",
       " Document(page_content=\"\\n        Key Inclusion Criteria:\\r\\n\\r\\n          -  Subject must be ≥18 years of age.\\r\\n\\r\\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\\r\\n             based on local or central evaluation.\\r\\n\\r\\n          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\\r\\n             and urine sampling during the study.\\r\\n\\r\\n          -  Subjects must have ECOG PS of 0 to 2.\\r\\n\\r\\n          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\\r\\n\\r\\n          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\\r\\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\\r\\n             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\\r\\n             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\\r\\n             disease\\r\\n\\r\\n          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\\r\\n             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\\r\\n             rate (GFR)\\r\\n\\r\\n          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\\r\\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\\r\\n\\r\\n          -  Female subjects with reproductive potential must have a negative serum pregnancy test\\r\\n             within 7 days prior to the start of therapy and on the first day of study drug\\r\\n             administration.\\r\\n\\r\\n        Key Exclusion Criteria:\\r\\n\\r\\n          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\\r\\n             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\\r\\n             time of screening, or with clinically significant graft-versus-host disease (GVHD).\\r\\n             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\\r\\n             GVHD is permitted.)\\r\\n\\r\\n          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\\r\\n             their first day of study drug administration. (Hydroxyurea is allowed prior to\\r\\n             enrollment and after the start of AG-120).\\r\\n\\r\\n          -  Subjects who received an investigational agent <14 days prior to their first day of\\r\\n             study drug administration.\\r\\n\\r\\n          -  Subjects who are pregnant or breastfeeding.\\r\\n\\r\\n          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\\r\\n             screening visits or on their first day of study drug administration (at the discretion\\r\\n             of the Investigator, subjects with tumor fever may be enrolled).\\r\\n\\r\\n          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\\r\\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\\r\\n             within approximately 28 days of C1D1.\\r\\n\\r\\n          -  Subjects with a history of myocardial infarction within the last 6 months of\\r\\n             screening.\\r\\n\\r\\n          -  Subjects with a known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\\r\\n\\r\\n          -  Subjects with known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\\r\\n             increase the risk of QT prolongation or arrhythmic events.\\r\\n\\r\\n          -  Patients taking medications that are known to prolong the QT interval\\r\\n\\r\\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\\r\\n             hepatitis B or C.\\r\\n\\r\\n          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\\r\\n             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\\r\\n             there is a clinical suspicion of CNS involvement by leukemia during screening.\\r\\n\\r\\n          -  Subjects with immediately life-threatening, severe complications of leukemia such as\\r\\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\\r\\n             intravascular coagulation.\\r\\n      \", metadata={'nctid': 'NCT02074839', 'status': 'recruiting', 'diseases': \"['relapsed or refractory acute myeloid leukemia (aml)', 'untreated aml', 'other idh1-mutated positive hematologic malignancies', 'myelodysplastic syndromes']\", 'disease_category': 'leukemia', 'drugs': \"['ag-120']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Participant has the ability and the willingness to sign the informed consent document\\r\\n             (for adults only, for participants with mild cognitive abilities may use a legally\\r\\n             authorized representative)\\r\\n\\r\\n          -  Documented (signed) informed consent; the patient, family member and transplant staff\\r\\n             physician (physician, nurse, and social worker) meet at least once prior to starting\\r\\n             the transplant procedure; during this meeting all pertinent information with respect\\r\\n             to risks and benefits to donor and recipient will be presented; alternative treatment\\r\\n             modalities will be discussed; the risks are explained in detail in the enclosed\\r\\n             consent forms\\r\\n\\r\\n          -  Karnofsky performance status >= 70% =< 2\\r\\n\\r\\n          -  Acute lymphocytic leukemia or acute myelogenous leukemia who are not in first\\r\\n             remission or second remission i.e. after failing induction therapy, or in relapse or\\r\\n             beyond second remission; (prior therapy with VP-16 and Cytoxan is allowed)\\r\\n\\r\\n          -  All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR)\\r\\n             identical siblings who is willing to donate bone marrow or primed blood stem cells or\\r\\n             a 10/10 allele matched unrelated donor; a single allele mismatch at A, B, C, DR or DQ\\r\\n             and a killer immunoglobulin-like receptor (KIR) mismatch at C will be allowed; all ABO\\r\\n             blood group combinations of the donor/recipient are acceptable\\r\\n\\r\\n          -  The time from the end last induction, re-induction, or consolidation regimen should be\\r\\n             greater than or equal to 14 days from planned start of study treatment; Note:\\r\\n             Chemotherapy given within 14 days of planned study enrollment for the purpose of\\r\\n             controlling counts is permitted\\r\\n\\r\\n          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) OR 3 x ULN for Gilbert\\'s disease\\r\\n\\r\\n          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\\r\\n             transaminase (SGPT) =< 5 x ULN\\r\\n\\r\\n          -  Measured creatinine clearance >= 80 ml/min per 24 hour urine collection OR serum\\r\\n             creatinine =< 1.3 mg/dL\\r\\n\\r\\n          -  Women of child bearing potential only: Negative urine or serum pregnancy test\\r\\n\\r\\n          -  Pulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon\\r\\n             monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted\\r\\n             normal value\\r\\n\\r\\n          -  Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >=\\r\\n             50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall\\r\\n             motion is \"abnormal\" or \"altered\")\\r\\n\\r\\n          -  Electrocardiogram (EKG) showing no ischemic changes and no abnormal rhythm\\r\\n\\r\\n          -  Agreement of men AND women-of-child-bearing-potential to use adequate contraception\\r\\n             (hormonal or barrier method of birth control or abstinence) prior to study entry and\\r\\n             for six months following duration of study participation; should a woman become\\r\\n             pregnant or suspect that she is pregnant while participating on the trial, she should\\r\\n             inform her treating physician immediately\\r\\n\\r\\n          -  DONOR ELIGIBILITY: Donor evaluation and eligibility will be assessed as per current\\r\\n             City of Hope standard operating procedure (SOP)\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Prior autologous or allogeneic hematopoietic stem cell\\r\\n\\r\\n          -  Prior radiation therapy that would exclude the use of TMLI\\r\\n\\r\\n          -  Plans during the trial to receive any other (non-trial) investigational agents, or\\r\\n             concurrent biological, chemotherapy, or radiation therapy; (chemotherapy for white\\r\\n             blood count control is permitted)\\r\\n\\r\\n          -  Uncontrolled illness including ongoing or active infection\\r\\n\\r\\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\\r\\n             composition to etoposide\\r\\n\\r\\n          -  Patients with other active malignancies are ineligible for this study, other than\\r\\n             localized malignancies\\r\\n\\r\\n          -  Patients with psychological or medical condition that patient\\'s physician deems\\r\\n             unacceptable to proceed to allogeneic hematopoietic stem cell transplantation\\r\\n\\r\\n          -  Women who are planning to become pregnant or breast feed during the trial\\r\\n\\r\\n          -  Subjects, who in the opinion of the investigator, may not be able to comply with the\\r\\n             safety monitoring requirements of the study\\r\\n      ', metadata={'nctid': 'NCT02094794', 'status': 'recruiting', 'diseases': \"['adult acute myeloid leukemia with 11q23 (mll) abnormalities', 'adult acute myeloid leukemia with del(5q)', 'adult acute myeloid leukemia with inv(16)(p13;q22)', 'adult acute myeloid leukemia with t(15;17)(q22;q12)', 'adult acute myeloid leukemia with t(16;16)(p13;q22)', 'adult acute myeloid leukemia with t(8;21)(q22;q22)', 'recurrent adult acute lymphoblastic leukemia', 'recurrent adult acute myeloid leukemia', 'recurrent childhood acute lymphoblastic leukemia', 'recurrent childhood acute myeloid leukemia']\", 'disease_category': 'leukemia', 'drugs': \"['etoposide', 'cyclophosphamide']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically proven non-small-cell lung cancer (core biopsy required).\\r\\n\\r\\n               -  Squamous or non-squamous histology\\r\\n\\r\\n               -  Diagnostic core biopsy specimens must be reviewed by a faculty pathologist at\\r\\n                  SKCCC or MSKCC\\r\\n\\r\\n               -  Either a formalin fixed paraffin block or a minimum of fifteen 5-micron tissue\\r\\n                  sections (slides) of tumor biopsy sample must be available for biomarker\\r\\n                  evaluation (study pathologist must review for adequacy of sampling). This can be\\r\\n                  obtained from archived tissues, or from a new biopsy if needed.\\r\\n\\r\\n          -  Stage - High risk NSCLC with resection option for potential cure, as assessed by a\\r\\n             faculty surgeon at SKCCC or MSKCC. This may include clinical stage IB (≥4cm), II and\\r\\n             IIIA(see Appendix A). Subjects with N3 nodal involvement are not included.\\r\\n\\r\\n        ECOG performance status 0-1\\r\\n\\r\\n        -Adequate organ function as follows:\\r\\n\\r\\n          -  Leukocytes ≥ 2,000/mm3\\r\\n\\r\\n          -  Absolute neutrophil count (ANC) ≥ 1000/mm3\\r\\n\\r\\n          -  Platelet count ≥ 100,000/mm3\\r\\n\\r\\n          -  Hemoglobin ≥ 9 g/dL\\r\\n\\r\\n          -  Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥40 mL/min (if using the\\r\\n             Cockcroft-Gault formula below):\\r\\n\\r\\n        Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL\\r\\n\\r\\n        Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL\\r\\n\\r\\n          -  Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total\\r\\n             bilirubin < 3.0 mg/dL)\\r\\n\\r\\n          -  AST(SGOT), ALT(SGPT), and alkaline phosphatase ≤ 3 times the upper limit of normal\\r\\n\\r\\n          -  Subjects must have adequate lung function to permit surgical resection determined by\\r\\n             pre-enrollment pulmonary function tests to include DLCO\\r\\n\\r\\n               -  The effects of nivolumab on the developing human fetus are unknown. For this\\r\\n                  reason, women of child-bearing potential (WOCBP) and men must agree to use\\r\\n                  adequate contraception (hormonal or barrier method of birth control; abstinence)\\r\\n                  prior to study entry and for the duration of study participation and for up to 23\\r\\n                  weeks after the last dose of nivolumab. Should a woman become pregnant or suspect\\r\\n                  she is pregnant while she or her partner is participating in this study, she\\r\\n                  should inform her treating physician immediately. Sexually active fertile men\\r\\n                  must use effective barrier birth control if their partners are WOCBP for up to 31\\r\\n                  weeks after the last dose of nivolumab. WOCBP must have a negative serum or urine\\r\\n                  pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within\\r\\n                  two weeks of registration. Women must not be breastfeeding.\\r\\n\\r\\n               -  Patient understands the study regimen, its requirements, risks and discomforts\\r\\n                  and is able and willing to sign the informed consent form. Voluntary signed and\\r\\n                  dated IRB/IEC approved written informed consent form in accordance with\\r\\n                  regulatory and institutional guidelines must be obtained before the performance\\r\\n                  of any protocol related procedures that are not part of normal patient care.\\r\\n                  Subjects must be competent to report AEs, understand the drug dosing schedule and\\r\\n                  use of medications to control AEs.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Subjects are excluded if they have an active, known or suspected autoimmune disease.\\r\\n             Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus,\\r\\n             residual hypothyroidism due to autoimmune condition only requiring hormone\\r\\n             replacement, psoriasis not requiring systemic treatment, or conditions not expected to\\r\\n             recur in the absence of an external trigger.\\r\\n\\r\\n          -  Subjects are excluded if they have a condition requiring systemic treatment with\\r\\n             either corticosteroids (> 10 mg daily prednisone equivalents) or other\\r\\n             immunosuppressive medications within 14 days of study drug administration. Inhaled or\\r\\n             topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents\\r\\n             are permitted in the absence of active autoimmune disease. As there is potential for\\r\\n             hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a\\r\\n             predisposition to hepatoxicity should be used with caution in patients treated with\\r\\n             nivolumab-containing regimen.\\r\\n\\r\\n          -  Administration of chemotherapy or any other cancer therapy in the pre-operative\\r\\n             period.\\r\\n\\r\\n          -  Subjects with active concurrent malignancies are excluded i.e. cancers other than\\r\\n             NSCLC (except non melanoma skin cancers, in situ bladder, gastric, breast, colon or\\r\\n             cervical cancers/dysplasia).\\r\\n\\r\\n          -  Subjects with brain metastasis are excluded from this study, and all patients should\\r\\n             have brain imaging (either MRI brain or CT brain with contrast) prior to enrollment.\\r\\n\\r\\n          -  Subjects with a history of symptomatic interstitial lung disease.\\r\\n\\r\\n          -  Active systemic infection requiring therapy, positive tests for Hepatitis B surface\\r\\n             antigen or Hepatitis C ribonucleic acid (RNA).\\r\\n\\r\\n          -  Known positive history or positive test for Human Immunodeficiency Virus or Acquired\\r\\n             ImmunoDeficiency Syndrome (AIDS).\\r\\n\\r\\n          -  History of allergy to study drug components.\\r\\n\\r\\n          -  Women who are pregnant or nursing.\\r\\n\\r\\n          -  Men with female partners (WOCBP) that are not willing to use contraception.\\r\\n\\r\\n          -  Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or\\r\\n             any other antibody targeting T cell co-regulatory pathways).\\r\\n\\r\\n          -  Underlying medical conditions that, in the Investigator's opinion, will make the\\r\\n             administration of study drug hazardous or obscure the interpretation of toxicity or\\r\\n             adverse events.\\r\\n\\r\\n          -  Prisoners or subjects who are involuntarily incarcerated or compulsorily detained for\\r\\n             treatment of either a psychiatric or physical (e.g. infectious disease) illness.\\r\\n      \", metadata={'nctid': 'NCT02259621', 'status': 'recruiting', 'diseases': \"['non-small cell lung cancer']\", 'disease_category': 'cancer', 'drugs': \"['nivolumab']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed locally advanced gastric (primary endpoint includes proximal\\r\\n             and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral)\\r\\n             adenocarcinomas are eligible for enrolment but will not be included in the primary\\r\\n             analysis\\r\\n\\r\\n          -  Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary\\r\\n             tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)\\r\\n\\r\\n          -  All patients must have diagnostic laparoscopy with diagnostic washings for cytology;\\r\\n             both cytology positive and negative patients are eligible for enrolment, but only\\r\\n             cytology negative patients will be included in the primary analyses; gross peritoneal\\r\\n             disease is not eligible\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1\\r\\n\\r\\n          -  Eligible for surgery with curative intent\\r\\n\\r\\n          -  Absolute neutrophil count (ANC) >= 1250/ul\\r\\n\\r\\n          -  Hemoglobin >= 9 g/dL\\r\\n\\r\\n          -  Platelets >= 100,000/ul\\r\\n\\r\\n          -  Total bilirubin < 1.5 x upper limit of normal\\r\\n\\r\\n          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\\r\\n             transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver\\r\\n             metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver\\r\\n             metastases\\r\\n\\r\\n          -  Creatinine =< 1.5 x upper limit of normal\\r\\n\\r\\n          -  Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor\\r\\n             (RECIST) 1.1 will be allowed\\r\\n\\r\\n          -  Women of child-bearing potential and men must agree to use adequate contraception\\r\\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and for\\r\\n             the duration of study participation, up until 30 days after final study treatment;\\r\\n             should a woman become pregnant or suspect that she is pregnant while participating in\\r\\n             this study, she should inform her treating physician immediately\\r\\n\\r\\n          -  Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3,\\r\\n             subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative\\r\\n             drugs whenever possible, given the potential for drug-drug interactions with\\r\\n             irinotecan\\r\\n\\r\\n          -  Signed informed consent\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Previous or concurrent malignancy, except for adequately treated basal cell or\\r\\n             squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the\\r\\n             patient has been previously treated and the lifetime recurrence risk is less than 30%\\r\\n\\r\\n          -  Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's\\r\\n             disease, ulcerative colitis)\\r\\n\\r\\n          -  Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology\\r\\n             Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)\\r\\n\\r\\n          -  Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0\\r\\n\\r\\n          -  Serious underlying medical or psychiatric illnesses that would, in the opinion of the\\r\\n             treating physician, substantially increase the risk for complications related to\\r\\n             treatment\\r\\n\\r\\n          -  Active uncontrolled bleeding\\r\\n\\r\\n          -  Pregnancy or breastfeeding\\r\\n\\r\\n          -  Major surgery within 4 weeks\\r\\n\\r\\n          -  Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be\\r\\n             allowed and treated as in the *28/*28 dosing group\\r\\n      \", metadata={'nctid': 'NCT02366819', 'status': 'recruiting', 'diseases': \"['esophageal adenocarcinoma', 'gastric adenocarcinoma', 'stage iib gastric cancer', 'stage iiia esophageal adenocarcinoma', 'stage iiia gastric cancer', 'stage iiib esophageal adenocarcinoma', 'stage iiib gastric cancer', 'stage iiic esophageal adenocarcinoma', 'stage iiic gastric cancer']\", 'disease_category': 'cancer', 'drugs': \"['oxaliplatin', 'leucovorin calcium', 'irinotecan hydrochloride', 'fluorouracil']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma\\r\\n             (Islet cell neoplasms or neuroendocrine carcinomas are excluded)\\r\\n\\r\\n          2. ≥ 18 years of age at the time of signing the informed consent document\\r\\n\\r\\n          3. ECOG 0-1\\r\\n\\r\\n          4. At least one measurable lesion according to recist v1.1\\r\\n\\r\\n          5. No prior palliative chemotherapy for the treatment of metastatic pancreatic cancer\\r\\n             (Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in\\r\\n             the adjuvant setting is allowed if the treatment had been received at least 6 months\\r\\n             before enroll).\\r\\n\\r\\n          6. Adequate BM function: ANC ≥1.5 × 109/L; Platelet count ≥100,000/mm2 (100 × 109/L); Hb\\r\\n             (Hb) ≥9 g/dL.\\r\\n\\r\\n          7. Adequate liver and renal function (obtained ≤14 days prior to enroll): AST (SGOT), ALT\\r\\n             (SGPT) ≤2.5 × upper limit of normal range (ULN), unless liver metastases are clearly\\r\\n             present, then ≤5 × ULN is allowed; Total bilirubin 1.5 ≤ ULN; Serum creatinine within\\r\\n             normal limits or calculated clearance ≥ 60 mL/min/1.73 m2\\r\\n\\r\\n          8. Albumin level ≥ 3 g/dl\\r\\n\\r\\n          9. Subjects should be asymptomatic for jaundice prior to Cycle 1 Day 1\\r\\n\\r\\n         10. Subject with signed the Informed Consent Form (ICF) prior to participation in any\\r\\n             study-related activities.\\r\\n\\r\\n         11. Female of childbearing potential (FCBP) (defined as a sexually mature woman who (1)\\r\\n             has not undergone hysterectomy [the surgical removal of the uterus] or bilateral\\r\\n             oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally\\r\\n             postmenopausal for at least 24 consecutive months [ie, has had menses at any time\\r\\n             during the preceding 24 consecutive months]) must:\\r\\n\\r\\n               -  Either commit to true abstinence or agree to the use of 2 physician-approved\\r\\n                  contraceptive methods (oral, injectable, or implantable hormonal contraceptive;\\r\\n                  tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or\\r\\n                  vasectomized partner) while on IP; and for 3 months following the last dose of\\r\\n                  IP; and\\r\\n\\r\\n               -  Has a negative serum pregnancy test (β-hCG) result at screening\\r\\n\\r\\n         12. Male subjects must practice true abstinence or agree to use a condom during sexual\\r\\n             contact with a pregnant female or a female of childbearing potential while\\r\\n             participating in the study, during dose interruptions, and for 6 months following IP\\r\\n             discontinuation, even if he has undergone a successful vasectomy\\r\\n\\r\\n         13. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Subject has known symptomatic brain metastases.\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Breast-feeding or pregnant female\\r\\n\\r\\n          4. Patients with plastic biliary stent (Metal biliary stents are allowed.)\\r\\n\\r\\n          5. Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring\\r\\n             systemic therapy.\\r\\n\\r\\n          6. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          7. Subject has undergone major surgery within 4 weeks prior to Cycle 1 Day 1 of treatment\\r\\n             in this study.\\r\\n\\r\\n          8. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n\\r\\n          9. Subject has a history of allergy or hypersensitivity to any of the study drugs\\r\\n\\r\\n         10. Subjects with history of connective tissue disorders (eg, lupus, scleroderma,\\r\\n             arteritis nodosa).\\r\\n\\r\\n         11. Subjects with a history of interstitial lung disease\\r\\n\\r\\n         12. Any other malignancy within 5 years prior to enrollment, with the exception of\\r\\n             adequately treated in-situ carcinoma of the prostate (Gleason score ≤ 7), cervix,\\r\\n             uteri, or nonmelanomatous skin cancer (all treatment of which should have been\\r\\n             completed 6 months prior to enrollment).\\r\\n\\r\\n         13. Patients has > Grade 1 pre-existing peripheral neuropathy (per CTCAE)\\r\\n\\r\\n         14. Subject has serious medical risk factors involving any of the major organ systems, or\\r\\n             serious psychiatric disorders, which could compromise the subject's safety or the\\r\\n             study data integrity.\\r\\n\\r\\n         15. Subject is enrolled in any other clinical protocol or investigational trial with an\\r\\n             interventional agent or assessments that may interfere with study procedures.\\r\\n\\r\\n         16. Subject is unwilling or unable to comply with study procedures\\r\\n\\r\\n         17. Any significant medical condition, laboratory abnormality, or psychiatric illness that\\r\\n             would prevent the subject from participating in the study.\\r\\n      \", metadata={'nctid': 'NCT02426281', 'status': 'recruiting', 'diseases': \"['pancreatic ductal adenocarcinoma']\", 'disease_category': 'cancer', 'drugs': \"['nab-paclitaxel', 'gemcitabine']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'nctid': 'NCT02588781', 'status': 'recruiting', 'diseases': \"['colorectal cancer']\", 'disease_category': 'cancer', 'drugs': \"['pemetrexed']\"}),\n",
       " Document(page_content=\"\\n        Main Inclusion Criteria:\\r\\n\\r\\n          1. Histology:\\r\\n\\r\\n               -  Phase Ib : Patient with histologically confirmed solid tumor\\r\\n\\r\\n               -  Phase II :\\r\\n\\r\\n                    -  Patients with histologically confirmed HER2 negative breast cancer\\r\\n                       (treatment by CP+JX-594), or triple negative (treatment by avelumab +\\r\\n                       CP+JX-594)\\r\\n\\r\\n                    -  Patients with histologically confirmed soft tissue sarcoma confirmed by the\\r\\n                       RRePS Network, b)Progressive disease or relapse, after standard therapy\\r\\n                       according to RECIST v1.1 criteria diagnosed on the basis of two CT scan or\\r\\n                       MRI obtained at an interval less than 6 months in the period of 12 months\\r\\n                       prior to inclusion and confirmed by central review\\r\\n\\r\\n          2. Metastatic or unresectable locally advanced disease\\r\\n\\r\\n          3. Age ≥ 18 years\\r\\n\\r\\n          4. ECOG ≤ 1 (Phase Ib), ≤ 2 (Phase II JX+CP) and ≤ 1 (Phase II avelumab+JX+CP).\\r\\n\\r\\n          5. Life expectancy > 3 months,\\r\\n\\r\\n          6. Measurable disease according to RECIST v1.1 outside any previously irradiated field.\\r\\n             For patients treated by avelumab+JX+CP, at least one injectable site ≥ 2 cm and ≤ 8 cm\\r\\n             in diameter and one distant non-injected measurable site (target site)\\r\\n\\r\\n          7. At least three weeks since last chemotherapy, immunotherapy or any other\\r\\n             pharmacological treatment and/or radiotherapy.\\r\\n\\r\\n          8. Adequate hematological, renal, metabolic and hepatic functions.\\r\\n\\r\\n          9. Women of childbearing potential must have a negative serum pregnancy test before study\\r\\n             entry. Both women and men must agree to use a medically acceptable method of\\r\\n             contraception throughout the treatment period and for six months after discontinuation\\r\\n             of treatment.\\r\\n\\r\\n         10. Patients informed of risks regarding drug interactions: patients receiving any\\r\\n             substances that are inhibitors or inducers of CYP450 2B6 are ineligible\\r\\n\\r\\n         11. Voluntarily signed and dated written informed consent prior to any study specific\\r\\n             procedure.\\r\\n\\r\\n         12. Patients with a social security in compliance with the French law.\\r\\n\\r\\n        Main Exclusion Criteria:\\r\\n\\r\\n          1. Previous treatment with JX-594 or other vaccina vector based treatment or with\\r\\n             PD1/PDL1 antagonist for treatment by avelumab.\\r\\n\\r\\n          2. Concomitant diseases/conditions (non exhaustive list):\\r\\n\\r\\n               1. Clinically significant immunodeficiency, such as HIV or active Hepatite B or C\\r\\n\\r\\n               2. Any other major illness that, in the Investigator's judgment, will substantially\\r\\n                  increase the risk associated with the patient's participation in this study.\\r\\n\\r\\n               3. History of severe exfoliative skins condition requiring systemic treatment for\\r\\n                  more than 4 weeks in the last two years.\\r\\n\\r\\n               4. active autoimmune disease for patients treated by avelumab\\r\\n\\r\\n          3. Active central nervous system metastasis (CNS)\\r\\n\\r\\n          4. Participation to a study involving a medical or therapeutic intervention in the last\\r\\n             30 days.\\r\\n\\r\\n          5. Previous enrolment in the present study.\\r\\n\\r\\n          6. Patient unable to follow and comply with the study procedures because of any\\r\\n             geographical, social or psychological reasons.\\r\\n\\r\\n          7. Known hypersensitivity to any involved study drug or any of its formulation\\r\\n             components.\\r\\n\\r\\n          8. Use of steroids (any route of administration), interferon/pegylated interferon or\\r\\n             ribavirin that cannot be discontinued within 14 days prior to any JX-594 dose.\\r\\n\\r\\n          9. No prior malignancy except for the following: adequately treated basal or squamous\\r\\n             cell skin cancer, in situ cervical cancer, adequately treated Stage 1 or Stage 2\\r\\n             cancer from which the patient is currently in complete remission or any other cancer\\r\\n             from which the patient has been disease-free for 3 years.\\r\\n\\r\\n         10. Active cardiovascular disease, including but not limited to significant coronary\\r\\n             artery disease (e.g. requiring angioplasty or stenting) or congestive heart failure\\r\\n             within the preceding 12 months. (treatment by CP+JX)\\r\\n\\r\\n         11. Inability to suspend treatment with anti-hypertensive medication for 48 hours prior to\\r\\n             and 48 hours after all JX-594 treatments.\\r\\n\\r\\n         12. Pulse oximetry O2 saturation < 90% at rest on room air.\\r\\n\\r\\n         13. Experienced a severe systemic reaction or side-effect as result of previous smallpox\\r\\n             vaccination.\\r\\n\\r\\n         14. Cardiac disease: LVEF out of normal limits ; cumulative dose of anthracyclines in\\r\\n             excess of 450 mg/m²\\r\\n\\r\\n         15. Known urinary tract obstruction\\r\\n\\r\\n         16. Household contact exclusions for patients enrolled: children< 1 year old ; People with\\r\\n             skin disease (e.g., eczema, atopic dermatitis and related diseases…),\\r\\n             Immunocompromised hosts (severe deficiencies in cell-mediated immunity, including\\r\\n             AIDS, organ transplant recipients, hematologic malignancies)\\r\\n\\r\\n         17. Vaccination within 4 weeks of the first dose of study treatment and while on trial is\\r\\n             prohibited except for administration of inactivated vaccines.\\r\\n      \", metadata={'nctid': 'NCT02630368', 'status': 'recruiting', 'diseases': \"['solid tumors', 'soft-tissue sarcoma', 'breast cancer']\", 'disease_category': 'cancer', 'drugs': \"['cyclophosphamide and jx-594 dose escalation', 'cyclophosphamide and jx-594', 'cyclophosphamide', 'avelumab and jx-594 and cyclophosphamide']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Cytologically or histologically confirmed esophageal carcinoma;\\r\\n\\r\\n          2. ECOG performance status: 0-1;\\r\\n\\r\\n          3. No treatments prior to enrollment;\\r\\n\\r\\n          4. At least one measurable lesion on CT, MRI or esophageal barium exam;\\r\\n\\r\\n          5. Normal functions of heart, lung, liver, kidney and bone marrow;\\r\\n\\r\\n          6. Blood exams qualified for chemotherapy, which included hemoglobulin ≥9 g/dl,\\r\\n             neutrophil ≥1.5×109/L and platelet (PLT) ≥100×109/L, creatinine ≤1.5 UNL;\\r\\n\\r\\n          7. Informed consent signed.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Prior treatments of chemotherapy or irradiation;\\r\\n\\r\\n          2. Poor bone marrow, liver and kidney functions, which would make chemotherapy\\r\\n             intolerable;\\r\\n\\r\\n          3. Contraindication for irradiation: complete obstruction of esophagus, deep esophageal\\r\\n             ulcer, fistula to mediastinum, or haematemesis;\\r\\n\\r\\n          4. Participating in other clinical trials;\\r\\n\\r\\n          5. Clinically significant and uncontrolled major medical conditions including but not\\r\\n             limited to: active uncontrolled infection, symptomatic congestive heart failure,\\r\\n             Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation\\r\\n             that would limit compliance with study requirements; any medical condition, which in\\r\\n             the opinion of the study investigator places the subject at an unacceptably high risk\\r\\n             for toxicities;\\r\\n\\r\\n          6. The subject has had another active malignancy within the past five years except for\\r\\n             cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of\\r\\n             the skin.\\r\\n      ', metadata={'nctid': 'NCT02716688', 'status': 'recruiting', 'diseases': \"['esophageal cancer', 's-1', 'radiotherapy']\", 'disease_category': 'cancer', 'drugs': \"['s-1']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'nctid': 'NCT02737787', 'status': 'recruiting', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'disease_category': 'cancer', 'drugs': \"['nivolumab']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'nctid': 'NCT02887313', 'status': 'recruiting', 'diseases': \"['rectal cancer']\", 'disease_category': 'cancer', 'drugs': \"['mfolfox6']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Able to understand and comply with the study procedures, understand the risks involved\\r\\n             in the study, and provide written informed consent before the first study-specific\\r\\n             procedure; specifically able to comply with the PK assessment schedule during the\\r\\n             first 2 treatment cycles.\\r\\n\\r\\n          2. Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or\\r\\n             European Medicines Agency (EMA) approved indications:\\r\\n\\r\\n               1. In North America: Participants with MDS previously treated or untreated with de\\r\\n                  novo or secondary MDS, including all French-American-British subtypes (refractory\\r\\n                  anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess\\r\\n                  blasts, refractory anemia with excess blasts in transformation, and chronic\\r\\n                  myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic\\r\\n                  Scoring System (IPSS) int-1, -2, or high-risk MDS.\\r\\n\\r\\n               2. In Europe: Participants with de novo or secondary AML, as defined by the World\\r\\n                  Health Organization (WHO) criteria, who are not candidates for standard induction\\r\\n                  chemotherapy.\\r\\n\\r\\n          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\\r\\n\\r\\n          4. Adequate organ function defined as follows:\\r\\n\\r\\n               1. Hepatic: Total or direct bilirubin ≤2 × upper limit of normal (ULN); aspartate\\r\\n                  transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine\\r\\n                  transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤2.5 × ULN.\\r\\n\\r\\n               2. Renal: serum creatinine ≤1.5 × ULN or calculated creatinine clearance or\\r\\n                  glomerular filtration rate >50 mL/min/1.73 m2 for subjects with creatinine levels\\r\\n                  above institutional normal.\\r\\n\\r\\n          5. No major surgery within 30 days of first study treatment.\\r\\n\\r\\n          6. Life expectancy of at least 3 months.\\r\\n\\r\\n          7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a\\r\\n             negative pregnancy test at screening. Women of non-childbearing potential are those\\r\\n             who have had a hysterectomy or bilateral oophorectomy, or who have completed\\r\\n             menopause, defined as no menses for at least 1 year AND either age ≥65 years or\\r\\n             follicle-stimulating hormone levels in the menopausal range.\\r\\n\\r\\n          8. Subjects and their partners with reproductive potential must agree to use effective\\r\\n             contraceptive measures during the study and for 3 months after the last dose of study\\r\\n             treatment. Effective contraception includes methods such as oral contraceptives or\\r\\n             double-barrier method (eg, use of a condom AND diaphragm, with spermicide).\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic\\r\\n             chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC)\\r\\n             counts.\\r\\n\\r\\n          2. Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia,\\r\\n             sepsis, or systemic infection in the 30 days before screening.\\r\\n\\r\\n          3. Treatment with any investigational drug or therapy within 2 weeks of study treatment,\\r\\n             or 5 half-lives, whichever is longer, before the first dose of study treatment, or\\r\\n             ongoing clinically significant adverse events (AEs) from previous treatment.\\r\\n\\r\\n          4. Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose\\r\\n             of study treatment.\\r\\n\\r\\n          5. Concurrent MDS therapies, including lenalidomide, erythropoietin,\\r\\n             cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF),\\r\\n             granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these\\r\\n             agents is permitted, provided that completion is at least 1 week before the first dose\\r\\n             of study treatment.)\\r\\n\\r\\n          6. Poor medical risk because of other conditions such as uncontrolled systemic diseases,\\r\\n             active uncontrolled infections, or comorbidities that may put the patient at risk of\\r\\n             not being able to complete at least 2 cycles of treatment.\\r\\n\\r\\n          7. Known significant mental illness or other condition, such as active alcohol or other\\r\\n             substance abuse or addiction, that in the opinion of the investigator predisposes the\\r\\n             subject to high risk of noncompliance with the protocol.\\r\\n\\r\\n          8. Rapidly progressive or highly proliferative disease (total white blood cell count of\\r\\n             >15 × 10^9/L) or other criteria that render the subject at high risk of requiring\\r\\n             intensive cytotoxic chemotherapy within the next 3 months.\\r\\n\\r\\n          9. Life-threatening illness or severe organ system dysfunction, such as uncontrolled\\r\\n             congestive heart failure or chronic obstructive pulmonary disease, or other reasons\\r\\n             including laboratory abnormalities, which, in the investigator's opinion, could\\r\\n             compromise the subject's safety, interfere with the absorption or metabolism of\\r\\n             ASTX727, or compromise completion of the study or integrity of the study outcomes.\\r\\n\\r\\n         10. Prior malignancy, except for adequately treated basal cell or squamous cell skin\\r\\n             cancer, in situ cervical cancer, prostate cancer or breast cancer under control with\\r\\n             hormone therapy, or other cancer from which the subject has been disease free for at\\r\\n             least 2 years.\\r\\n      \", metadata={'nctid': 'NCT03306264', 'status': 'recruiting', 'diseases': \"['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\", 'disease_category': 'leukemia', 'drugs': \"['astx727', 'dacogen']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Patients must have biopsy proven metastatic NSCLC (Stage IV).\\r\\n\\r\\n          2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved\\r\\n             stable disease or a partial response.\\r\\n\\r\\n          3. Patients receiving first-line erlotinib, gefitinib, or icotinib for EGFR\\r\\n             mutant-positive for 3 months and achieved stable disease, partial response or\\r\\n             completely response.\\r\\n\\r\\n          4. Age 18 to 75 years old.\\r\\n\\r\\n          5. Patients must have measurable disease at baseline.\\r\\n\\r\\n          6. The amount of metastatic focus <5.\\r\\n\\r\\n          7. ECOG score 0-2\\r\\n\\r\\n          8. Adequate normal organ and marrow function for TKI treatment and radiotherapy.\\r\\n\\r\\n          9. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R)\\r\\n\\r\\n         10. Patients must provide written informed consent to participate in the study.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Patients who previously received radiotherapy to the primary site.\\r\\n\\r\\n          2. Patient can't tolerate radiotherapy or targeted therapy;\\r\\n\\r\\n          3. Pregnant or nursing women\\r\\n      \", metadata={'nctid': 'NCT03595644', 'status': 'recruiting', 'diseases': \"['stage iv non-small cell lung cancer']\", 'disease_category': 'cancer', 'drugs': \"['tki']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients of both sexes\\r\\n\\r\\n          -  Eighteen years of age and older\\r\\n\\r\\n          -  Clinical diagnosis of Generalized Anxiety Disorder\\r\\n\\r\\n          -  Eighteen points or more on Hamilton Anxiety Scale\\r\\n\\r\\n          -  Without previous treatment for this disease (for at least one month before).\\r\\n\\r\\n          -  In case of being women of reproductive age, who are not pregnant or lactating.\\r\\n\\r\\n          -  To sign an informed consent letter of participation in the investigation.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Patients who have treatment for their condition\\r\\n\\r\\n          -  Patients who have another mental disorder added\\r\\n\\r\\n          -  Patients with alcoholism, smoking or drug addiction\\r\\n\\r\\n          -  Patients who live alone\\r\\n\\r\\n          -  Ingest of drugs for insomnia\\r\\n\\r\\n          -  Ingest of drugs of the Monoamine Oxidase Inhibitors group\\r\\n\\r\\n          -  Patients with epilepsy\\r\\n\\r\\n          -  Patients who operate dangerous machinery\\r\\n\\r\\n          -  Patients who have to drive at work (car, truck or other motor vehicle) for a long\\r\\n             time.\\r\\n      ', metadata={'nctid': 'NCT03702803', 'status': 'recruiting', 'diseases': \"['generalized anxiety disorder']\", 'disease_category': 'mental_health', 'drugs': \"['alprazolam 1mg']\"})]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# from langchain.document_loaders import CSVLoader\n",
    "# file = '../../data/trials_data.csv'\n",
    "# df_trials = pd.read_csv(file)\n",
    "from helper_functions import disease_map\n",
    "\n",
    "vstore_delete = False\n",
    "\n",
    "trial_docs = []\n",
    "for i, row in df_trials.iterrows():\n",
    "    disease = disease_map(row['diseases'])\n",
    "    if disease == 'other_conditions':\n",
    "        continue\n",
    "    doc = Document(\n",
    "        page_content=row['criteria'],\n",
    "        metadata={\n",
    "            \"nctid\": row['nctid'],\n",
    "            \"status\": row['status'],\n",
    "            # \"why_stop\": row['why_stop'],\n",
    "            # \"label\": row['label'],\n",
    "            # \"phase\": row['phase'],\n",
    "            \"diseases\": str(row['diseases']),\n",
    "            \"disease_category\": disease[0],\n",
    "            \"drugs\": row['drugs'],            \n",
    "        }\n",
    "    )\n",
    "    trial_docs.append(doc)\n",
    "# trial_docs\n",
    "\n",
    "print(trial_docs[0].metadata)\n",
    "\n",
    "list_remove = set()\n",
    "for i, doc in enumerate(trial_docs):\n",
    "    if len(doc.page_content)>10000:\n",
    "        list_remove.add(i)\n",
    "        # print(doc.metadata)\n",
    "    if doc.metadata['disease_category'] == 'other_conditions':\n",
    "        list_remove.add(i)\n",
    "        # print(doc.metadata)\n",
    "# remove list_remove indexes from trial_docs\n",
    "trial_docs = [doc for i, doc in enumerate(trial_docs) if i not in list_remove]\n",
    "\n",
    "# print(len(trial_docs[11].page_content))\n",
    "# trial_docs.pop(11)\n",
    "\n",
    "persistent_client = chromadb.PersistentClient(path = chromadb_path)\n",
    "\n",
    "\n",
    "if vstore_delete == True:\n",
    "    vectorstore_trials.delete_collection()\n",
    "    trials_vstore_created = False\n",
    "    vstore_delete = False\n",
    "    print(\"vstore deleted\")\n",
    "\n",
    "# if chromadb_path exists\n",
    "# if trials_vstore_created:\n",
    "\n",
    "vectorstore_trials = Chroma(\n",
    "    client=persistent_client,\n",
    "    collection_name=trial_collection,\n",
    "    embedding_function=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                            inference_mode='local'),\n",
    ")\n",
    "if vectorstore_trials._collection.count() == 0:\n",
    "    vectorstore_trials = Chroma.from_documents(\n",
    "        documents=trial_docs,\n",
    "        client=persistent_client,\n",
    "        collection_name=trial_collection,\n",
    "        # persist_directory=chromadb_path,\n",
    "        embedding=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                                inference_mode='local'),\n",
    "    )\n",
    "    trials_vstore_created = True\n",
    "    print(\"Vectorstore is created now\")\n",
    "else:\n",
    "    print(\"Loading the vectorstore from persistent client\")\n",
    "\n",
    "print(vectorstore_trials._collection.count())\n",
    "trial_docs\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retriever Trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains.query_constructor.base import AttributeInfo\n",
    "from langchain.retrievers.self_query.base import SelfQueryRetriever\n",
    "\n",
    "metadata_field_info = [\n",
    "    AttributeInfo(\n",
    "        name=\"disease_category\",\n",
    "        description=\"Defines the disease group of patients related to this trial. One of ['cancer', 'leukemia', 'mental_health']\",\n",
    "        # description=\"The trial is for patients when their disease is related to this category. One of ['cancer', 'leukemia', 'mental_health']\",\n",
    "        type=\"string\",\n",
    "    ),\n",
    "    AttributeInfo(\n",
    "        name=\"drugs\",\n",
    "        description=\"List of drug names used in the trial\",\n",
    "        type=\"str\",\n",
    "    ),    \n",
    "]\n",
    "\n",
    "document_content_description = \"The list of patient conditions to include or exclude them from the trial\"\n",
    "retriever_trial_sq = SelfQueryRetriever.from_llm(\n",
    "    model,\n",
    "    vectorstore_trials,\n",
    "    # vectorstore_trials_mpnet,\n",
    "    document_content_description,\n",
    "    metadata_field_info\n",
    "    # enable_limit=True\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "6\n",
      "cancer ['prostate cancer']\n",
      "cancer ['metastatic pancreatic cancer']\n",
      "cancer ['rectal cancer']\n",
      "cancer ['colorectal cancer']\n",
      "cancer ['pancreatic ductal adenocarcinoma']\n",
      "cancer ['stage iv non-small cell lung cancer']\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\\r\\n             previously treated with docetaxel-based therapy and has progressed during treatment of\\r\\n             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\\r\\n\\r\\n          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\\r\\n             or radiographic evidence of disease progression in soft tissue or bone\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\\r\\n\\r\\n          -  Adequate hematologic and organ function\\r\\n\\r\\n          -  Documented willingness to use an effective means of contraception\\r\\n\\r\\n          -  Safety cohort only: agreement to use CGM for first cycle of treatment\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\\r\\n             patients who are receiving any pharmacologic treatment for diabetes are not eligible\\r\\n\\r\\n          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\\r\\n             fraction < 50% or ventricular arrhythmia requiring medication\\r\\n\\r\\n          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\\r\\n             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\\r\\n             within 6 months prior to Day 1\\r\\n\\r\\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\\r\\n             drugs or active inflammatory disease which requires immunosuppressive therapy\\r\\n\\r\\n          -  Clinically significant history of liver disease\\r\\n\\r\\n          -  History of adrenal insufficiency or hyperaldosteronism\\r\\n\\r\\n          -  Phase II only: Previous therapy for prostate cancer with 17\\r\\n             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\\r\\n\\r\\n          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\\r\\n             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\\r\\n\\r\\n          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\\r\\n             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['prostate cancer']\", 'drugs': \"['abiraterone', 'apitolisib', 'ipatasertib', 'placebo', 'prednisone', 'prednisolone']\", 'nctid': 'NCT01485861', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['metastatic pancreatic cancer']\", 'drugs': \"['mfolfirinox']\", 'nctid': 'NCT02028806', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['rectal cancer']\", 'drugs': \"['mfolfox6']\", 'nctid': 'NCT02887313', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma\\r\\n             (Islet cell neoplasms or neuroendocrine carcinomas are excluded)\\r\\n\\r\\n          2. ≥ 18 years of age at the time of signing the informed consent document\\r\\n\\r\\n          3. ECOG 0-1\\r\\n\\r\\n          4. At least one measurable lesion according to recist v1.1\\r\\n\\r\\n          5. No prior palliative chemotherapy for the treatment of metastatic pancreatic cancer\\r\\n             (Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in\\r\\n             the adjuvant setting is allowed if the treatment had been received at least 6 months\\r\\n             before enroll).\\r\\n\\r\\n          6. Adequate BM function: ANC ≥1.5 × 109/L; Platelet count ≥100,000/mm2 (100 × 109/L); Hb\\r\\n             (Hb) ≥9 g/dL.\\r\\n\\r\\n          7. Adequate liver and renal function (obtained ≤14 days prior to enroll): AST (SGOT), ALT\\r\\n             (SGPT) ≤2.5 × upper limit of normal range (ULN), unless liver metastases are clearly\\r\\n             present, then ≤5 × ULN is allowed; Total bilirubin 1.5 ≤ ULN; Serum creatinine within\\r\\n             normal limits or calculated clearance ≥ 60 mL/min/1.73 m2\\r\\n\\r\\n          8. Albumin level ≥ 3 g/dl\\r\\n\\r\\n          9. Subjects should be asymptomatic for jaundice prior to Cycle 1 Day 1\\r\\n\\r\\n         10. Subject with signed the Informed Consent Form (ICF) prior to participation in any\\r\\n             study-related activities.\\r\\n\\r\\n         11. Female of childbearing potential (FCBP) (defined as a sexually mature woman who (1)\\r\\n             has not undergone hysterectomy [the surgical removal of the uterus] or bilateral\\r\\n             oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally\\r\\n             postmenopausal for at least 24 consecutive months [ie, has had menses at any time\\r\\n             during the preceding 24 consecutive months]) must:\\r\\n\\r\\n               -  Either commit to true abstinence or agree to the use of 2 physician-approved\\r\\n                  contraceptive methods (oral, injectable, or implantable hormonal contraceptive;\\r\\n                  tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or\\r\\n                  vasectomized partner) while on IP; and for 3 months following the last dose of\\r\\n                  IP; and\\r\\n\\r\\n               -  Has a negative serum pregnancy test (β-hCG) result at screening\\r\\n\\r\\n         12. Male subjects must practice true abstinence or agree to use a condom during sexual\\r\\n             contact with a pregnant female or a female of childbearing potential while\\r\\n             participating in the study, during dose interruptions, and for 6 months following IP\\r\\n             discontinuation, even if he has undergone a successful vasectomy\\r\\n\\r\\n         13. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Subject has known symptomatic brain metastases.\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Breast-feeding or pregnant female\\r\\n\\r\\n          4. Patients with plastic biliary stent (Metal biliary stents are allowed.)\\r\\n\\r\\n          5. Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring\\r\\n             systemic therapy.\\r\\n\\r\\n          6. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          7. Subject has undergone major surgery within 4 weeks prior to Cycle 1 Day 1 of treatment\\r\\n             in this study.\\r\\n\\r\\n          8. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n\\r\\n          9. Subject has a history of allergy or hypersensitivity to any of the study drugs\\r\\n\\r\\n         10. Subjects with history of connective tissue disorders (eg, lupus, scleroderma,\\r\\n             arteritis nodosa).\\r\\n\\r\\n         11. Subjects with a history of interstitial lung disease\\r\\n\\r\\n         12. Any other malignancy within 5 years prior to enrollment, with the exception of\\r\\n             adequately treated in-situ carcinoma of the prostate (Gleason score ≤ 7), cervix,\\r\\n             uteri, or nonmelanomatous skin cancer (all treatment of which should have been\\r\\n             completed 6 months prior to enrollment).\\r\\n\\r\\n         13. Patients has > Grade 1 pre-existing peripheral neuropathy (per CTCAE)\\r\\n\\r\\n         14. Subject has serious medical risk factors involving any of the major organ systems, or\\r\\n             serious psychiatric disorders, which could compromise the subject's safety or the\\r\\n             study data integrity.\\r\\n\\r\\n         15. Subject is enrolled in any other clinical protocol or investigational trial with an\\r\\n             interventional agent or assessments that may interfere with study procedures.\\r\\n\\r\\n         16. Subject is unwilling or unable to comply with study procedures\\r\\n\\r\\n         17. Any significant medical condition, laboratory abnormality, or psychiatric illness that\\r\\n             would prevent the subject from participating in the study.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['pancreatic ductal adenocarcinoma']\", 'drugs': \"['nab-paclitaxel', 'gemcitabine']\", 'nctid': 'NCT02426281', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Patients must have biopsy proven metastatic NSCLC (Stage IV).\\r\\n\\r\\n          2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved\\r\\n             stable disease or a partial response.\\r\\n\\r\\n          3. Patients receiving first-line erlotinib, gefitinib, or icotinib for EGFR\\r\\n             mutant-positive for 3 months and achieved stable disease, partial response or\\r\\n             completely response.\\r\\n\\r\\n          4. Age 18 to 75 years old.\\r\\n\\r\\n          5. Patients must have measurable disease at baseline.\\r\\n\\r\\n          6. The amount of metastatic focus <5.\\r\\n\\r\\n          7. ECOG score 0-2\\r\\n\\r\\n          8. Adequate normal organ and marrow function for TKI treatment and radiotherapy.\\r\\n\\r\\n          9. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R)\\r\\n\\r\\n         10. Patients must provide written informed consent to participate in the study.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Patients who previously received radiotherapy to the primary site.\\r\\n\\r\\n          2. Patient can't tolerate radiotherapy or targeted therapy;\\r\\n\\r\\n          3. Pregnant or nursing women\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['stage iv non-small cell lung cancer']\", 'drugs': \"['tki']\", 'nctid': 'NCT03595644', 'status': 'recruiting'})]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever_trials = vectorstore_trials.as_retriever(search_kwargs={\"k\": n_retrieved_trials})\n",
    "# question = trial_docs[trail_smp].page_content\n",
    "question = \"\"\"\n",
    "Which trials are relevant to patient who has adenocarcinoma illness?\n",
    "\"\"\"\n",
    "\n",
    "# question = f\"\"\"\n",
    "# Which trials are relevant to the patient with the following medical history?\\n\n",
    "# patient_profile: {patient_profile}\n",
    "# \"\"\"\n",
    "# nprint(question)\n",
    "\n",
    "# Which four trials are for patients with mental problem?\n",
    "# print(trial_docs[trail_smp].metadata['nctid'])\n",
    "# question = \"Inclusion Criteria:\\r\\n\\r\\n          1. Subject\"\n",
    "docs_retrieved = retriever_trials.get_relevant_documents(question)\n",
    "# docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "print(len(docs_retrieved))\n",
    "doc_txt = docs_retrieved[0].page_content[:]\n",
    "nctid = docs_retrieved[0].metadata['nctid']\n",
    "for doc in docs_retrieved:\n",
    "    diseases = doc.metadata['diseases']\n",
    "    disease_category = doc.metadata['disease_category']\n",
    "    print(disease_category, diseases)\n",
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Tools:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.tools import tool\n",
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "def get_patient_data(patient_id: int) -> dict:\n",
    "    \"\"\"Fetch all fields for the patient based on the given patient_id as an integer.\n",
    "\n",
    "    Returns:\n",
    "        A dictionary containing the patient's medical history.        \n",
    "    \"\"\"\n",
    "\n",
    "    # config = ensure_config()  # Fetch from the context\n",
    "    # configuration = config.get(\"configurable\", {})\n",
    "    # patient_id = configuration.get(\"patient_id\", None)\n",
    "\n",
    "    # if not patient_id:\n",
    "    #     raise ValueError(\"No patient ID given.\")\n",
    "\n",
    "    conn = sqlite3.connect(db)\n",
    "    cursor = conn.cursor()    \n",
    "    query = 'SELECT * FROM patients WHERE patient_id=?'\n",
    "    cursor.execute(query, (patient_id,))\n",
    "    patient_data = cursor.fetchone()\n",
    "    # rows = cursor.fetchall()\n",
    "    column_names = [column[0] for column in cursor.description]\n",
    "    conn.close()\n",
    "    if patient_data is None:\n",
    "        return None\n",
    "    else:    \n",
    "        results = dict(zip(column_names, patient_data))    \n",
    "    return results\n",
    "\n",
    "\n",
    "def add_patient_data(patient_data: dict):    \n",
    "    \"\"\"Adds a new patient to the SQLite database.\"\"\"\n",
    "    \n",
    "    name = patient_data['name']\n",
    "    age = patient_data['age']\n",
    "    medical_history = patient_data['medical_history']\n",
    "    previous_trials = patient_data['previous_trials']\n",
    "    trial_status = patient_data['trial_status']\n",
    "    last_trial_dates = patient_data['last_trial_dates']\n",
    "\n",
    "    conn = sqlite3.connect(db)\n",
    "    cursor = conn.cursor()\n",
    "    \n",
    "    # Insert the new patient data into the database\n",
    "    cursor.execute('''\n",
    "    INSERT INTO patients (name, age, medical_history, previous_trials, trial_status, last_trial_dates)\n",
    "    VALUES (?, ?, ?, ?, ?, ?)\n",
    "    ''', (name, age, medical_history, previous_trials, trial_status, last_trial_dates))\n",
    "    \n",
    "    conn.commit()\n",
    "    conn.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'patient_id': 4, 'name': 'Daniel Doe', 'age': 44, 'medical_history': 'suicidal ideation', 'previous_trials': 'NCT08404176', 'trial_status': 'Withdrawn', 'trial_completion_date': '2023-07-31'}\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'patient_id': 4,\n",
       " 'name': 'Daniel Doe',\n",
       " 'age': 44,\n",
       " 'medical_history': 'suicidal ideation',\n",
       " 'previous_trials': 'NCT08404176',\n",
       " 'trial_status': 'Withdrawn',\n",
       " 'trial_completion_date': '2023-07-31'}"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample_patient_id = 4\n",
    "patient_data = get_patient_data(sample_patient_id)\n",
    "print(patient_data)\n",
    "patient_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "dummy : profile creator llm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'patient_id': 2,\n",
       " 'name': 'Sophia Thomas',\n",
       " 'age': 56,\n",
       " 'medical_history': 'Obesity',\n",
       " 'previous_trials': None,\n",
       " 'trial_status': None,\n",
       " 'trial_completion_date': None}"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def patient_data_to_string(patient_data):\n",
    "    return \" \\n \".join([f\"{key}: {value}\" for key, value in patient_data.items()])\n",
    "\n",
    "patient_id = 2\n",
    "patient_data = get_patient_data(patient_id)\n",
    "patient_data\n",
    "# keys_to_include = ['age', 'medical_history']\n",
    "# patient_data = {key: patient_data[key] for key in keys_to_include}\n",
    "\n",
    "# patient_medical_history = patient_data_to_string(patient_data)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Profile Creator"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Patient is a 56-year-old with a history of obesity. No previous trials or '\n",
      " 'current trial status. Potential trials for obesity management may be '\n",
      " 'suitable for this patient.')\n"
     ]
    }
   ],
   "source": [
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain.prompts import PromptTemplate\n",
    "parser = StrOutputParser()\n",
    "\n",
    "# def patient_data_to_string(patient_data):\n",
    "    # return \" \\n\".join([f\"{key}: {value}\" for key, value in patient_data.items()])\n",
    "\n",
    "prompt_profile = PromptTemplate(\n",
    "    template=\"\"\"\n",
    "    You are the Clinical Research Coordinator in the screening phase of a clinical trial. \n",
    "    Use the following patient data to write the patient profile for the screening phase.\n",
    "    The patient profile is a summary of patient information.\n",
    "    The patient profile also suggests relevant medical trials based on patient's medical history.\n",
    "    Write the patient profile in 3 to 4 short sentences.\\n\\n\n",
    "    {patient_data}\"\"\",\n",
    "    input_variables=[\"patient_data\"],\n",
    ")\n",
    "# model = ChatOpenAI(temperature = 0.0, model=modelID)\n",
    "\n",
    "chain_profile = prompt_profile | model | parser\n",
    "# keys_to_include = ['age', 'medical_history']\n",
    "# patient_data = {key: patient_data[key] for key in keys_to_include}\n",
    "if patient_data.get('name'):\n",
    "    del patient_data['name']\n",
    "    del patient_data['patient_id']\n",
    "patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "nprint(patient_profile)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('\\n'\n",
      " 'Which trials are relevant to the patient with the following medical '\n",
      " 'history?\\n'\n",
      " '\\n'\n",
      " 'patient_profile: Patient is a 56-year-old with a history of obesity. No '\n",
      " 'previous trials or current trial status. Potential trials for obesity '\n",
      " 'management may be suitable for this patient.\\n')\n",
      "4\n",
      "cancer ['prostate cancer']\n",
      "cancer ['esophageal adenocarcinoma', 'gastric adenocarcinoma', 'stage iib gastric cancer', 'stage iiia esophageal adenocarcinoma', 'stage iiia gastric cancer', 'stage iiib esophageal adenocarcinoma', 'stage iiib gastric cancer', 'stage iiic esophageal adenocarcinoma', 'stage iiic gastric cancer']\n",
      "leukemia ['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\n",
      "cancer ['multiple myeloma']\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\\r\\n             previously treated with docetaxel-based therapy and has progressed during treatment of\\r\\n             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\\r\\n\\r\\n          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\\r\\n             or radiographic evidence of disease progression in soft tissue or bone\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\\r\\n\\r\\n          -  Adequate hematologic and organ function\\r\\n\\r\\n          -  Documented willingness to use an effective means of contraception\\r\\n\\r\\n          -  Safety cohort only: agreement to use CGM for first cycle of treatment\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\\r\\n             patients who are receiving any pharmacologic treatment for diabetes are not eligible\\r\\n\\r\\n          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\\r\\n             fraction < 50% or ventricular arrhythmia requiring medication\\r\\n\\r\\n          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\\r\\n             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\\r\\n             within 6 months prior to Day 1\\r\\n\\r\\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\\r\\n             drugs or active inflammatory disease which requires immunosuppressive therapy\\r\\n\\r\\n          -  Clinically significant history of liver disease\\r\\n\\r\\n          -  History of adrenal insufficiency or hyperaldosteronism\\r\\n\\r\\n          -  Phase II only: Previous therapy for prostate cancer with 17\\r\\n             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\\r\\n\\r\\n          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\\r\\n             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\\r\\n\\r\\n          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\\r\\n             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['prostate cancer']\", 'drugs': \"['abiraterone', 'apitolisib', 'ipatasertib', 'placebo', 'prednisone', 'prednisolone']\", 'nctid': 'NCT01485861', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed locally advanced gastric (primary endpoint includes proximal\\r\\n             and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral)\\r\\n             adenocarcinomas are eligible for enrolment but will not be included in the primary\\r\\n             analysis\\r\\n\\r\\n          -  Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary\\r\\n             tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)\\r\\n\\r\\n          -  All patients must have diagnostic laparoscopy with diagnostic washings for cytology;\\r\\n             both cytology positive and negative patients are eligible for enrolment, but only\\r\\n             cytology negative patients will be included in the primary analyses; gross peritoneal\\r\\n             disease is not eligible\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1\\r\\n\\r\\n          -  Eligible for surgery with curative intent\\r\\n\\r\\n          -  Absolute neutrophil count (ANC) >= 1250/ul\\r\\n\\r\\n          -  Hemoglobin >= 9 g/dL\\r\\n\\r\\n          -  Platelets >= 100,000/ul\\r\\n\\r\\n          -  Total bilirubin < 1.5 x upper limit of normal\\r\\n\\r\\n          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\\r\\n             transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver\\r\\n             metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver\\r\\n             metastases\\r\\n\\r\\n          -  Creatinine =< 1.5 x upper limit of normal\\r\\n\\r\\n          -  Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor\\r\\n             (RECIST) 1.1 will be allowed\\r\\n\\r\\n          -  Women of child-bearing potential and men must agree to use adequate contraception\\r\\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and for\\r\\n             the duration of study participation, up until 30 days after final study treatment;\\r\\n             should a woman become pregnant or suspect that she is pregnant while participating in\\r\\n             this study, she should inform her treating physician immediately\\r\\n\\r\\n          -  Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3,\\r\\n             subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative\\r\\n             drugs whenever possible, given the potential for drug-drug interactions with\\r\\n             irinotecan\\r\\n\\r\\n          -  Signed informed consent\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Previous or concurrent malignancy, except for adequately treated basal cell or\\r\\n             squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the\\r\\n             patient has been previously treated and the lifetime recurrence risk is less than 30%\\r\\n\\r\\n          -  Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's\\r\\n             disease, ulcerative colitis)\\r\\n\\r\\n          -  Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology\\r\\n             Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)\\r\\n\\r\\n          -  Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0\\r\\n\\r\\n          -  Serious underlying medical or psychiatric illnesses that would, in the opinion of the\\r\\n             treating physician, substantially increase the risk for complications related to\\r\\n             treatment\\r\\n\\r\\n          -  Active uncontrolled bleeding\\r\\n\\r\\n          -  Pregnancy or breastfeeding\\r\\n\\r\\n          -  Major surgery within 4 weeks\\r\\n\\r\\n          -  Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be\\r\\n             allowed and treated as in the *28/*28 dosing group\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['esophageal adenocarcinoma', 'gastric adenocarcinoma', 'stage iib gastric cancer', 'stage iiia esophageal adenocarcinoma', 'stage iiia gastric cancer', 'stage iiib esophageal adenocarcinoma', 'stage iiib gastric cancer', 'stage iiic esophageal adenocarcinoma', 'stage iiic gastric cancer']\", 'drugs': \"['oxaliplatin', 'leucovorin calcium', 'irinotecan hydrochloride', 'fluorouracil']\", 'nctid': 'NCT02366819', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Able to understand and comply with the study procedures, understand the risks involved\\r\\n             in the study, and provide written informed consent before the first study-specific\\r\\n             procedure; specifically able to comply with the PK assessment schedule during the\\r\\n             first 2 treatment cycles.\\r\\n\\r\\n          2. Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or\\r\\n             European Medicines Agency (EMA) approved indications:\\r\\n\\r\\n               1. In North America: Participants with MDS previously treated or untreated with de\\r\\n                  novo or secondary MDS, including all French-American-British subtypes (refractory\\r\\n                  anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess\\r\\n                  blasts, refractory anemia with excess blasts in transformation, and chronic\\r\\n                  myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic\\r\\n                  Scoring System (IPSS) int-1, -2, or high-risk MDS.\\r\\n\\r\\n               2. In Europe: Participants with de novo or secondary AML, as defined by the World\\r\\n                  Health Organization (WHO) criteria, who are not candidates for standard induction\\r\\n                  chemotherapy.\\r\\n\\r\\n          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\\r\\n\\r\\n          4. Adequate organ function defined as follows:\\r\\n\\r\\n               1. Hepatic: Total or direct bilirubin ≤2 × upper limit of normal (ULN); aspartate\\r\\n                  transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine\\r\\n                  transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤2.5 × ULN.\\r\\n\\r\\n               2. Renal: serum creatinine ≤1.5 × ULN or calculated creatinine clearance or\\r\\n                  glomerular filtration rate >50 mL/min/1.73 m2 for subjects with creatinine levels\\r\\n                  above institutional normal.\\r\\n\\r\\n          5. No major surgery within 30 days of first study treatment.\\r\\n\\r\\n          6. Life expectancy of at least 3 months.\\r\\n\\r\\n          7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a\\r\\n             negative pregnancy test at screening. Women of non-childbearing potential are those\\r\\n             who have had a hysterectomy or bilateral oophorectomy, or who have completed\\r\\n             menopause, defined as no menses for at least 1 year AND either age ≥65 years or\\r\\n             follicle-stimulating hormone levels in the menopausal range.\\r\\n\\r\\n          8. Subjects and their partners with reproductive potential must agree to use effective\\r\\n             contraceptive measures during the study and for 3 months after the last dose of study\\r\\n             treatment. Effective contraception includes methods such as oral contraceptives or\\r\\n             double-barrier method (eg, use of a condom AND diaphragm, with spermicide).\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic\\r\\n             chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC)\\r\\n             counts.\\r\\n\\r\\n          2. Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia,\\r\\n             sepsis, or systemic infection in the 30 days before screening.\\r\\n\\r\\n          3. Treatment with any investigational drug or therapy within 2 weeks of study treatment,\\r\\n             or 5 half-lives, whichever is longer, before the first dose of study treatment, or\\r\\n             ongoing clinically significant adverse events (AEs) from previous treatment.\\r\\n\\r\\n          4. Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose\\r\\n             of study treatment.\\r\\n\\r\\n          5. Concurrent MDS therapies, including lenalidomide, erythropoietin,\\r\\n             cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF),\\r\\n             granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these\\r\\n             agents is permitted, provided that completion is at least 1 week before the first dose\\r\\n             of study treatment.)\\r\\n\\r\\n          6. Poor medical risk because of other conditions such as uncontrolled systemic diseases,\\r\\n             active uncontrolled infections, or comorbidities that may put the patient at risk of\\r\\n             not being able to complete at least 2 cycles of treatment.\\r\\n\\r\\n          7. Known significant mental illness or other condition, such as active alcohol or other\\r\\n             substance abuse or addiction, that in the opinion of the investigator predisposes the\\r\\n             subject to high risk of noncompliance with the protocol.\\r\\n\\r\\n          8. Rapidly progressive or highly proliferative disease (total white blood cell count of\\r\\n             >15 × 10^9/L) or other criteria that render the subject at high risk of requiring\\r\\n             intensive cytotoxic chemotherapy within the next 3 months.\\r\\n\\r\\n          9. Life-threatening illness or severe organ system dysfunction, such as uncontrolled\\r\\n             congestive heart failure or chronic obstructive pulmonary disease, or other reasons\\r\\n             including laboratory abnormalities, which, in the investigator's opinion, could\\r\\n             compromise the subject's safety, interfere with the absorption or metabolism of\\r\\n             ASTX727, or compromise completion of the study or integrity of the study outcomes.\\r\\n\\r\\n         10. Prior malignancy, except for adequately treated basal cell or squamous cell skin\\r\\n             cancer, in situ cervical cancer, prostate cancer or breast cancer under control with\\r\\n             hormone therapy, or other cancer from which the subject has been disease free for at\\r\\n             least 2 years.\\r\\n      \", metadata={'disease_category': 'leukemia', 'diseases': \"['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\", 'drugs': \"['astx727', 'dacogen']\", 'nctid': 'NCT03306264', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients with a confirmed diagnosis of symptomatic multiple myeloma stage I to III\\r\\n             according to the International Staging System ISS (see appendix A), i.e. at least one\\r\\n             of the CRAB criteria should be present;\\r\\n\\r\\n          -  Measurable disease as defined by the presence of M-protein in serum or urine (serum\\r\\n             M-protein> 10 g/l or urine M-protein > 200 mg/24 hours), or abnormal free light chain\\r\\n             ratio;\\r\\n\\r\\n          -  Age 18-65 years inclusive;\\r\\n\\r\\n          -  WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by\\r\\n             comorbid conditions);\\r\\n\\r\\n          -  Negative pregnancy test at inclusion if applicable;\\r\\n\\r\\n          -  Written informed consent.\\r\\n\\r\\n        Inclusion for randomisation 1:\\r\\n\\r\\n          -  WHO performance 0-2;\\r\\n\\r\\n          -  Bilirubin and transaminases < 2.5 times the upper limit of normal values;\\r\\n\\r\\n          -  A suitable stem cell graft containing at least 4 x 106 CD34+ cells/kg (or according to\\r\\n             national guidelines).\\r\\n\\r\\n        Inclusion for randomisation 2:\\r\\n\\r\\n          -  Bilirubin and transaminases < 2.5 times the upper limit of normal values;\\r\\n\\r\\n          -  ANC >= 0.5 x 109/l and platelets > 20 x 10^9/l;\\r\\n\\r\\n          -  Patient is able to adhere to the requirements of the Lenalidomide Pregnancy Prevention\\r\\n             Risk Management Plan.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Known intolerance of Boron;\\r\\n\\r\\n          -  Systemic AL amyloidosis;\\r\\n\\r\\n          -  Primary Plasmacell Leukemia;\\r\\n\\r\\n          -  Non-secretory MM;\\r\\n\\r\\n          -  Previous chemotherapy or radiotherapy except local radiotherapy in case of local\\r\\n             myeloma progression or corticosteroids maximum 5 days for symptom control;\\r\\n\\r\\n          -  Severe cardiac dysfunction (NYHA classification II-IV);\\r\\n\\r\\n          -  Significant hepatic dysfunction, unless related to myeloma;\\r\\n\\r\\n          -  Patients with GFR <15 ml/min,\\r\\n\\r\\n          -  Patients known to be HIV-positive;\\r\\n\\r\\n          -  Patients with active, uncontrolled infections;\\r\\n\\r\\n          -  Patients with neuropathy, CTC grade 2 or higher;\\r\\n\\r\\n          -  Patients with a history of active malignancy during the past 5 years with the\\r\\n             exception of basal carcinoma of the skin or stage 0 cervical carcinoma;\\r\\n\\r\\n          -  Patients who are not willing or capable to use adequate contraception during the\\r\\n             therapy (all men, all pre-menopausal women);\\r\\n\\r\\n          -  Lactating women.\\r\\n\\r\\n        Exclusion for randomisation 1:\\r\\n\\r\\n          -  Severe pulmonary, neurologic, or psychiatric disease;\\r\\n\\r\\n          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment;\\r\\n\\r\\n          -  Allogeneic Stem Cell Transplantation (Allo SCT) planned;\\r\\n\\r\\n          -  Progressive disease.'\\r\\n\\r\\n        Exclusion for randomisation 2:\\r\\n\\r\\n          -  Progressive disease;\\r\\n\\r\\n          -  Neuropathy, except CTCAE grade 1;\\r\\n\\r\\n          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['multiple myeloma']\", 'drugs': \"['bortezomib, melphalan, prednisone (vmp)', '1 or 2 cycle(s) hdm (high dose melphalan)', '2 cycles of bortezomib, lenalidomide, dexamethasone (vrd)']\", 'nctid': 'NCT01208766', 'status': 'recruiting'})]"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = f\"\"\"\n",
    "Which trials are relevant to the patient with the following medical history?\\n\n",
    "patient_profile: {patient_profile}\n",
    "\"\"\"\n",
    "# patient_profile: {patient_profile}\n",
    "# question = \"\"\"\n",
    "# Which trials are relevant to the patient with the medical history of myeloid leukemia?\n",
    "# \"\"\"\n",
    "nprint(question)\n",
    "\n",
    "# docs_retrieved = retriever_trials.get_relevant_documents(question)\n",
    "docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "print(len(docs_retrieved))\n",
    "doc_txt = docs_retrieved[0].page_content[:]\n",
    "nctid = docs_retrieved[0].metadata['nctid']\n",
    "for doc in docs_retrieved:\n",
    "    diseases = doc.metadata['diseases']\n",
    "    disease_category = doc.metadata['disease_category']\n",
    "    print(disease_category, diseases)\n",
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### profile maker"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Patient Profile:\\n'\n",
      " 'The patient is a 56-year-old with a history of obesity. They have not '\n",
      " 'participated in any previous trials and their trial status and completion '\n",
      " 'date are currently unknown.\\n'\n",
      " '\\n'\n",
      " \"Based on the patient's medical history of obesity, relevant medical trials \"\n",
      " 'may include studies on weight management, obesity treatments, or lifestyle '\n",
      " 'interventions for improving overall health. It is important to consider '\n",
      " 'trials that focus on addressing obesity-related health concerns in this '\n",
      " 'patient population.')\n"
     ]
    }
   ],
   "source": [
    "parser = StrOutputParser()\n",
    "prompt_profile = PromptTemplate(\n",
    "    template=\"\"\"\n",
    "    You are the Clinical Research Coordinator in the screening phase of a clinical trial. \n",
    "    Use the following patient data to write the patient profile for the screening phase.\n",
    "    The patient profile is a summary of patient information.\n",
    "    The patient profile also suggest relevant medical trials based on patient's medical history.\n",
    "    Write the patient profile in 3 to 4 short sentences.\\n\\n\n",
    "    {patient_data}\"\"\",\n",
    "    input_variables=[\"patient_data\"],\n",
    ")\n",
    "# model = ChatOpenAI(temperature = 0.0, model=modelID)\n",
    "\n",
    "chain_profile = prompt_profile | model | parser\n",
    "\n",
    "# to preserve the patient's private information\n",
    "if patient_data.get('name'):\n",
    "    del patient_data['patient_id']\n",
    "    del patient_data['name']\n",
    "\n",
    "patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "nprint(patient_profile) # patient_profile"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "patient_profile = \"\"\"\n",
    "Patient is an 76-year-old individual with a history of leiomyosarcoma. \n",
    "They have previously participated in the clinical trial NCT03923948, which has been completed as of April 13, 2024. \n",
    "Based on their medical history, relevant trials may include those focused on sarcoma treatments or geriatric oncology.\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### policy checker"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "================================\u001b[1m System Message \u001b[0m================================\n",
      "\n",
      "You are a Principal Investigator (PI) for evaluating patients for clinical trials.You compare the patient profile to the clinical trial policies to determine if the patient is eligible for clinical trials or not.Read the input information about the patient profile and relevant clinical trial policies: \n",
      "can you determine if patient is eligible for clinical trials?\n",
      "if you can't say I can't\n",
      "You have access to the following tools: \u001b[33;1m\u001b[1;3m{tool_names}\u001b[0m.\n",
      " You may generate only safe python code. ALWAYS print the output using `print(...)` as the last line.\n",
      "\n",
      "=============================\u001b[1m Messages Placeholder \u001b[0m=============================\n",
      "\n",
      "\u001b[33;1m\u001b[1;3m{messages}\u001b[0m\n",
      "\n",
      "=============================\u001b[1m Messages Placeholder \u001b[0m=============================\n",
      "\n",
      "\u001b[33;1m\u001b[1;3m{agent_scratchpad}\u001b[0m\n",
      "\n",
      "================================\u001b[1m System Message \u001b[0m================================\n",
      "\n",
      "Note: Current date is \u001b[33;1m\u001b[1;3m{date}\u001b[0m.\n",
      "\n",
      "\n",
      "=============================\u001b[1m Messages Placeholder \u001b[0m=============================\n",
      "\n",
      "\u001b[33;1m\u001b[1;3m{examples}\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "import langchain\n",
    "from langchain import hub\n",
    "from langchain_core.pydantic_v1 import BaseModel, Field\n",
    "\n",
    "from langchain.prompts import PromptTemplate\n",
    "from operator import itemgetter\n",
    "from langchain_core.prompts import ChatPromptTemplate, MessagesPlaceholder\n",
    "from langchain_core.messages import BaseMessage, HumanMessage\n",
    "from langchain.agents import AgentExecutor, create_openai_tools_agent\n",
    "from typing import Annotated\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "@tool\n",
    "def python_repl(\n",
    "    code: Annotated[str, \"The python code to execute. The code must ALWAYS end print the output using `print(...)` as the last line to see the result.\"],\n",
    "):\n",
    "    \"\"\"A Python shell. Use this to execute python commands. \n",
    "    Input should be a valid python command. \n",
    "    If you want to see the output of a value, you should print it out with `print(...)`.\"\"\"\n",
    "    try:\n",
    "        result = repl.run(code)\n",
    "        # return result\n",
    "    except BaseException as e:\n",
    "        return f\"Failed to execute. Error: {repr(e)}\"\n",
    "    result_str = f\"Successfully executed:\\n```python\\n{code}\\n```\\nStdout: {result}\"\n",
    "    return (\n",
    "        # result_str\n",
    "        result_str + \"\\n\\nIf you have completed all tasks, respond with FINAL ANSWER.\"\n",
    "    )\n",
    "\n",
    "\n",
    "# patient_profile = patient_data_to_string(patient_data)\n",
    "\n",
    "# print(patient_profile)\n",
    "model = ChatOpenAI(temperature = 0.0, model=\"gpt-3.5-turbo\")\n",
    "langchain.debug = False\n",
    "\n",
    "question = f\"\"\"\n",
    "Does the following patient profile comply with the institutional policies?\\n\n",
    "{patient_profile}\n",
    "\"\"\"\n",
    "\n",
    "# prompt = hub.pull(\"rlm/rag-prompt\").pretty_print()  # Show what the prompt looks like\n",
    "\n",
    "from langchain.chains import RetrievalQA\n",
    "\n",
    "\n",
    "class comply(BaseModel):\n",
    "        \"\"\"Binary score for trial eligibility check.\"\"\"\n",
    "\n",
    "        binary_score: str = Field(description=\"Patient eligible for the clinical trials 'yes' or 'no'\")\n",
    "        reason: str = Field(description=\"Reason(s) only if the patient is not eligible for clinical trials. Othereise use NA\")\n",
    "        \n",
    "llm_with_tool = model.with_structured_output(comply)\n",
    "\n",
    "# docs_retrieved = retriever_policy.get_relevant_documents(question)\n",
    "docs = \"\\n\\n\".join(doc.page_content for doc in docs_retrieved)\n",
    "# docs = docs_retrieved[5].page_content\n",
    "# docs = docs_retrieved[1].page_content\n",
    "# for doc in docs_retrieved:\n",
    "\n",
    "\n",
    "prompt_repl = ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        (\n",
    "            \"system\",\n",
    "            \"You are a Principal Investigator (PI) for evaluating patients for clinical trials.\" \n",
    "            \"You compare the patient profile to the institution policies to determine if the patient is eligible for clinical trials or not.\"\n",
    "            # \"Use the following institution policy(s) to find if the patient is eligibile for trials.\"\n",
    "            \"\\n #### Here is the patient profile: \\n {patient_profile}\\n\\n\"\n",
    "            # \"\\n Here is/are the retrieved policy(s) document: \\n {context}\\n\\n\"\n",
    "\n",
    "            \"-------------------\\n\"\n",
    "            \n",
    "            \"Restrict your judgment Only to the information given in patient's profile and the policy given by the user\\n\"\n",
    "            # \"Restrict your judgment Only to the above retrieved policy(s) and the information in patient's profile by the user\\n\"\n",
    "            # \"You are a helpful AI assistant.\"\n",
    "            # \"You may generate safe python code to do numerical operations and data conversions.\" \n",
    "            # \"To see the result of the code execution, print the output value at thr end with `print(...)`\"\n",
    "            \"You have access to the following tools: {tool_names}.\"\n",
    "            \"\\n You may generate only safe python code.\"\n",
    "            # \"\\n Use python code ONLY IF if the retrieved policy document contain numerical or time related information.\", \n",
    "        ),\n",
    "        # MessagesPlaceholder(variable_name=\"examples\"),\n",
    "        MessagesPlaceholder(variable_name=\"messages\"),\n",
    "        MessagesPlaceholder(variable_name=\"agent_scratchpad\"),\n",
    "        (\n",
    "            \"system\",\n",
    "            \"Note: Current date is {date}.\\n\"\n",
    "\n",
    "            \"Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible for clinical trials.\"\n",
    "            \"If the patient is not eligible then also include the reason in your response.\"\n",
    "            # Use it as the reference date to evaluate time related regulations.\"\n",
    "        ),\n",
    "        MessagesPlaceholder(variable_name=\"examples\"),\n",
    "    ]\n",
    ")\n",
    "\n",
    "\n",
    "prompt_repl = ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        (\n",
    "            \"system\",\n",
    "            \"You are a Principal Investigator (PI) for evaluating patients for clinical trials.\" \n",
    "            \"You compare the patient profile to the clinical trial policies to determine if the patient is eligible for clinical trials or not.\"            \n",
    "            \n",
    "            \"Read the input information about the patient profile and relevant clinical trial policies: \\n\"            \n",
    "                                   \n",
    "            \"can you determine if patient is eligible for clinical trials?\\n\"\n",
    "            \"if you can't say I can't\\n\"\n",
    "            \"You have access to the following tools: {tool_names}.\"\n",
    "            \"\\n You may generate only safe python code. ALWAYS print the output using `print(...)` as the last line.\"\n",
    "            # \"\\n Use python code ONLY IF if the retrieved policy document contain numerical or time related information.\", \n",
    "        ),\n",
    "        # MessagesPlaceholder(variable_name=\"examples\"),\n",
    "        MessagesPlaceholder(variable_name=\"messages\"),\n",
    "        MessagesPlaceholder(variable_name=\"agent_scratchpad\"),\n",
    "        (\n",
    "            \"system\",\n",
    "            \"Note: Current date is {date}.\\n\"\n",
    "\n",
    "            # \"Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible for clinical trials.\"\n",
    "            # \"If the patient is not eligible then also include the reason in your response.\"\n",
    "            # Use it as the reference date to evaluate time related regulations.\"\n",
    "        ),\n",
    "        MessagesPlaceholder(variable_name=\"examples\"),\n",
    "    ]\n",
    ")\n",
    "\n",
    "examples = \"\"\"\n",
    "Example of date comparison:\n",
    "query: is November 25, 2023 within the 5 months before the current date, 25-03-2024?\n",
    "\n",
    "generated code:\n",
    "```\n",
    "gap_months = 5\n",
    "today = datetime.strptime('25-03-2024', '%d-%m-%Y')\n",
    "trial_completion_date = datetime.strptime('25-11-2023', '%d-%m-%Y')\n",
    "days_difference = (today - trial_completion_date).days\n",
    "if days_difference < gap_months*30:\n",
    "    trial_within_5_months = True\n",
    "else:\n",
    "    trial_within_5_months = False\n",
    "# print the output value with\n",
    "print(trial_within_5_months)\n",
    "```\n",
    "\"\"\"\n",
    "\n",
    "\n",
    "\n",
    "prompt_policy = PromptTemplate(\n",
    "    template=\"\"\" You are a Principal Investigator (PI) for evaluating patients for clinical trials. \n",
    "        Use the following institution policy to find if the patient is eligibile for trials.\n",
    "        Here are the retrieved policy: \\n\\n {context} \\n\\n\n",
    "        Here is the agent profile: {patient_profile} \\n\n",
    "        \n",
    "        Note:Current date is {date}. Use it as the reference date to evaluate time related regulations.\\n\n",
    "        Give a binary 'yes' or 'no' score to indicate whether the patient is eligible for clinical trials.\\n\n",
    "        If the patient is not eligible then also give the reason as a string.\n",
    "        \"\"\",\n",
    "    input_variables=[\"context\", \"patient_profile\", \"date\"],\n",
    ")\n",
    "\n",
    "\n",
    "from typing import Annotated\n",
    "# To compare different dates, convert them to days before any comparison.\n",
    "from langchain_core.tools import Tool\n",
    "\n",
    "python_repl_tool = Tool(\n",
    "    name=\"python_repl\",\n",
    "    description=\"A Python shell. Use this to execute python commands. Input should be a valid python command. If you want to see the output of a value, you should print it out with `print(...)`.\",\n",
    "    func=python_repl.run,\n",
    ")\n",
    "\n",
    "\n",
    "# prompt_repl = ChatPromptTemplate.from_messages(\n",
    "#     [\n",
    "#         (\n",
    "#             \"system\",\n",
    "#             \"You are a helpful AI assistant.\"\n",
    "#             \"You may generate safe python code to do numerical operations and data conversions.\" \n",
    "#             \"To see the result of the code execution, print the output value at thr end with `print(...)`\"\n",
    "#             \"You have access to the following tools: {tool_names}.\",\n",
    "#         ),\n",
    "#         # MessagesPlaceholder(variable_name=\"examples\"),\n",
    "#         MessagesPlaceholder(variable_name=\"messages\"),\n",
    "#         MessagesPlaceholder(variable_name=\"agent_scratchpad\"),\n",
    "#     ]\n",
    "# )\n",
    "from langchain_experimental.agents.agent_toolkits import create_python_agent\n",
    "\n",
    "\n",
    "date = datetime.today().date()\n",
    "tools = [python_repl]\n",
    "prompt_repl = prompt_repl.partial(tool_names=\", \".join([tool.name for tool in tools]))\n",
    "prompt_repl = prompt_repl.partial(date=date)\n",
    "# prompt_repl = prompt_repl.partial(context=docs)\n",
    "prompt_repl = prompt_repl.partial(patient_profile=patient_profile)\n",
    "prompt_repl = prompt_repl.partial(examples= [HumanMessage(content=examples)])\n",
    "\n",
    "prompt_repl.pretty_print()\n",
    "\n",
    "# agent = create_openai_tools_agent(model, tools, prompt_repl)\n",
    "agent = create_python_agent(\n",
    "    model,\n",
    "    tool=python_repl_tool,\n",
    "    handle_parsing_errors=True,\n",
    "    verbose=True\n",
    ")\n",
    "agent_with_tool = AgentExecutor(\n",
    "    agent=agent, \n",
    "    tools=tools,\n",
    "    handle_parsing_errors=True\n",
    "    )\n",
    "# agent_with_tool = prompt_policy | model.bind_tools([python_repl])\n",
    "\n",
    "# prompt_policy = PromptTemplate(\n",
    "#     template=\"\"\" You are a Principal Investigator (PI) for evaluating patients for clinical trials. \n",
    "#         Use the following pieces of retrieved context from the institution's policies to answer the question about the patient's eligibility. \n",
    "#         Here are the retrieved policies: \\n\\n {context} \\n\\n\n",
    "#         Here is the user question: {question} \\n\n",
    "        \n",
    "#         Note:Current date is {date}. Use it as the reference date to evaluate time related policies.\\n\n",
    "#         Giving a reason is required only for rejection cases.\n",
    "#         Give a binary score 'yes' or 'no' score to indicate whether the patient is eligible for clinical trials.\"\"\",\n",
    "#     input_variables=[\"context\", \"question\"],\n",
    "# )\n",
    "\n",
    "# date = datetime.now().strftime(\"%Y-%m-%d\")\n",
    "\n",
    "\n",
    "chain = prompt_policy | llm_with_tool\n",
    "\n",
    "if patient_data.get('name'):\n",
    "    del patient_data['name']\n",
    "    del patient_data['patient_id']\n",
    "\n",
    "# scored_result = chain.invoke(\n",
    "#     {\n",
    "#         \"patient_profile\": patient_profile, \n",
    "#         \"context\": docs, \n",
    "#         \"date\": date\n",
    "#         # \"patient_data\": patient_data\n",
    "#     }\n",
    "# )\n",
    "# scored_result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "------------\n"
     ]
    }
   ],
   "source": [
    "policy = docs_retrieved[0].page_content\n",
    "\n",
    "promptA = PromptTemplate(\n",
    "    template=\"\"\" You are a Principal Investigator (PI) for clinical trials. \n",
    "        Use the following clinial trials policy and simplify it.\n",
    "        Use simpler language to define the regulations.\n",
    "        Remove headers.\n",
    "        Remove topic titles.\n",
    "        Only keep the regulations that define the cases that prevent patients from being eligible for clinical trials.\n",
    "        \n",
    "        The retrieved policies: \\n\\n {context} \\n\\n        \n",
    "        \"\"\",\n",
    "    input_variables=[\"context\"],\n",
    ")\n",
    "\n",
    "\n",
    "promptB = PromptTemplate(\n",
    "    template=\"\"\" You are a Principal Investigator (PI) for clinical trials. \n",
    "        You are given the following patient's profile:\\n\n",
    "        {patient_profile}\\n\n",
    "        \n",
    "        You also have access to the following trial policies:\\n\n",
    "        {policies}\\n\n",
    "        \n",
    "        Simplify the policies.\\n\n",
    "        Determine which policy is relevant to which information in patient's profile.        \n",
    "        \"\"\",\n",
    "    input_variables=[\"patient_profile\", \"policies\"],\n",
    ")\n",
    "# For each policy, if the information you need does not exist in the patient's profile remove the policy it.\\n\n",
    "# At the end, suggest how to determine whether the patient is eligible according to the remaining policies.\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "\n",
    "outputparse = StrOutputParser()\n",
    "\n",
    "chainA = promptA | model | outputparse\n",
    "result = chainA.invoke(\n",
    "    {\"context\": policy}\n",
    ")\n",
    "# nprint(result) # result\n",
    "print(\"------------\")\n",
    "\n",
    "chainB = promptB | model | outputparse\n",
    "# resultB = chainB.invoke(\n",
    "#     {\"patient_profile\": patient_profile, \n",
    "#     \"policies\": result\n",
    "#     }\n",
    "# )\n",
    "# nprint(resultB) # result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "langchain.debug = True\n",
    "# message = f\"Here is the agent profile:\\n {patient_profile}\"\n",
    "policy = docs_retrieved[0].page_content\n",
    "# policy = doc.page_content\n",
    "# message = f\"Here is the retrieved policy document: \\n {policy}\\n\\n\"\n",
    "# message = resultB\n",
    "# nprint(message)\n",
    "# message = f\"Here is the agent profile:\\n {patient_profile}\"\n",
    "# result = agent_with_tool.invoke(\n",
    "#     {\n",
    "#         \"messages\": [\n",
    "#             HumanMessage(content=message)\n",
    "#             # HumanMessage(content=\"is November 25, 2023 5 months before February 26, 2024?\")\n",
    "#             # HumanMessage(content=\"The patient age is 74. Patients must be between 18 and 75 years old. Does the patient's age fall within this range?\" \n",
    "#             # HumanMessage(content=message)\n",
    "#         ]\n",
    "#     }\n",
    "# )\n",
    "\n",
    "# nprint(result['output'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.agents import initialize_agent, AgentType\n",
    "from langchain_experimental.utilities import PythonREPL\n",
    "from langchain_experimental.tools import PythonREPLTool\n",
    "repl_tool = PythonREPLTool()\n",
    "\n",
    "agent= initialize_agent(\n",
    "    [python_repl], \n",
    "    model, \n",
    "    agent=AgentType.CHAT_ZERO_SHOT_REACT_DESCRIPTION,\n",
    "    handle_parsing_errors=True,\n",
    "    verbose = True)\n",
    "policy = docs_retrieved[1].page_content\n",
    "message = f\"\"\"\n",
    "Here is the retrieved policy document: \\n {policy}\\n\\n\n",
    "Here is the agent profile:\\n {patient_profile}\\n\\n\n",
    "Is there any information in the agent's profile that can make them not eligible for clinical trials based on the retrieved policy?\n",
    "\\n Use the python tool only for numerical evaluations.\n",
    "\"\"\"\n",
    "# message = \"what is 2.5 times 3.5?\"\n",
    "# agent(message)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### loop of policty checks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "langchain.debug = False\n",
    "results = []\n",
    "for doc in docs_retrieved:\n",
    "    policy = doc.page_content\n",
    "    # message = f\"Here is the agent profile:\\n {patient_profile}\"\n",
    "    message = f\"Here is the retrieved policy document: \\n {policy}\\n\\n\"\n",
    "    # nprint(message)\n",
    "    # message = f\"Here is the agent profile:\\n {patient_profile}\"\n",
    "    # result = agent_with_tool.invoke(\n",
    "    #     {\n",
    "    #         \"messages\": [\n",
    "    #             HumanMessage(content=message)\n",
    "    #             # HumanMessage(content=\"is November 25, 2023 5 months before February 26, 2024?\")\n",
    "    #             # HumanMessage(content=\"The patient age is 74. Patients must be between 18 and 75 years old. Does the patient's age fall within this range?\" \n",
    "    #             # HumanMessage(content=message)\n",
    "    #         ]\n",
    "    #     }\n",
    "    # )\n",
    "\n",
    "    # nprint(result['output'])\n",
    "    # results.append({'policy': policy, 'output': result['output']})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Here is the agent profile: {patient_profile} \\n\n",
    "# Note:Current date is {date}. Use it as the reference date to evaluate time related regulations.\\n\n",
    "evaluations = (\"\\n\\n\"+7*\"------------\"+\"\\n\\n\")+(\"\\n\\n\"+7*\"------------\"+\"\\n\\n\").join([result['output'] for result in results])\n",
    "# nprint(evaluations)\n",
    "prompt_evaluate = PromptTemplate(\n",
    "    template=\"\"\" You are a Principal Investigator (PI) for evaluating patients for clinical trials. \n",
    "        You task is to find if the patient is eligible for all trial policies.\n",
    "        \\n The following is a list of policy evaluations for the patient:\n",
    "        \\n\\n {evaluations} \\n\\n\n",
    "                        \n",
    "        Give a binary 'yes' or 'no' score to indicate whether the patient is eligible for all clinical trials.\\n\n",
    "        If the patient is not eligible then also give the reason as a string.\n",
    "        \"\"\",\n",
    "    input_variables=[\"evaluations\"],\n",
    ")\n",
    "\n",
    "llm_with_tool = model.with_structured_output(comply)\n",
    "chain = prompt_evaluate | llm_with_tool\n",
    "# scored_result = chain.invoke(\n",
    "#     {\n",
    "#         # \"patient_profile\": patient_profile, \n",
    "#         \"evaluations\": evaluations, \n",
    "#         # \"date\": date\n",
    "#         # \"patient_data\": patient_data\n",
    "#     }\n",
    "# )\n",
    "# scored_result\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\\r\\n             previously treated with docetaxel-based therapy and has progressed during treatment of\\r\\n             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\\r\\n\\r\\n          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\\r\\n             or radiographic evidence of disease progression in soft tissue or bone\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\\r\\n\\r\\n          -  Adequate hematologic and organ function\\r\\n\\r\\n          -  Documented willingness to use an effective means of contraception\\r\\n\\r\\n          -  Safety cohort only: agreement to use CGM for first cycle of treatment\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\\r\\n             patients who are receiving any pharmacologic treatment for diabetes are not eligible\\r\\n\\r\\n          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\\r\\n             fraction < 50% or ventricular arrhythmia requiring medication\\r\\n\\r\\n          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\\r\\n             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\\r\\n             within 6 months prior to Day 1\\r\\n\\r\\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\\r\\n             drugs or active inflammatory disease which requires immunosuppressive therapy\\r\\n\\r\\n          -  Clinically significant history of liver disease\\r\\n\\r\\n          -  History of adrenal insufficiency or hyperaldosteronism\\r\\n\\r\\n          -  Phase II only: Previous therapy for prostate cancer with 17\\r\\n             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\\r\\n\\r\\n          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\\r\\n             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\\r\\n\\r\\n          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\\r\\n             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['prostate cancer']\", 'drugs': \"['abiraterone', 'apitolisib', 'ipatasertib', 'placebo', 'prednisone', 'prednisolone']\", 'nctid': 'NCT01485861', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed locally advanced gastric (primary endpoint includes proximal\\r\\n             and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral)\\r\\n             adenocarcinomas are eligible for enrolment but will not be included in the primary\\r\\n             analysis\\r\\n\\r\\n          -  Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary\\r\\n             tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)\\r\\n\\r\\n          -  All patients must have diagnostic laparoscopy with diagnostic washings for cytology;\\r\\n             both cytology positive and negative patients are eligible for enrolment, but only\\r\\n             cytology negative patients will be included in the primary analyses; gross peritoneal\\r\\n             disease is not eligible\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1\\r\\n\\r\\n          -  Eligible for surgery with curative intent\\r\\n\\r\\n          -  Absolute neutrophil count (ANC) >= 1250/ul\\r\\n\\r\\n          -  Hemoglobin >= 9 g/dL\\r\\n\\r\\n          -  Platelets >= 100,000/ul\\r\\n\\r\\n          -  Total bilirubin < 1.5 x upper limit of normal\\r\\n\\r\\n          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\\r\\n             transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver\\r\\n             metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver\\r\\n             metastases\\r\\n\\r\\n          -  Creatinine =< 1.5 x upper limit of normal\\r\\n\\r\\n          -  Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor\\r\\n             (RECIST) 1.1 will be allowed\\r\\n\\r\\n          -  Women of child-bearing potential and men must agree to use adequate contraception\\r\\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and for\\r\\n             the duration of study participation, up until 30 days after final study treatment;\\r\\n             should a woman become pregnant or suspect that she is pregnant while participating in\\r\\n             this study, she should inform her treating physician immediately\\r\\n\\r\\n          -  Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3,\\r\\n             subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative\\r\\n             drugs whenever possible, given the potential for drug-drug interactions with\\r\\n             irinotecan\\r\\n\\r\\n          -  Signed informed consent\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Previous or concurrent malignancy, except for adequately treated basal cell or\\r\\n             squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the\\r\\n             patient has been previously treated and the lifetime recurrence risk is less than 30%\\r\\n\\r\\n          -  Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's\\r\\n             disease, ulcerative colitis)\\r\\n\\r\\n          -  Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology\\r\\n             Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)\\r\\n\\r\\n          -  Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0\\r\\n\\r\\n          -  Serious underlying medical or psychiatric illnesses that would, in the opinion of the\\r\\n             treating physician, substantially increase the risk for complications related to\\r\\n             treatment\\r\\n\\r\\n          -  Active uncontrolled bleeding\\r\\n\\r\\n          -  Pregnancy or breastfeeding\\r\\n\\r\\n          -  Major surgery within 4 weeks\\r\\n\\r\\n          -  Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be\\r\\n             allowed and treated as in the *28/*28 dosing group\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['esophageal adenocarcinoma', 'gastric adenocarcinoma', 'stage iib gastric cancer', 'stage iiia esophageal adenocarcinoma', 'stage iiia gastric cancer', 'stage iiib esophageal adenocarcinoma', 'stage iiib gastric cancer', 'stage iiic esophageal adenocarcinoma', 'stage iiic gastric cancer']\", 'drugs': \"['oxaliplatin', 'leucovorin calcium', 'irinotecan hydrochloride', 'fluorouracil']\", 'nctid': 'NCT02366819', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Able to understand and comply with the study procedures, understand the risks involved\\r\\n             in the study, and provide written informed consent before the first study-specific\\r\\n             procedure; specifically able to comply with the PK assessment schedule during the\\r\\n             first 2 treatment cycles.\\r\\n\\r\\n          2. Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or\\r\\n             European Medicines Agency (EMA) approved indications:\\r\\n\\r\\n               1. In North America: Participants with MDS previously treated or untreated with de\\r\\n                  novo or secondary MDS, including all French-American-British subtypes (refractory\\r\\n                  anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess\\r\\n                  blasts, refractory anemia with excess blasts in transformation, and chronic\\r\\n                  myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic\\r\\n                  Scoring System (IPSS) int-1, -2, or high-risk MDS.\\r\\n\\r\\n               2. In Europe: Participants with de novo or secondary AML, as defined by the World\\r\\n                  Health Organization (WHO) criteria, who are not candidates for standard induction\\r\\n                  chemotherapy.\\r\\n\\r\\n          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\\r\\n\\r\\n          4. Adequate organ function defined as follows:\\r\\n\\r\\n               1. Hepatic: Total or direct bilirubin ≤2 × upper limit of normal (ULN); aspartate\\r\\n                  transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine\\r\\n                  transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤2.5 × ULN.\\r\\n\\r\\n               2. Renal: serum creatinine ≤1.5 × ULN or calculated creatinine clearance or\\r\\n                  glomerular filtration rate >50 mL/min/1.73 m2 for subjects with creatinine levels\\r\\n                  above institutional normal.\\r\\n\\r\\n          5. No major surgery within 30 days of first study treatment.\\r\\n\\r\\n          6. Life expectancy of at least 3 months.\\r\\n\\r\\n          7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a\\r\\n             negative pregnancy test at screening. Women of non-childbearing potential are those\\r\\n             who have had a hysterectomy or bilateral oophorectomy, or who have completed\\r\\n             menopause, defined as no menses for at least 1 year AND either age ≥65 years or\\r\\n             follicle-stimulating hormone levels in the menopausal range.\\r\\n\\r\\n          8. Subjects and their partners with reproductive potential must agree to use effective\\r\\n             contraceptive measures during the study and for 3 months after the last dose of study\\r\\n             treatment. Effective contraception includes methods such as oral contraceptives or\\r\\n             double-barrier method (eg, use of a condom AND diaphragm, with spermicide).\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic\\r\\n             chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC)\\r\\n             counts.\\r\\n\\r\\n          2. Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia,\\r\\n             sepsis, or systemic infection in the 30 days before screening.\\r\\n\\r\\n          3. Treatment with any investigational drug or therapy within 2 weeks of study treatment,\\r\\n             or 5 half-lives, whichever is longer, before the first dose of study treatment, or\\r\\n             ongoing clinically significant adverse events (AEs) from previous treatment.\\r\\n\\r\\n          4. Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose\\r\\n             of study treatment.\\r\\n\\r\\n          5. Concurrent MDS therapies, including lenalidomide, erythropoietin,\\r\\n             cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF),\\r\\n             granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these\\r\\n             agents is permitted, provided that completion is at least 1 week before the first dose\\r\\n             of study treatment.)\\r\\n\\r\\n          6. Poor medical risk because of other conditions such as uncontrolled systemic diseases,\\r\\n             active uncontrolled infections, or comorbidities that may put the patient at risk of\\r\\n             not being able to complete at least 2 cycles of treatment.\\r\\n\\r\\n          7. Known significant mental illness or other condition, such as active alcohol or other\\r\\n             substance abuse or addiction, that in the opinion of the investigator predisposes the\\r\\n             subject to high risk of noncompliance with the protocol.\\r\\n\\r\\n          8. Rapidly progressive or highly proliferative disease (total white blood cell count of\\r\\n             >15 × 10^9/L) or other criteria that render the subject at high risk of requiring\\r\\n             intensive cytotoxic chemotherapy within the next 3 months.\\r\\n\\r\\n          9. Life-threatening illness or severe organ system dysfunction, such as uncontrolled\\r\\n             congestive heart failure or chronic obstructive pulmonary disease, or other reasons\\r\\n             including laboratory abnormalities, which, in the investigator's opinion, could\\r\\n             compromise the subject's safety, interfere with the absorption or metabolism of\\r\\n             ASTX727, or compromise completion of the study or integrity of the study outcomes.\\r\\n\\r\\n         10. Prior malignancy, except for adequately treated basal cell or squamous cell skin\\r\\n             cancer, in situ cervical cancer, prostate cancer or breast cancer under control with\\r\\n             hormone therapy, or other cancer from which the subject has been disease free for at\\r\\n             least 2 years.\\r\\n      \", metadata={'disease_category': 'leukemia', 'diseases': \"['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\", 'drugs': \"['astx727', 'dacogen']\", 'nctid': 'NCT03306264', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients with a confirmed diagnosis of symptomatic multiple myeloma stage I to III\\r\\n             according to the International Staging System ISS (see appendix A), i.e. at least one\\r\\n             of the CRAB criteria should be present;\\r\\n\\r\\n          -  Measurable disease as defined by the presence of M-protein in serum or urine (serum\\r\\n             M-protein> 10 g/l or urine M-protein > 200 mg/24 hours), or abnormal free light chain\\r\\n             ratio;\\r\\n\\r\\n          -  Age 18-65 years inclusive;\\r\\n\\r\\n          -  WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by\\r\\n             comorbid conditions);\\r\\n\\r\\n          -  Negative pregnancy test at inclusion if applicable;\\r\\n\\r\\n          -  Written informed consent.\\r\\n\\r\\n        Inclusion for randomisation 1:\\r\\n\\r\\n          -  WHO performance 0-2;\\r\\n\\r\\n          -  Bilirubin and transaminases < 2.5 times the upper limit of normal values;\\r\\n\\r\\n          -  A suitable stem cell graft containing at least 4 x 106 CD34+ cells/kg (or according to\\r\\n             national guidelines).\\r\\n\\r\\n        Inclusion for randomisation 2:\\r\\n\\r\\n          -  Bilirubin and transaminases < 2.5 times the upper limit of normal values;\\r\\n\\r\\n          -  ANC >= 0.5 x 109/l and platelets > 20 x 10^9/l;\\r\\n\\r\\n          -  Patient is able to adhere to the requirements of the Lenalidomide Pregnancy Prevention\\r\\n             Risk Management Plan.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Known intolerance of Boron;\\r\\n\\r\\n          -  Systemic AL amyloidosis;\\r\\n\\r\\n          -  Primary Plasmacell Leukemia;\\r\\n\\r\\n          -  Non-secretory MM;\\r\\n\\r\\n          -  Previous chemotherapy or radiotherapy except local radiotherapy in case of local\\r\\n             myeloma progression or corticosteroids maximum 5 days for symptom control;\\r\\n\\r\\n          -  Severe cardiac dysfunction (NYHA classification II-IV);\\r\\n\\r\\n          -  Significant hepatic dysfunction, unless related to myeloma;\\r\\n\\r\\n          -  Patients with GFR <15 ml/min,\\r\\n\\r\\n          -  Patients known to be HIV-positive;\\r\\n\\r\\n          -  Patients with active, uncontrolled infections;\\r\\n\\r\\n          -  Patients with neuropathy, CTC grade 2 or higher;\\r\\n\\r\\n          -  Patients with a history of active malignancy during the past 5 years with the\\r\\n             exception of basal carcinoma of the skin or stage 0 cervical carcinoma;\\r\\n\\r\\n          -  Patients who are not willing or capable to use adequate contraception during the\\r\\n             therapy (all men, all pre-menopausal women);\\r\\n\\r\\n          -  Lactating women.\\r\\n\\r\\n        Exclusion for randomisation 1:\\r\\n\\r\\n          -  Severe pulmonary, neurologic, or psychiatric disease;\\r\\n\\r\\n          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment;\\r\\n\\r\\n          -  Allogeneic Stem Cell Transplantation (Allo SCT) planned;\\r\\n\\r\\n          -  Progressive disease.'\\r\\n\\r\\n        Exclusion for randomisation 2:\\r\\n\\r\\n          -  Progressive disease;\\r\\n\\r\\n          -  Neuropathy, except CTCAE grade 1;\\r\\n\\r\\n          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['multiple myeloma']\", 'drugs': \"['bortezomib, melphalan, prednisone (vmp)', '1 or 2 cycle(s) hdm (high dose melphalan)', '2 cycles of bortezomib, lenalidomide, dexamethasone (vrd)']\", 'nctid': 'NCT01208766', 'status': 'recruiting'})]"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retrieval Grader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'age': 60,\n",
       " 'medical_history': 'anxiety disorder',\n",
       " 'previous_trials': 'NCT01052103',\n",
       " 'trial_status': 'Completed',\n",
       " 'trial_completion_date': '2023-12-12'}"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# patient_data['medical_history'] = \"Chronic Pain, Pregnant\"\n",
    "# cancer:22, asthma:4, leukemia: 8, anx disorder: 7\n",
    "sample_patient_id = 8\n",
    "patient_data = get_patient_data(sample_patient_id)\n",
    "# patient_data['trial_completion_date'] = '2024-04-01'\n",
    "del patient_data['name']\n",
    "del patient_data['patient_id']\n",
    "# patient_data['trial_status'] = 'Complete'\n",
    "patient_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Patient is a 60-year-old with a history of anxiety disorder. They have '\n",
      " 'previously participated in the clinical trial NCT01052103, which was '\n",
      " 'completed on December 12, 2023. Based on their medical history, they may be '\n",
      " 'eligible for trials related to anxiety disorders or mental health.')\n"
     ]
    }
   ],
   "source": [
    "# date\n",
    "patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "nprint(patient_profile)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "mental_health ['generalized anxiety disorder']\n",
      "cancer ['colorectal cancer']\n",
      "leukemia ['relapsed or refractory acute myeloid leukemia (aml)', 'untreated aml', 'other idh1-mutated positive hematologic malignancies', 'myelodysplastic syndromes']\n",
      "leukemia ['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients of both sexes\\r\\n\\r\\n          -  Eighteen years of age and older\\r\\n\\r\\n          -  Clinical diagnosis of Generalized Anxiety Disorder\\r\\n\\r\\n          -  Eighteen points or more on Hamilton Anxiety Scale\\r\\n\\r\\n          -  Without previous treatment for this disease (for at least one month before).\\r\\n\\r\\n          -  In case of being women of reproductive age, who are not pregnant or lactating.\\r\\n\\r\\n          -  To sign an informed consent letter of participation in the investigation.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Patients who have treatment for their condition\\r\\n\\r\\n          -  Patients who have another mental disorder added\\r\\n\\r\\n          -  Patients with alcoholism, smoking or drug addiction\\r\\n\\r\\n          -  Patients who live alone\\r\\n\\r\\n          -  Ingest of drugs for insomnia\\r\\n\\r\\n          -  Ingest of drugs of the Monoamine Oxidase Inhibitors group\\r\\n\\r\\n          -  Patients with epilepsy\\r\\n\\r\\n          -  Patients who operate dangerous machinery\\r\\n\\r\\n          -  Patients who have to drive at work (car, truck or other motor vehicle) for a long\\r\\n             time.\\r\\n      ', metadata={'disease_category': 'mental_health', 'diseases': \"['generalized anxiety disorder']\", 'drugs': \"['alprazolam 1mg']\", 'nctid': 'NCT03702803', 'status': 'recruiting'}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['colorectal cancer']\", 'drugs': \"['pemetrexed']\", 'nctid': 'NCT02588781', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Key Inclusion Criteria:\\r\\n\\r\\n          -  Subject must be ≥18 years of age.\\r\\n\\r\\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\\r\\n             based on local or central evaluation.\\r\\n\\r\\n          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\\r\\n             and urine sampling during the study.\\r\\n\\r\\n          -  Subjects must have ECOG PS of 0 to 2.\\r\\n\\r\\n          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\\r\\n\\r\\n          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\\r\\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\\r\\n             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\\r\\n             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\\r\\n             disease\\r\\n\\r\\n          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\\r\\n             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\\r\\n             rate (GFR)\\r\\n\\r\\n          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\\r\\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\\r\\n\\r\\n          -  Female subjects with reproductive potential must have a negative serum pregnancy test\\r\\n             within 7 days prior to the start of therapy and on the first day of study drug\\r\\n             administration.\\r\\n\\r\\n        Key Exclusion Criteria:\\r\\n\\r\\n          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\\r\\n             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\\r\\n             time of screening, or with clinically significant graft-versus-host disease (GVHD).\\r\\n             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\\r\\n             GVHD is permitted.)\\r\\n\\r\\n          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\\r\\n             their first day of study drug administration. (Hydroxyurea is allowed prior to\\r\\n             enrollment and after the start of AG-120).\\r\\n\\r\\n          -  Subjects who received an investigational agent <14 days prior to their first day of\\r\\n             study drug administration.\\r\\n\\r\\n          -  Subjects who are pregnant or breastfeeding.\\r\\n\\r\\n          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\\r\\n             screening visits or on their first day of study drug administration (at the discretion\\r\\n             of the Investigator, subjects with tumor fever may be enrolled).\\r\\n\\r\\n          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\\r\\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\\r\\n             within approximately 28 days of C1D1.\\r\\n\\r\\n          -  Subjects with a history of myocardial infarction within the last 6 months of\\r\\n             screening.\\r\\n\\r\\n          -  Subjects with a known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\\r\\n\\r\\n          -  Subjects with known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\\r\\n             increase the risk of QT prolongation or arrhythmic events.\\r\\n\\r\\n          -  Patients taking medications that are known to prolong the QT interval\\r\\n\\r\\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\\r\\n             hepatitis B or C.\\r\\n\\r\\n          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\\r\\n             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\\r\\n             there is a clinical suspicion of CNS involvement by leukemia during screening.\\r\\n\\r\\n          -  Subjects with immediately life-threatening, severe complications of leukemia such as\\r\\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\\r\\n             intravascular coagulation.\\r\\n      \", metadata={'disease_category': 'leukemia', 'diseases': \"['relapsed or refractory acute myeloid leukemia (aml)', 'untreated aml', 'other idh1-mutated positive hematologic malignancies', 'myelodysplastic syndromes']\", 'drugs': \"['ag-120']\", 'nctid': 'NCT02074839', 'status': 'recruiting'}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Able to understand and comply with the study procedures, understand the risks involved\\r\\n             in the study, and provide written informed consent before the first study-specific\\r\\n             procedure; specifically able to comply with the PK assessment schedule during the\\r\\n             first 2 treatment cycles.\\r\\n\\r\\n          2. Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or\\r\\n             European Medicines Agency (EMA) approved indications:\\r\\n\\r\\n               1. In North America: Participants with MDS previously treated or untreated with de\\r\\n                  novo or secondary MDS, including all French-American-British subtypes (refractory\\r\\n                  anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess\\r\\n                  blasts, refractory anemia with excess blasts in transformation, and chronic\\r\\n                  myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic\\r\\n                  Scoring System (IPSS) int-1, -2, or high-risk MDS.\\r\\n\\r\\n               2. In Europe: Participants with de novo or secondary AML, as defined by the World\\r\\n                  Health Organization (WHO) criteria, who are not candidates for standard induction\\r\\n                  chemotherapy.\\r\\n\\r\\n          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\\r\\n\\r\\n          4. Adequate organ function defined as follows:\\r\\n\\r\\n               1. Hepatic: Total or direct bilirubin ≤2 × upper limit of normal (ULN); aspartate\\r\\n                  transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine\\r\\n                  transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤2.5 × ULN.\\r\\n\\r\\n               2. Renal: serum creatinine ≤1.5 × ULN or calculated creatinine clearance or\\r\\n                  glomerular filtration rate >50 mL/min/1.73 m2 for subjects with creatinine levels\\r\\n                  above institutional normal.\\r\\n\\r\\n          5. No major surgery within 30 days of first study treatment.\\r\\n\\r\\n          6. Life expectancy of at least 3 months.\\r\\n\\r\\n          7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a\\r\\n             negative pregnancy test at screening. Women of non-childbearing potential are those\\r\\n             who have had a hysterectomy or bilateral oophorectomy, or who have completed\\r\\n             menopause, defined as no menses for at least 1 year AND either age ≥65 years or\\r\\n             follicle-stimulating hormone levels in the menopausal range.\\r\\n\\r\\n          8. Subjects and their partners with reproductive potential must agree to use effective\\r\\n             contraceptive measures during the study and for 3 months after the last dose of study\\r\\n             treatment. Effective contraception includes methods such as oral contraceptives or\\r\\n             double-barrier method (eg, use of a condom AND diaphragm, with spermicide).\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic\\r\\n             chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC)\\r\\n             counts.\\r\\n\\r\\n          2. Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia,\\r\\n             sepsis, or systemic infection in the 30 days before screening.\\r\\n\\r\\n          3. Treatment with any investigational drug or therapy within 2 weeks of study treatment,\\r\\n             or 5 half-lives, whichever is longer, before the first dose of study treatment, or\\r\\n             ongoing clinically significant adverse events (AEs) from previous treatment.\\r\\n\\r\\n          4. Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose\\r\\n             of study treatment.\\r\\n\\r\\n          5. Concurrent MDS therapies, including lenalidomide, erythropoietin,\\r\\n             cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF),\\r\\n             granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these\\r\\n             agents is permitted, provided that completion is at least 1 week before the first dose\\r\\n             of study treatment.)\\r\\n\\r\\n          6. Poor medical risk because of other conditions such as uncontrolled systemic diseases,\\r\\n             active uncontrolled infections, or comorbidities that may put the patient at risk of\\r\\n             not being able to complete at least 2 cycles of treatment.\\r\\n\\r\\n          7. Known significant mental illness or other condition, such as active alcohol or other\\r\\n             substance abuse or addiction, that in the opinion of the investigator predisposes the\\r\\n             subject to high risk of noncompliance with the protocol.\\r\\n\\r\\n          8. Rapidly progressive or highly proliferative disease (total white blood cell count of\\r\\n             >15 × 10^9/L) or other criteria that render the subject at high risk of requiring\\r\\n             intensive cytotoxic chemotherapy within the next 3 months.\\r\\n\\r\\n          9. Life-threatening illness or severe organ system dysfunction, such as uncontrolled\\r\\n             congestive heart failure or chronic obstructive pulmonary disease, or other reasons\\r\\n             including laboratory abnormalities, which, in the investigator's opinion, could\\r\\n             compromise the subject's safety, interfere with the absorption or metabolism of\\r\\n             ASTX727, or compromise completion of the study or integrity of the study outcomes.\\r\\n\\r\\n         10. Prior malignancy, except for adequately treated basal cell or squamous cell skin\\r\\n             cancer, in situ cervical cancer, prostate cancer or breast cancer under control with\\r\\n             hormone therapy, or other cancer from which the subject has been disease free for at\\r\\n             least 2 years.\\r\\n      \", metadata={'disease_category': 'leukemia', 'diseases': \"['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\", 'drugs': \"['astx727', 'dacogen']\", 'nctid': 'NCT03306264', 'status': 'recruiting'})]"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docs = retriever_trial_sq.get_relevant_documents(patient_profile)\n",
    "for doc in docs:\n",
    "    print(doc.metadata.get(\"disease_category\"), doc.metadata.get(\"diseases\"))\n",
    "docs    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('relevance_score', 'Yes')\n",
      "( 'explanation',\n",
      "  'The patient meets the inclusion criteria for the clinical trial related to '\n",
      "  'Generalized Anxiety Disorder. They are of the required age, have a clinical '\n",
      "  'diagnosis of Generalized Anxiety Disorder, and have a Hamilton Anxiety '\n",
      "  'Scale score of eighteen points or more. Additionally, they have not '\n",
      "  'received previous treatment for at least one month before, are not pregnant '\n",
      "  \"or lactating, and have signed an informed consent letter. The patient's \"\n",
      "  \"medical history aligns with the trial's focus on anxiety disorders.\")\n",
      "( 'further_information',\n",
      "  'Further information needed: 1. Confirmation that the patient does not have '\n",
      "  'any of the exclusion criteria such as previous treatment, other mental '\n",
      "  'disorders, alcoholism, smoking, or drug addiction. 2. Confirmation that the '\n",
      "  'patient does not live alone, does not ingest drugs for insomnia or '\n",
      "  'Monoamine Oxidase Inhibitors, does not have epilepsy, does not operate '\n",
      "  'dangerous machinery, and does not have to drive for work for a long time.')\n",
      "('Patient is a 60-year-old with a history of anxiety disorder. They have '\n",
      " 'previously participated in the clinical trial NCT01052103, which was '\n",
      " 'completed on December 12, 2023. Based on their medical history, they may be '\n",
      " 'eligible for trials related to anxiety disorders or mental health.')\n",
      "['generalized anxiety disorder']\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients of both sexes\n",
      "\n",
      "          -  Eighteen years of age and older\n",
      "\n",
      "          -  Clinical diagnosis of Generalized Anxiety Disorder\n",
      "\n",
      "          -  Eighteen points or more on Hamilton Anxiety Scale\n",
      "\n",
      "          -  Without previous treatment for this disease (for at least one month before).\n",
      "\n",
      "          -  In case of being women of reproductive age, who are not pregnant or lactating.\n",
      "\n",
      "          -  To sign an informed consent letter of participation in the investigation.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have treatment for their condition\n",
      "\n",
      "          -  Patients who have another mental disorder added\n",
      "\n",
      "          -  Patients with alcoholism, smoking or drug addiction\n",
      "\n",
      "          -  Patients who live alone\n",
      "\n",
      "          -  Ingest of drugs for insomnia\n",
      "\n",
      "          -  Ingest of drugs of the Monoamine Oxidase Inhibitors group\n",
      "\n",
      "          -  Patients with epilepsy\n",
      "\n",
      "          -  Patients who operate dangerous machinery\n",
      "\n",
      "          -  Patients who have to drive at work (car, truck or other motor vehicle) for a long\n",
      "             time.\n",
      "      \n"
     ]
    }
   ],
   "source": [
    "from langchain_core.output_parsers import JsonOutputParser\n",
    "\n",
    "class grade(BaseModel):\n",
    "        \"\"\"The result of the trial's relevance check as relevance score and explanation.\"\"\"\n",
    "\n",
    "        relevance_score: str        \n",
    "        explanation: str = Field(description=\"Reasons to the given relevance score.\")        \n",
    "        further_information: str\n",
    "\n",
    "prompt_grader = PromptTemplate(\n",
    "        template=\"\"\" \n",
    "        You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n\n",
    "        Your task is to evaluate the relevance of a clinical trial to the given patient's medical profile. \\n\n",
    "        \n",
    "        \n",
    "        The clinical trial is related to these diseases: {trial_diseases} \\n\n",
    "        Here are the inclusion and exclusion criteria of the trial: \\n\\n {document} \\n\\n\n",
    "        \n",
    "        ===============                \n",
    "        Use the following steps to determine relevance and provide the necessary fields in your response: \\n\n",
    "        1- If the patient's profile meets any exclusion criteria, then the trial is not relevant --> relevance_score = 'No'. \\n\n",
    "        2- If the patient's has or had the trial's inclusion diseases, then it is relevant --> relevance_score = 'Yes'.\\n        \n",
    "                       \n",
    "        Example 1: \n",
    "The patient has Arthritis and the trial is related to pancreatic cancer. --> relevance_score = 'No' \\n\n",
    "        \n",
    "        Example 2: \n",
    "The patient has pancreatic cancer and the trial is also related to carcinoma pancreatic cancer. --> relevance_score = 'Yes' \\n\n",
    "\n",
    "        Example 3: \n",
    "The patient has pancreatic cancer and the trial is related to breast cancer or ovarian cancer. --> relevance_score = 'No'. \\n \n",
    "\n",
    "        Bring your justification in the explanation. \\n\n",
    "\n",
    "        Mention further information that is needed from the patient's medical history related to the trial's criteria \\n\n",
    "\n",
    "        ===============\n",
    "        Here is the patient's medical profile: {patient_profile} \\n\\n\n",
    "        \"\"\",\n",
    "        input_variables=[\"document\", \"patient_profile\", \"trial_diseases\"],\n",
    "    )\n",
    "\n",
    "llm_with_tool = model.with_structured_output(grade)\n",
    "\n",
    "retrieval_grader = prompt_grader | llm_with_tool\n",
    "\n",
    "doc = docs[0]\n",
    "doc_txt = doc.page_content\n",
    "trial_diseases = doc.metadata.get(\"diseases\")\n",
    "trial_score = retrieval_grader.invoke({\"patient_profile\": patient_profile, \"document\": doc_txt, \"trial_diseases\": trial_diseases})\n",
    "\n",
    "for score in trial_score:\n",
    "    nprint(score)\n",
    "nprint(patient_profile)\n",
    "print(trial_diseases)\n",
    "print(doc_txt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "trial_score\n",
    "trial_score_dic = dict(trial_score)\n",
    "trial_score_dic\n",
    "nctid = 'NCT00785735'\n",
    "trial_score_dic['nctid'] = nctid\n",
    "# relevant_trials.append(score)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('relevance_score', 'Yes')\n",
      "( 'explanation',\n",
      "  'The patient meets the inclusion criteria for the clinical trial related to '\n",
      "  'Generalized Anxiety Disorder. They are of the required age, have a clinical '\n",
      "  'diagnosis of Generalized Anxiety Disorder, and have a Hamilton Anxiety '\n",
      "  'Scale score of eighteen points or more. Additionally, they have not '\n",
      "  'received previous treatment for at least one month before, are not pregnant '\n",
      "  \"or lactating, and have signed an informed consent letter. The patient's \"\n",
      "  \"medical history aligns with the trial's focus on anxiety disorders.\")\n",
      "( 'further_information',\n",
      "  'Further information needed: 1. Confirmation that the patient does not have '\n",
      "  'any of the exclusion criteria such as previous treatment, other mental '\n",
      "  'disorders, alcoholism, smoking, or drug addiction. 2. Confirmation that the '\n",
      "  'patient does not live alone, does not ingest drugs for insomnia or '\n",
      "  'Monoamine Oxidase Inhibitors, does not have epilepsy, does not operate '\n",
      "  'dangerous machinery, and does not have to drive for work for a long time.')\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Patients of both sexes\n",
      "\n",
      "          -  Eighteen years of age and older\n",
      "\n",
      "          -  Clinical diagnosis of Generalized Anxiety Disorder\n",
      "\n",
      "          -  Eighteen points or more on Hamilton Anxiety Scale\n",
      "\n",
      "          -  Without previous treatment for this disease (for at least one month before).\n",
      "\n",
      "          -  In case of being women of reproductive age, who are not pregnant or lactating.\n",
      "\n",
      "          -  To sign an informed consent letter of participation in the investigation.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have treatment for their condition\n",
      "\n",
      "          -  Patients who have another mental disorder added\n",
      "\n",
      "          -  Patients with alcoholism, smoking or drug addiction\n",
      "\n",
      "          -  Patients who live alone\n",
      "\n",
      "          -  Ingest of drugs for insomnia\n",
      "\n",
      "          -  Ingest of drugs of the Monoamine Oxidase Inhibitors group\n",
      "\n",
      "          -  Patients with epilepsy\n",
      "\n",
      "          -  Patients who operate dangerous machinery\n",
      "\n",
      "          -  Patients who have to drive at work (car, truck or other motor vehicle) for a long\n",
      "             time.\n",
      "      \n"
     ]
    }
   ],
   "source": [
    "for score in trial_score:\n",
    "    nprint(score)\n",
    "print(doc_txt)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Python REPL"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:langchain_experimental.utilities.python:Python REPL can execute arbitrary code. Use with caution.\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'11\\n'"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain_experimental.utilities import PythonREPL\n",
    "from typing import Annotated, List\n",
    "from langchain_experimental.tools import PythonREPLTool\n",
    "from langchain_core.prompts import ChatPromptTemplate, MessagesPlaceholder\n",
    "from langchain.agents import AgentExecutor, create_openai_tools_agent\n",
    "import functools\n",
    "from langchain_core.messages import BaseMessage, HumanMessage\n",
    "\n",
    "\n",
    "# Warning: This executes code locally, which can be unsafe when not sandboxed\n",
    "\n",
    "repl = PythonREPL()\n",
    "\n",
    "@tool\n",
    "def python_repl(\n",
    "    code: Annotated[str, \"The python code to execute to compare dates, ages, and other numerical values to references.\"],\n",
    "):\n",
    "    \"\"\"Use this to execute python code. \n",
    "    To compare different dates, convert them to days before any comparison.\n",
    "    Always print the output value with `print(...)` to be visible to the user.\"\"\"\n",
    "    try:\n",
    "        result = repl.run(code)\n",
    "        return result\n",
    "    except BaseException as e:\n",
    "        return f\"Failed to execute. Error: {repr(e)}\"\n",
    "    result_str = f\"Successfully executed:\\n```python\\n{code}\\n```\\nStdout: {result}\"\n",
    "    return (\n",
    "        # result_str\n",
    "        result_str + \"\\n\\nIf you have completed all tasks, respond with FINAL ANSWER.\"\n",
    "    )\n",
    "python_repl(\"print(5+6)\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "================================\u001b[1m System Message \u001b[0m================================\n",
      "\n",
      "You are a helpful AI assistant.You may generate safe python code to do numerical operations and data conversions.To see the result of the code execution, print the output value at thr end with `print(...)`You have access to the following tools: \u001b[33;1m\u001b[1;3m{tool_names}\u001b[0m.\n",
      "\n",
      "=============================\u001b[1m Messages Placeholder \u001b[0m=============================\n",
      "\n",
      "\u001b[33;1m\u001b[1;3m{examples}\u001b[0m\n",
      "\n",
      "=============================\u001b[1m Messages Placeholder \u001b[0m=============================\n",
      "\n",
      "\u001b[33;1m\u001b[1;3m{messages}\u001b[0m\n",
      "\n",
      "=============================\u001b[1m Messages Placeholder \u001b[0m=============================\n",
      "\n",
      "\u001b[33;1m\u001b[1;3m{agent_scratchpad}\u001b[0m\n",
      "'The result of multiplying 2.5 by 4.5 is 11.25.'\n"
     ]
    }
   ],
   "source": [
    "# PythonREPL()\n",
    "langchain.debug=False\n",
    "from langchain_core.prompts import ChatPromptTemplate, MessagesPlaceholder\n",
    "from langchain_experimental.tools import PythonREPLTool\n",
    "from langchain.agents import AgentExecutor, create_openai_tools_agent\n",
    "from langchain_core.messages import SystemMessage\n",
    "\n",
    "\n",
    "python_repl_tool = PythonREPLTool()\n",
    "\n",
    "\n",
    "# prompt = ChatPromptTemplate.from_messages(\n",
    "#     [\n",
    "#         (\n",
    "#             \"system\",\n",
    "#             \"You are a helpful AI assistant.\"\n",
    "#             \" Use the provided tools to progress towards answering the question.\"\n",
    "#             \" If you are unable to fully answer, that's OK, execute what you can to make progress.\"\n",
    "#             \" You have access to the following tools: {tool_names}.\\n{system_message}\",\n",
    "#         ),\n",
    "#         MessagesPlaceholder(variable_name=\"messages\"),\n",
    "#     ]\n",
    "# )\n",
    "prompt = ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        (\n",
    "            \"system\",\n",
    "            \"You are a helpful AI assistant.\"\n",
    "            \"You may generate safe python code to do numerical operations and data conversions.\" \n",
    "            \"To see the result of the code execution, print the output value at thr end with `print(...)`\"\n",
    "            \"You have access to the following tools: {tool_names}.\",\n",
    "        ),\n",
    "        MessagesPlaceholder(variable_name=\"examples\"),\n",
    "        MessagesPlaceholder(variable_name=\"messages\"),\n",
    "        MessagesPlaceholder(variable_name=\"agent_scratchpad\"),\n",
    "    ]\n",
    ")\n",
    "examples = \"\"\"\n",
    "\"question: is November 25, 2023 within the 5 months before the current date, 25-03-2024?\"\n",
    "\n",
    "python code:\n",
    "\n",
    "```\n",
    "today = datetime.strptime('05-03-2024', '%d-%m-%Y')\n",
    "trial_completion_date = datetime.strptime('25-11-2023', '%d-%m-%Y')\n",
    "within_5_months = (today - trialX_completion_date).days < 5*30\n",
    "print(within_5_months)\n",
    "```\n",
    "\"\"\"\n",
    "\n",
    "# python_repl.run(\"is November 25, 2023 within the 5 months before the current date, 25-06-2024?\")\n",
    "# prompt.pretty_print()\n",
    "# prompt.pretty_print()\n",
    "tools = [python_repl]\n",
    "# tools=[]\n",
    "# tools = [python_repl_tool]\n",
    "# system_message=\"To compare numerical values, use the python repl tool. As the output print the result for the user.\",\n",
    "prompt = prompt.partial(examples=[SystemMessage(content=examples)])\n",
    "prompt = prompt.partial(tool_names=\", \".join([tool.name for tool in tools]))\n",
    "prompt.pretty_print()\n",
    "# agent = prompt | model.bind_tools(tools) \n",
    "# agent = prompt | model\n",
    "\n",
    "agent = create_openai_tools_agent(model, tools, prompt)\n",
    "Agent_executor = AgentExecutor(agent=agent, tools=tools)\n",
    "# system_prompt = \"You may generate safe python code to do numerical comparisons and calculations.\"\n",
    "message = \"\"\"\n",
    "The policies:\\n\n",
    "- **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n\n",
    "- **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now. \\n\n",
    "\n",
    "Today data is 20-02-2024.\\n\n",
    "\n",
    "Patient profile:\\n\n",
    "Patient participated in trialX which was completed by November 25, 2023.\\n\n",
    "\n",
    "Is the patient eligible according to trial policies?\n",
    "\"\"\"\n",
    "\n",
    "\n",
    "result = Agent_executor.invoke(\n",
    "    {\n",
    "        \"messages\": [\n",
    "            HumanMessage(content=\"multiply 2.5 by 4.5\")\n",
    "            # HumanMessage(content=\"is November 25, 2023 5 months before February 26, 2024?\")\n",
    "            # HumanMessage(content=\"The patient age is 74. Patients must be between 18 and 75 years old. Does the patient's age fall within this range?\" \n",
    "            # HumanMessage(content=message)\n",
    "        ]\n",
    "    }\n",
    ")\n",
    "\n",
    "nprint(result['output'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### policy retriever tool"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "@tool\n",
    "def lookup_policy(query: str) -> str:\n",
    "    \"\"\"Consult the company policies to check whether certain options are permitted.\n",
    "    Use this before making any flight changes performing other 'write' events.\"\"\"\n",
    "    docs = retriever.query(query, k=2)\n",
    "    return \"\\n\\n\".join([doc[\"page_content\"] for doc in docs])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Graph"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## State"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import Annotated, List\n",
    "from typing_extensions import TypedDict\n",
    "from langgraph.graph.message import AnyMessage, add_messages\n",
    "from langchain_core.messages import AIMessage, SystemMessage, HumanMessage, ToolMessage\n",
    "from langchain_core.documents import Document\n",
    "\n",
    "# from typing import TypedDict\n",
    "\n",
    "class AgentState(TypedDict):\n",
    "    # messages: Annotated[Sequence[BaseMessage], operator.add]\n",
    "    last_node: str\n",
    "    patient_prompt: str\n",
    "    patient_id: int\n",
    "    policy_eligible: bool\n",
    "    rejection_reason: str\n",
    "    patient_data: dict\n",
    "    patient_profile: str\n",
    "    revision_number: int\n",
    "    max_revisions: int\n",
    "    policies: List[Document]\n",
    "    checked_policy: Document\n",
    "    unchecked_policies: List[Document]\n",
    "    trials: List[Document]\n",
    "    relevant_trials: list[dict]\n",
    "    ask_expert: str"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Agent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langgraph.checkpoint.sqlite import SqliteSaver\n",
    "from langgraph.prebuilt import ToolNode\n",
    "from langgraph.prebuilt import tools_condition\n",
    "from langchain_core.pydantic_v1 import BaseModel, Field\n",
    "from operator import itemgetter\n",
    "from typing import Literal\n",
    "from langgraph.graph import StateGraph, END\n",
    "\n",
    "\n",
    "model = ChatOpenAI(model=\"gpt-3.5-turbo\")  #reduce inference cost\n",
    "\n",
    "memory = SqliteSaver.from_conn_string(\":memory:\")\n",
    "\n",
    "\n",
    "\n",
    "# ------- Agents:\n",
    "class Patient_ID(BaseModel):\n",
    "    patient_id: int\n",
    "    # no_id: bool\n",
    "\n",
    "# model = ChatOpenAI(model=\"gpt-3.5-turbo\", temperature=0)  #reduce inference cost\n",
    "patient_data_prompt = \"\"\"You are a helpful assistance in extrcting patient's medical history.\n",
    "Based on the following request identify and return the patient's ID number.\n",
    "\"\"\"\n",
    "# If you cannot find patient ID in the request text then return 10000 as response.\n",
    "\n",
    "def patient_collector_node(state: AgentState):\n",
    "    response = model.with_structured_output(Patient_ID).invoke([\n",
    "        SystemMessage(content=patient_data_prompt),\n",
    "        HumanMessage(content=state['patient_prompt'])\n",
    "    ])\n",
    "    patient_id = response.patient_id\n",
    "    # print(response)\n",
    "    print(f\"Patient ID: {patient_id}\")\n",
    "    patient_data = get_patient_data(patient_id)\n",
    "    print(patient_data)\n",
    "    if result is not None:        \n",
    "        if patient_data.get('name'):\n",
    "            del patient_data['patient_id']\n",
    "            del patient_data['name']\n",
    "        patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "\n",
    "    return {\n",
    "        \"last_node\": \"patient_collector\",\n",
    "        \"patient_data\": patient_data,\n",
    "        \"patient_profile\": patient_profile,\n",
    "        \"patient_id\": patient_id,\n",
    "        \"revision_number\": state.get(\"revision_number\", 1) + 1,\n",
    "        'policy_eligible': 'N/A'\n",
    "        }\n",
    "\n",
    "def policy_search(state: AgentState) -> List[Document]:    \n",
    "    question = f\"\"\"\n",
    "    Does the following patient profile comply with the institutional policies?\\n\n",
    "    {patient_profile}\n",
    "    \"\"\"\n",
    "    docs_retrieved = retriever_policy.get_relevant_documents(question)\n",
    "    if docs_retrieved is None:\n",
    "        docs_retrieved = retriever_policy.get_relevant_documents(question)\n",
    "    return {\n",
    "        \"last_node\": \"policy_search\",\n",
    "        \"policies\": docs_retrieved,\n",
    "        \"unchecked_policies\": docs_retrieved.copy(),\n",
    "    }\n",
    "\n",
    "from helper_functions import policy_evaluator\n",
    "\n",
    "\n",
    "def policy_checker(state: AgentState, docs_retrieved: List[Document] = None):\n",
    "    # Convert patient_data to string    \n",
    "    \n",
    "    docs_retrieved = policy_search(state)\n",
    "\n",
    "    results = []\n",
    "    for doc in docs_retrieved:\n",
    "        policy = doc.page_content\n",
    "        result = policy_evaluator(state['patient_profile'], policy)\n",
    "        results.append(result)\n",
    "    \n",
    "    evaluations = (\"\\n\\n\"+7*\"------------\"+\"\\n\\n\")+(\"\\n\\n\"+7*\"------------\"+\"\\n\\n\").join([result for result in results])\n",
    "        \n",
    "    class comply(BaseModel):\n",
    "        \"\"\"score and reason for trial eligibility check.\"\"\"\n",
    "\n",
    "        binary_score: str = Field(description=\"Patient eligible for the clinical trial 'yes' or 'no'\")\n",
    "        reason: str = Field(description=\"Reason(s) only if the patient is not eligible for clinical trials. Othereise use N/A\")\n",
    "\n",
    "        class Config:\n",
    "            schema_extra = {\n",
    "                \"example\": {\n",
    "                    \"binary_score\": 'yes',\n",
    "                    \"reason\": \"N/A\",\n",
    "                },\n",
    "                \"example 2\": {\n",
    "                    \"binary_score\": 'no',\n",
    "                    \"reason\": \"The patient is pregnant at the moment.\",\n",
    "                },                \n",
    "            }\n",
    "\n",
    "    prompt_evaluate = PromptTemplate(\n",
    "        template=\"\"\" You are a Principal Investigator (PI) for evaluating patients for clinical trials. \n",
    "            You task is to find if the patient is eligible for all trial policies.\n",
    "            \\n The following is a list of policy evaluations for the patient:\n",
    "            \\n\\n {evaluations} \\n\\n\n",
    "                            \n",
    "            Give a binary 'yes' or 'no' score to indicate whether the patient is eligible for all clinical trials.\\n\n",
    "            If the patient is not eligible then also give the reason as a string.\n",
    "            \"\"\",\n",
    "        input_variables=[\"evaluations\"],\n",
    "    )\n",
    "\n",
    "    llm_with_tool = model.with_structured_output(comply)\n",
    "\n",
    "    chain = prompt_evaluate | llm_with_tool\n",
    "\n",
    "    # print(f'today is: {date}')\n",
    "    scored_result = chain.invoke(\n",
    "        {\n",
    "            \"evaluations\": evaluations,\n",
    "            # \"question\": question, \n",
    "            # \"context\": docs, \n",
    "            # \"date\": date\n",
    "            # \"patient_data\": patient_data\n",
    "        }\n",
    "    )\n",
    "    # print(scored_result)\n",
    "    # scored_result    \n",
    "    state['policy_eligible'] = True\n",
    "    if scored_result.binary_score == 'no':\n",
    "        state['policy_eligible'] = False    \n",
    "        state['rejection_reason'] = scored_result.reason\n",
    "        # state['ask_expert'] = 'policy_checker'\n",
    "    \n",
    "    state['policies'] = docs_retrieved\n",
    "    state['patient_profile'] = patient_profile\n",
    "    state[\"revision_number\"] = state.get(\"revision_number\", 1) + 1\n",
    "\n",
    "    return state\n",
    "\n",
    "def trial_search(state: AgentState):\n",
    "    \"\"\"\n",
    "    This node searches the trial database to retrieve a list of clinical trials that match the patient's medical history.\n",
    "    \"\"\"\n",
    "\n",
    "    patient_profile = state['patient_profile']\n",
    "\n",
    "    question = f\"\"\"\n",
    "    Which trials are relevant to the patient with the following medical history?\\n\n",
    "    patient_profile: {patient_profile}\n",
    "    \"\"\"        \n",
    "    docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "    \n",
    "    return {\n",
    "        'last_node': 'trial_search',\n",
    "        'trials': docs_retrieved\n",
    "        }\n",
    "\n",
    "def grade_trials(state: AgentState, trials: List[Document] = None):\n",
    "    \"\"\"\n",
    "    Determines whether the retrieved documents are relevant to the question.\n",
    "\n",
    "    Args:\n",
    "        state (dict): The current graph state\n",
    "\n",
    "    Returns:\n",
    "        state (dict): Updates documents key with only filtered relevant documents\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"----- CHECKING THE TRIALS RELEVANCE TO PATIENT PROFILE ----- \")\n",
    "    \n",
    "    if trials is None:\n",
    "        trials = state['trials']\n",
    "    patient_profile = state['patient_profile']\n",
    "\n",
    "    # Score each doc\n",
    "    relevant_trials = []\n",
    "    for trial in trials:\n",
    "        doc_txt = trial.page_content\n",
    "        trial_diseases = trial.metadata['diseases']\n",
    "        nctid = trial.metadata['nctid']\n",
    "        trial_score = retrieval_grader.invoke(\n",
    "            {\n",
    "                \"patient_profile\": patient_profile, \n",
    "                \"document\": doc_txt, \n",
    "                \"trial_diseases\": trial_diseases\n",
    "            }\n",
    "        )\n",
    "            \n",
    "        relevance_score = trial_score.relevance_score\n",
    "        if relevance_score.lower() == \"yes\":\n",
    "            print(f\"---GRADER: TRIAL {nctid} RELEVANT---\")            \n",
    "            trial_score_dic = dict(trial_score)\n",
    "            trial_score_dic['nctid'] = nctid            \n",
    "            relevant_trials.append(trial_score_dic)\n",
    "        else:\n",
    "            print(f\"---GRADER: TRIAL {nctid} NOT RELEVANT---\")\n",
    "    return {\n",
    "        'last_node': 'trial_search',\n",
    "        \"relevant_trials\": relevant_trials\n",
    "        }\n",
    "        \n",
    "# ========= continue functions =========\n",
    "def should_continue_patient(state: AgentState):\n",
    "    # end = False\n",
    "    if state.get(\"patient_data\"):\n",
    "        # print('patient data found')\n",
    "        print(state.get(\"patient_profile\", 'No profile generated'))\n",
    "        return \"policy_search\"\n",
    "    else:\n",
    "        print('Patient data not found in the database')\n",
    "        return END\n",
    "        \n",
    "    if state[\"revision_number\"] > state[\"max_revisions\"]:\n",
    "        print('max revision reached')\n",
    "        # print(state.get(\"patient_data\", 1))\n",
    "        return END        \n",
    "\n",
    "def should_continue_policy(state: AgentState):\n",
    "    if state[\"revision_number\"] > state[\"max_revisions\"]:\n",
    "        print('max revision reached')        \n",
    "        return END\n",
    "    more_policies = len(state[\"unchecked_policies\"]) > 0\n",
    "    if state[\"policy_eligible\"]:\n",
    "        if more_policies:\n",
    "            print(\"-------------- Check the next policy --------------\")\n",
    "            return \"policy_evaluator\"\n",
    "        else:\n",
    "            print(\"-------------- Patient passed the general trials policies --------------\")\n",
    "            return \"trial_search\"\n",
    "    else:\n",
    "        print(\"Patient did not pass this policy.\\n\")\n",
    "        print(state['checked_policy'].page_content)\n",
    "        # print(\"Patient did not pass the general trials policies.\\n\")        \n",
    "        print('Rejection Reason: ')\n",
    "        nprint(state['rejection_reason'])\n",
    "        print(\"You can correct the patient's medical profile if required.\")\n",
    "        # state['ask_expert'] = 'policy_check'\n",
    "        # print(\"state['ask_expert'] = 'policy_check'\")\n",
    "        # return \"expert\"\n",
    "        return END\n",
    "\n",
    "def should_continue_expert(state: AgentState) -> Literal[\"policy_checker\", END]:\n",
    "    if state[\"policy_eligible\"] == False:\n",
    "        print('to policy check')\n",
    "        next = \"policy_checker\"\n",
    "        # state[\"ask_expert\"] = \"\"\n",
    "    else:\n",
    "        next = END\n",
    "        print('to end')\n",
    "    return next\n",
    "\n",
    "# ==== define graph nodes====\n",
    "\n",
    "builder = StateGraph(AgentState)\n",
    "builder.set_entry_point(\"patient_collector\")\n",
    "builder.add_node(\"patient_collector\", patient_collector_node)\n",
    "builder.add_node(\"policy_search\", policy_search)\n",
    "builder.add_node(\"policy_evaluator\", policy_evaluator)\n",
    "# builder.add_node(\"policy_checker\", policy_checker)\n",
    "builder.add_node(\"trial_search\", trial_search)\n",
    "builder.add_node(\"grade_trials\", grade_trials)\n",
    "# builder.add_node(\"expert\", expert_node)\n",
    "\n",
    "# retrieve = ToolNode([retriever_tool])\n",
    "# builder.add_node(\"retrieve\", retrieve)  # retrieval\n",
    "\n",
    "\n",
    "# ===== define graph edges====\n",
    "# builder.add_edge(\"patient_collector\", \"\")\n",
    "# builder.add_edge(\"patient_adder\", \"patient_collector\")\n",
    "builder.add_conditional_edges(\n",
    "    \"patient_collector\", \n",
    "    should_continue_patient, \n",
    "    {END: END\n",
    "    # \"patient_collector\": \"patient_collector\"\n",
    "    ,\"policy_search\": \"policy_search\"\n",
    "    # , \"policy_checker\": \"policy_checker\"\n",
    "    # ,\"patient_adder\": \"patient_adder\"\n",
    "    }\n",
    ")\n",
    "\n",
    "builder.add_conditional_edges(\n",
    "    \"policy_evaluator\", \n",
    "    should_continue_policy, \n",
    "    {\n",
    "    \"trial_search\": \"trial_search\"\n",
    "    , \"policy_evaluator\": \"policy_evaluator\"\n",
    "    , END: END\n",
    "    }\n",
    ")\n",
    "\n",
    "builder.add_edge(\"policy_search\", \"policy_evaluator\")\n",
    "builder.add_edge(\"trial_search\", \"grade_trials\")\n",
    "# builder.add_edge(\"grade_trials\", END)\n",
    "builder.set_finish_point(\"grade_trials\")\n",
    "\n",
    "\n",
    "graph = builder.compile(\n",
    "    checkpointer=memory\n",
    "    # ,interrupt_before=[\"__end__\"]\n",
    "    # , interrupt_after=['patient_collector', 'policy_search', 'policy_evaluator', 'trial_search', 'grade_trials']\n",
    ")\n",
    "\n",
    "from IPython.display import Image\n",
    "\n",
    "Image(graph.get_graph().draw_png())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'get_patient_data' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[1], line 3\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[38;5;66;03m# patient_data['medical_history'] = \"Chronic Pain, Pregnant\"\u001b[39;00m\n\u001b[0;32m      2\u001b[0m sample_patient_id \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m16\u001b[39m\n\u001b[1;32m----> 3\u001b[0m patient_data \u001b[38;5;241m=\u001b[39m \u001b[43mget_patient_data\u001b[49m(sample_patient_id)\n\u001b[0;32m      4\u001b[0m \u001b[38;5;66;03m# patient_data['trial_completion_date'] = '2024-04-01'\u001b[39;00m\n\u001b[0;32m      5\u001b[0m patient_data\n",
      "\u001b[1;31mNameError\u001b[0m: name 'get_patient_data' is not defined"
     ]
    }
   ],
   "source": [
    "# patient_data['medical_history'] = \"Chronic Pain, Pregnant\"\n",
    "sample_patient_id = 16\n",
    "patient_data = get_patient_data(sample_patient_id)\n",
    "# patient_data['trial_completion_date'] = '2024-04-01'\n",
    "patient_data\n",
    "# date"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 380,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient ID: 32\n",
      "{'patient_id': 32, 'name': 'John Johnson', 'age': 49, 'medical_history': 'Depression', 'previous_trials': 'NCT01611731', 'trial_status': 'Ongoing', 'trial_completion_date': None}\n",
      "Patient is a 49-year-old with a history of depression. They have previously participated in the clinical trial NCT01611731, which is currently ongoing. No trial completion date is available. Based on their medical history, they may be eligible for trials focusing on mental health and depression treatments.\n",
      "Evaluating Policy: \n",
      "#### 1. **General Eligibility Criteria**\n",
      "   - **Age Restrictions**: Patients must be between 18 and 75 years old.\n",
      "   - **Gender**: No restrictions unless specified by the trial protocol.\n",
      "   - **Informed Consent**: All patients must provide informed consent prior to participation.\n",
      "   - **Residency**: Patients must be residents of the country where the trial is conducted.\n",
      "   - **Health Insurance**: Patients must have valid health insurance coverage.\n",
      "\n",
      "-------------- Check the next policy --------------\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[380], line 11\u001b[0m\n\u001b[0;32m      3\u001b[0m \u001b[38;5;28mlist\u001b[39m(graph\u001b[38;5;241m.\u001b[39mget_state_history(thread))\n\u001b[0;32m      4\u001b[0m config \u001b[38;5;241m=\u001b[39m {\n\u001b[0;32m      5\u001b[0m     \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mpatient_prompt\u001b[39m\u001b[38;5;124m'\u001b[39m: \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mIs patient \u001b[39m\u001b[38;5;132;01m{\u001b[39;00msample_patient_id\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m eligible for any medical trial?\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m      6\u001b[0m     \u001b[38;5;66;03m# 'patient_prompt': \"Is patient Max eligible for any medical trial?\",\u001b[39;00m\n\u001b[0;32m      7\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmax_revisions\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;241m10\u001b[39m,\n\u001b[0;32m      8\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mrevision_number\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;241m1\u001b[39m,\n\u001b[0;32m      9\u001b[0m }\n\u001b[1;32m---> 11\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mgraph\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43minvoke\u001b[49m\u001b[43m(\u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mthread\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32md:\\Portfolio\\LLMs Applications\\.llmenv\\Lib\\site-packages\\langgraph\\pregel\\__init__.py:1400\u001b[0m, in \u001b[0;36mPregel.invoke\u001b[1;34m(self, input, config, stream_mode, output_keys, input_keys, interrupt_before, interrupt_after, debug, **kwargs)\u001b[0m\n\u001b[0;32m   1398\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m   1399\u001b[0m     chunks \u001b[38;5;241m=\u001b[39m []\n\u001b[1;32m-> 1400\u001b[0m \u001b[43m\u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mchunk\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1401\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1402\u001b[0m \u001b[43m    \u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1403\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstream_mode\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_mode\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1404\u001b[0m \u001b[43m    \u001b[49m\u001b[43moutput_keys\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43moutput_keys\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1405\u001b[0m \u001b[43m    \u001b[49m\u001b[43minput_keys\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43minput_keys\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1406\u001b[0m \u001b[43m    \u001b[49m\u001b[43minterrupt_before\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43minterrupt_before\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1407\u001b[0m \u001b[43m    \u001b[49m\u001b[43minterrupt_after\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43minterrupt_after\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1408\u001b[0m \u001b[43m    \u001b[49m\u001b[43mdebug\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mdebug\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1409\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1410\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\u001b[43m:\u001b[49m\n\u001b[0;32m   1411\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mstream_mode\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m==\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mvalues\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\n\u001b[0;32m   1412\u001b[0m \u001b[43m        \u001b[49m\u001b[43mlatest\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mchunk\u001b[49m\n",
      "File \u001b[1;32md:\\Portfolio\\LLMs Applications\\.llmenv\\Lib\\site-packages\\langgraph\\pregel\\__init__.py:929\u001b[0m, in \u001b[0;36mPregel.stream\u001b[1;34m(self, input, config, stream_mode, output_keys, input_keys, interrupt_before, interrupt_after, debug)\u001b[0m\n\u001b[0;32m    923\u001b[0m end_time \u001b[38;5;241m=\u001b[39m (\n\u001b[0;32m    924\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mstep_timeout \u001b[38;5;241m+\u001b[39m time\u001b[38;5;241m.\u001b[39mmonotonic()\n\u001b[0;32m    925\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mstep_timeout\n\u001b[0;32m    926\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m    927\u001b[0m )\n\u001b[0;32m    928\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m futures:\n\u001b[1;32m--> 929\u001b[0m     done, inflight \u001b[38;5;241m=\u001b[39m \u001b[43mconcurrent\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfutures\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mwait\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    930\u001b[0m \u001b[43m        \u001b[49m\u001b[43mfutures\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    931\u001b[0m \u001b[43m        \u001b[49m\u001b[43mreturn_when\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mconcurrent\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfutures\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mFIRST_COMPLETED\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    932\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mmax\u001b[39;49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mend_time\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m-\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mtime\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmonotonic\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    933\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mend_time\u001b[49m\n\u001b[0;32m    934\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m    935\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    936\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m fut \u001b[38;5;129;01min\u001b[39;00m done:\n\u001b[0;32m    937\u001b[0m         task \u001b[38;5;241m=\u001b[39m futures\u001b[38;5;241m.\u001b[39mpop(fut)\n",
      "File \u001b[1;32m~\\.pyenv\\pyenv-win\\versions\\3.12.0\\Lib\\concurrent\\futures\\_base.py:305\u001b[0m, in \u001b[0;36mwait\u001b[1;34m(fs, timeout, return_when)\u001b[0m\n\u001b[0;32m    301\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m DoneAndNotDoneFutures(done, not_done)\n\u001b[0;32m    303\u001b[0m     waiter \u001b[38;5;241m=\u001b[39m _create_and_install_waiters(fs, return_when)\n\u001b[1;32m--> 305\u001b[0m \u001b[43mwaiter\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mevent\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mwait\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    306\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m f \u001b[38;5;129;01min\u001b[39;00m fs:\n\u001b[0;32m    307\u001b[0m     \u001b[38;5;28;01mwith\u001b[39;00m f\u001b[38;5;241m.\u001b[39m_condition:\n",
      "File \u001b[1;32m~\\.pyenv\\pyenv-win\\versions\\3.12.0\\Lib\\threading.py:634\u001b[0m, in \u001b[0;36mEvent.wait\u001b[1;34m(self, timeout)\u001b[0m\n\u001b[0;32m    632\u001b[0m signaled \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_flag\n\u001b[0;32m    633\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m signaled:\n\u001b[1;32m--> 634\u001b[0m     signaled \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_cond\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mwait\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    635\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m signaled\n",
      "File \u001b[1;32m~\\.pyenv\\pyenv-win\\versions\\3.12.0\\Lib\\threading.py:334\u001b[0m, in \u001b[0;36mCondition.wait\u001b[1;34m(self, timeout)\u001b[0m\n\u001b[0;32m    332\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:    \u001b[38;5;66;03m# restore state no matter what (e.g., KeyboardInterrupt)\u001b[39;00m\n\u001b[0;32m    333\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m timeout \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m--> 334\u001b[0m         \u001b[43mwaiter\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43macquire\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    335\u001b[0m         gotit \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[0;32m    336\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "thread = {\"configurable\": {\"thread_id\": \"0\"}}\n",
    "\n",
    "list(graph.get_state_history(thread))\n",
    "config = {\n",
    "    'patient_prompt': f\"Is patient {sample_patient_id} eligible for any medical trial?\",\n",
    "    # 'patient_prompt': \"Is patient Max eligible for any medical trial?\",\n",
    "    \"max_revisions\": 10,\n",
    "    \"revision_number\": 1,\n",
    "}\n",
    "\n",
    "response = graph.invoke(config, thread)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 436,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient ID: 16\n",
      "{'patient_id': 16, 'name': 'Emma Smith', 'age': 80, 'medical_history': 'pancreatic cancer', 'previous_trials': 'NCT04589611', 'trial_status': 'Completed', 'trial_completion_date': '2023-05-27'}\n",
      "Patient is an 80-year-old with a history of pancreatic cancer. They have previously participated in the clinical trial NCT04589611, which has been completed as of May 27, 2023. Based on their medical history, they may be eligible for future pancreatic cancer clinical trials.\n",
      "{'patient_collector': {'last_node': 'patient_collector', 'patient_id': 16, 'policy_eligible': 'N/A', 'patient_data': {'age': 80, 'medical_history': 'pancreatic cancer', 'previous_trials': 'NCT04589611', 'trial_status': 'Completed', 'trial_completion_date': '2023-05-27'}, 'patient_profile': 'Patient is an 80-year-old with a history of pancreatic cancer. They have previously participated in the clinical trial NCT04589611, which has been completed as of May 27, 2023. Based on their medical history, they may be eligible for future pancreatic cancer clinical trials.', 'revision_number': 2}}\n",
      "{'policy_search': {'last_node': 'policy_search', 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'unchecked_policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})]}}\n",
      "Evaluating Policy: \n",
      "#### 1. **General Eligibility Criteria**\n",
      "   - **Age Restrictions**: Patients must be between 18 and 75 years old.\n",
      "   - **Gender**: No restrictions unless specified by the trial protocol.\n",
      "   - **Informed Consent**: All patients must provide informed consent prior to participation.\n",
      "   - **Residency**: Patients must be residents of the country where the trial is conducted.\n",
      "   - **Health Insurance**: Patients must have valid health insurance coverage.\n",
      "\n",
      "Patient did not pass this policy.\n",
      "\n",
      "\n",
      "#### 1. **General Eligibility Criteria**\n",
      "   - **Age Restrictions**: Patients must be between 18 and 75 years old.\n",
      "   - **Gender**: No restrictions unless specified by the trial protocol.\n",
      "   - **Informed Consent**: All patients must provide informed consent prior to participation.\n",
      "   - **Residency**: Patients must be residents of the country where the trial is conducted.\n",
      "   - **Health Insurance**: Patients must have valid health insurance coverage.\n",
      "\n",
      "Rejection Reason: \n",
      "'Age exceeds the maximum limit of 75 years.'\n",
      "You can correct the patient's medical profile if required.\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[436], line 10\u001b[0m\n\u001b[0;32m      3\u001b[0m thread \u001b[38;5;241m=\u001b[39m {\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mconfigurable\u001b[39m\u001b[38;5;124m\"\u001b[39m: {\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mthread_id\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m1\u001b[39m\u001b[38;5;124m\"\u001b[39m}}\n\u001b[0;32m      4\u001b[0m events_gen \u001b[38;5;241m=\u001b[39m graph\u001b[38;5;241m.\u001b[39mstream({\n\u001b[0;32m      5\u001b[0m     \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mpatient_prompt\u001b[39m\u001b[38;5;124m'\u001b[39m: \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mIs patient \u001b[39m\u001b[38;5;132;01m{\u001b[39;00msample_patient_id\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m eligible for any medical trial?\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m      6\u001b[0m     \u001b[38;5;66;03m# 'patient_prompt': \"Is patient Max eligible for any medical trial?\",\u001b[39;00m\n\u001b[0;32m      7\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmax_revisions\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;241m10\u001b[39m,\n\u001b[0;32m      8\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mrevision_number\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;241m1\u001b[39m,\n\u001b[0;32m      9\u001b[0m }, thread)\n\u001b[1;32m---> 10\u001b[0m \u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mevent\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mevents_gen\u001b[49m\u001b[43m:\u001b[49m\n\u001b[0;32m     11\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43mprint\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mevent\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     12\u001b[0m \u001b[38;5;66;03m# event = events_gen.__next__()\u001b[39;00m\n",
      "File \u001b[1;32md:\\Portfolio\\LLMs Applications\\.llmenv\\Lib\\site-packages\\langgraph\\pregel\\__init__.py:929\u001b[0m, in \u001b[0;36mPregel.stream\u001b[1;34m(self, input, config, stream_mode, output_keys, input_keys, interrupt_before, interrupt_after, debug)\u001b[0m\n\u001b[0;32m    923\u001b[0m end_time \u001b[38;5;241m=\u001b[39m (\n\u001b[0;32m    924\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mstep_timeout \u001b[38;5;241m+\u001b[39m time\u001b[38;5;241m.\u001b[39mmonotonic()\n\u001b[0;32m    925\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mstep_timeout\n\u001b[0;32m    926\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m    927\u001b[0m )\n\u001b[0;32m    928\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m futures:\n\u001b[1;32m--> 929\u001b[0m     done, inflight \u001b[38;5;241m=\u001b[39m \u001b[43mconcurrent\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfutures\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mwait\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    930\u001b[0m \u001b[43m        \u001b[49m\u001b[43mfutures\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    931\u001b[0m \u001b[43m        \u001b[49m\u001b[43mreturn_when\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mconcurrent\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfutures\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mFIRST_COMPLETED\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    932\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mmax\u001b[39;49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mend_time\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m-\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mtime\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmonotonic\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    933\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mend_time\u001b[49m\n\u001b[0;32m    934\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m    935\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    936\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m fut \u001b[38;5;129;01min\u001b[39;00m done:\n\u001b[0;32m    937\u001b[0m         task \u001b[38;5;241m=\u001b[39m futures\u001b[38;5;241m.\u001b[39mpop(fut)\n",
      "File \u001b[1;32m~\\.pyenv\\pyenv-win\\versions\\3.12.0\\Lib\\concurrent\\futures\\_base.py:305\u001b[0m, in \u001b[0;36mwait\u001b[1;34m(fs, timeout, return_when)\u001b[0m\n\u001b[0;32m    301\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m DoneAndNotDoneFutures(done, not_done)\n\u001b[0;32m    303\u001b[0m     waiter \u001b[38;5;241m=\u001b[39m _create_and_install_waiters(fs, return_when)\n\u001b[1;32m--> 305\u001b[0m \u001b[43mwaiter\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mevent\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mwait\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    306\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m f \u001b[38;5;129;01min\u001b[39;00m fs:\n\u001b[0;32m    307\u001b[0m     \u001b[38;5;28;01mwith\u001b[39;00m f\u001b[38;5;241m.\u001b[39m_condition:\n",
      "File \u001b[1;32m~\\.pyenv\\pyenv-win\\versions\\3.12.0\\Lib\\threading.py:634\u001b[0m, in \u001b[0;36mEvent.wait\u001b[1;34m(self, timeout)\u001b[0m\n\u001b[0;32m    632\u001b[0m signaled \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_flag\n\u001b[0;32m    633\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m signaled:\n\u001b[1;32m--> 634\u001b[0m     signaled \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_cond\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mwait\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    635\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m signaled\n",
      "File \u001b[1;32m~\\.pyenv\\pyenv-win\\versions\\3.12.0\\Lib\\threading.py:334\u001b[0m, in \u001b[0;36mCondition.wait\u001b[1;34m(self, timeout)\u001b[0m\n\u001b[0;32m    332\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:    \u001b[38;5;66;03m# restore state no matter what (e.g., KeyboardInterrupt)\u001b[39;00m\n\u001b[0;32m    333\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m timeout \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m--> 334\u001b[0m         \u001b[43mwaiter\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43macquire\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    335\u001b[0m         gotit \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[0;32m    336\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "langchain.debug = False\n",
    "\n",
    "thread = {\"configurable\": {\"thread_id\": \"1\"}}\n",
    "events_gen = graph.stream({\n",
    "    'patient_prompt': f\"Is patient {sample_patient_id} eligible for any medical trial?\",\n",
    "    # 'patient_prompt': \"Is patient Max eligible for any medical trial?\",\n",
    "    \"max_revisions\": 10,\n",
    "    \"revision_number\": 1,\n",
    "}, thread)\n",
    "for event in events_gen:\n",
    "    print(event)\n",
    "# event = events_gen.__next__()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 387,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[StateSnapshot(values={'last_node': 'patient_collector', 'patient_prompt': 'Is patient 32 eligible for any medical trial?', 'patient_id': 32, 'patient_data': {'messages': [HumanMessage(content='multiply 2.5 by 4.5')], 'output': 'The result of multiplying 2.5 by 4.5 is 11.25.'}, 'patient_profile': 'Patient is a 49-year-old with a history of depression. They have previously participated in the clinical trial NCT01611731, which is currently ongoing. No trial completion date is available at this time. Based on their medical history, relevant medical trials may include those focusing on depression treatments or mental health interventions.', 'revision_number': 2, 'max_revisions': 10}, next=('policy_search',), config={'configurable': {'thread_id': '1', 'thread_ts': '1ef38741-26fb-62ca-8001-43f97bb7c0ea'}}, metadata={'source': 'loop', 'step': 1, 'writes': {'patient_collector': {'last_node': 'patient_collector', 'patient_id': 32, 'patient_data': {'messages': [HumanMessage(content='multiply 2.5 by 4.5')], 'output': 'The result of multiplying 2.5 by 4.5 is 11.25.'}, 'patient_profile': 'Patient is a 49-year-old with a history of depression. They have previously participated in the clinical trial NCT01611731, which is currently ongoing. No trial completion date is available at this time. Based on their medical history, relevant medical trials may include those focusing on depression treatments or mental health interventions.', 'revision_number': 2}}}, created_at='2024-07-02T13:07:44.844666+00:00', parent_config={'configurable': {'thread_id': '1', 'thread_ts': '1ef38741-09de-60b2-8000-58465a0dd255'}}),\n",
       " StateSnapshot(values={'patient_prompt': 'Is patient 32 eligible for any medical trial?', 'revision_number': 1, 'max_revisions': 10}, next=('patient_collector',), config={'configurable': {'thread_id': '1', 'thread_ts': '1ef38741-09de-60b2-8000-58465a0dd255'}}, metadata={'source': 'loop', 'step': 0, 'writes': None}, created_at='2024-07-02T13:07:41.791864+00:00', parent_config={'configurable': {'thread_id': '1', 'thread_ts': '1ef38741-093c-6925-bfff-a6a8349fdf52'}}),\n",
       " StateSnapshot(values={}, next=('__start__',), config={'configurable': {'thread_id': '1', 'thread_ts': '1ef38741-093c-6925-bfff-a6a8349fdf52'}}, metadata={'source': 'input', 'step': -1, 'writes': {'patient_prompt': 'Is patient 32 eligible for any medical trial?', 'max_revisions': 10, 'revision_number': 1}}, created_at='2024-07-02T13:07:41.725725+00:00', parent_config=None)]"
      ]
     },
     "execution_count": 387,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from helper_functions import fn_get_state, resume_from_state\n",
    "states, state_next, state_last  = fn_get_state(graph, thread, vernose = False, next = 'policy_evaluator')\n",
    "# states\n",
    "# states[-3].next\n",
    "# state_next = states[-3]\n",
    "# print(state_next.next)\n",
    "# state_next.values['patient_profile']\n",
    "# states[1].next\n",
    "# state_next.values\n",
    "state = states[0]\n",
    "state.values\n",
    "# state.next\n",
    "states\n",
    "# patient_profile = states[0].values['patient_profile']\n",
    "# nprint(patient_profile)\n",
    "# states[0].values\n",
    "# for s in state:\n",
    "    # print(s)\n",
    "# states[0].created_at\n",
    "# docs = states[0].values['policies']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 327,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Evaluating Policy: \n",
      "#### 1. **General Eligibility Criteria**\n",
      "   - **Age Restrictions**: Patients must be between 18 and 75 years old.\n",
      "   - **Gender**: No restrictions unless specified by the trial protocol.\n",
      "   - **Informed Consent**: All patients must provide informed consent prior to participation.\n",
      "   - **Residency**: Patients must be residents of the country where the trial is conducted.\n",
      "   - **Health Insurance**: Patients must have valid health insurance coverage.\n",
      "\n",
      "-------------- Check the next policy --------------\n",
      "{'policy_evaluator': {'last_node': 'policy_evaluator', 'patient_prompt': 'Is patient 16 eligible for any medical trial?', 'patient_id': 16, 'policy_eligible': True, 'rejection_reason': 'N/A', 'patient_data': {'patient_id': 16, 'name': 'Emma Smith', 'age': 80, 'medical_history': 'pancreatic cancer', 'previous_trials': 'NCT04589611', 'trial_status': 'Completed', 'trial_completion_date': '2023-05-27'}, 'patient_profile': '\\n    Patient is a 30-year-old with a history of mesothelioma. They have \\n    previously participated in the clinical trial NCT04068836, which is \\n    FINISHED 6 months ago. Based on their medical history, they may be eligible for other mesothelioma \\n    clinical trials.\\n    ', 'revision_number': 3, 'max_revisions': 10, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n",
      "Evaluating Policy: \n",
      "#### 4. **Medication and Treatment Restrictions**\n",
      "   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\n",
      "   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\n",
      "   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\n",
      "\n",
      "-------------- Check the next policy --------------\n",
      "{'policy_evaluator': {'last_node': 'policy_evaluator', 'patient_prompt': 'Is patient 16 eligible for any medical trial?', 'patient_id': 16, 'policy_eligible': True, 'rejection_reason': 'N/A', 'patient_data': {'patient_id': 16, 'name': 'Emma Smith', 'age': 80, 'medical_history': 'pancreatic cancer', 'previous_trials': 'NCT04589611', 'trial_status': 'Completed', 'trial_completion_date': '2023-05-27'}, 'patient_profile': '\\n    Patient is a 30-year-old with a history of mesothelioma. They have \\n    previously participated in the clinical trial NCT04068836, which is \\n    FINISHED 6 months ago. Based on their medical history, they may be eligible for other mesothelioma \\n    clinical trials.\\n    ', 'revision_number': 4, 'max_revisions': 10, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n",
      "Evaluating Policy: \n",
      "#### 2. **Medical History Restrictions**\n",
      "   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\n",
      "   - **Uncontrolled Diabetes Mellitus**     \n",
      "   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \n",
      "   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\n",
      "\n",
      "-------------- Check the next policy --------------\n",
      "{'policy_evaluator': {'last_node': 'policy_evaluator', 'patient_prompt': 'Is patient 16 eligible for any medical trial?', 'patient_id': 16, 'policy_eligible': True, 'rejection_reason': 'N/A', 'patient_data': {'patient_id': 16, 'name': 'Emma Smith', 'age': 80, 'medical_history': 'pancreatic cancer', 'previous_trials': 'NCT04589611', 'trial_status': 'Completed', 'trial_completion_date': '2023-05-27'}, 'patient_profile': '\\n    Patient is a 30-year-old with a history of mesothelioma. They have \\n    previously participated in the clinical trial NCT04068836, which is \\n    FINISHED 6 months ago. Based on their medical history, they may be eligible for other mesothelioma \\n    clinical trials.\\n    ', 'revision_number': 5, 'max_revisions': 10, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n",
      "Evaluating Policy: \n",
      "#### 3. **Previous Trial Participation**   \n",
      "   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\n",
      "   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\n",
      "   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\n",
      "   - **Trial Outcomes**:\n",
      "     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\n",
      "     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\n",
      "\n",
      "Patient did not pass this policy.\n",
      "\n",
      "\n",
      "#### 3. **Previous Trial Participation**   \n",
      "   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\n",
      "   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\n",
      "   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\n",
      "   - **Trial Outcomes**:\n",
      "     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\n",
      "     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\n",
      "\n",
      "Rejection Reason: \n",
      "('The patient participated in a previous trial that finished 182 days ago, '\n",
      " 'which is within the past 5 months (150 days) from now. The patient '\n",
      " 'participated in the previous trial 213 days ago, which is less than 150 '\n",
      " 'days, and the policy states that patients cannot have participated in any '\n",
      " 'other clinical trial within the past 5 months.')\n",
      "You can correct the patient's medical profile if required.\n",
      "{'policy_evaluator': {'last_node': 'policy_evaluator', 'patient_prompt': 'Is patient 16 eligible for any medical trial?', 'patient_id': 16, 'policy_eligible': False, 'rejection_reason': 'The patient participated in a previous trial that finished 182 days ago, which is within the past 5 months (150 days) from now. The patient participated in the previous trial 213 days ago, which is less than 150 days, and the policy states that patients cannot have participated in any other clinical trial within the past 5 months.', 'patient_data': {'patient_id': 16, 'name': 'Emma Smith', 'age': 80, 'medical_history': 'pancreatic cancer', 'previous_trials': 'NCT04589611', 'trial_status': 'Completed', 'trial_completion_date': '2023-05-27'}, 'patient_profile': '\\n    Patient is a 30-year-old with a history of mesothelioma. They have \\n    previously participated in the clinical trial NCT04068836, which is \\n    FINISHED 6 months ago. Based on their medical history, they may be eligible for other mesothelioma \\n    clinical trials.\\n    ', 'revision_number': 6, 'max_revisions': 10, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n"
     ]
    }
   ],
   "source": [
    "skip_policy = False\n",
    "profile_corection = True\n",
    "\n",
    "\n",
    "if profile_corection:\n",
    "    new_profile= \"\"\"\n",
    "    Patient is a 30-year-old with a history of mesothelioma. They have \n",
    "    previously participated in the clinical trial NCT04068836, which is \n",
    "    FINISHED 6 months ago. Based on their medical history, they may be eligible for other mesothelioma \n",
    "    clinical trials.\n",
    "    \"\"\"\n",
    "\n",
    "    # add_to_profile = \"\"\"\n",
    "    # Exlusion term: ignore age limits in the policies.\n",
    "    # \"\"\"    \n",
    "    state = states[1]\n",
    "    # state.values['patient_profile'] = new_profile\n",
    "    # branch_state = graph.update_state(state.config, state.values, as_node = None)\n",
    "    # events = []\n",
    "    # for event in graph.stream(None, branch_state):\n",
    "    #     events.append(event)\n",
    "    #     print(event)\n",
    "    resume_from_state(graph, state, key = 'patient_profile', value = new_profile) # to continue with new profile\n",
    "\n",
    "# patient_profile = state.values['patient_profile']\n",
    "\n",
    "# new_profile = patient_profile + add_to_profile\n",
    "# nprint(new_profile)\n",
    "\n",
    "if skip_policy:\n",
    "    state = states[1]\n",
    "    # state.values\n",
    "    state.values['policy_eligible'] = True\n",
    "    state.values['unchecked_policies'].pop(0)\n",
    "    # state.values['max_revisions'] = 10\n",
    "    state.values['rejection_reason'] = 'N/A'\n",
    "    resume_from_state(graph, state, key = None, value = None , as_node = \"policy_evaluator\") # go to next policy        \n",
    "# state.values\n",
    "\n",
    "# resume_from_state(graph, state)\n",
    "# resume_from_state(graph, state, key = 'patient_profile', value = new_profile) # to continue with new profile\n",
    "# resume_from_state(graph, state, key = 'patient_profile', value = new_profile , as_node = \"policy_evaluator\")\n",
    "# resume_from_state(graph, state, key = None, value = None , as_node = \"policy_evaluator\") # go to next policy\n",
    "# branch_and_add = graph.update_state(state.config, state.values, as_node=\"policy_evaluator\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### HIL"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Continue from modified state"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 378,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "-------------- Check the next policy --------------\n",
      "--------- continue from modified state ---------\n",
      "-------------- Check the next policy --------------\n",
      "{'policy_evaluator': {'patient_prompt': 'Is patient 20 eligible for any medical trial?', 'patient_id': 20, 'policy_eligible': True, 'rejection_reason': 'N/A', 'patient_data': {'patient_id': 20, 'name': 'Alice Doe', 'age': 60, 'medical_history': 'myeloma', 'previous_trials': 'NCT01391532', 'trial_status': 'Completed', 'trial_completion_date': '2023-01-19'}, 'patient_profile': 'Patient is a 60-year-old with a history of myeloma. They have previously participated in the clinical trial NCT01391532, which was completed on January 19, 2023. Based on their medical history, they may be eligible for ongoing clinical trials for myeloma treatment.', 'revision_number': 5, 'max_revisions': 6, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n",
      "-------------- Check the next policy --------------\n",
      "{'policy_evaluator': {'patient_prompt': 'Is patient 20 eligible for any medical trial?', 'patient_id': 20, 'policy_eligible': True, 'rejection_reason': 'N/A', 'patient_data': {'patient_id': 20, 'name': 'Alice Doe', 'age': 60, 'medical_history': 'myeloma', 'previous_trials': 'NCT01391532', 'trial_status': 'Completed', 'trial_completion_date': '2023-01-19'}, 'patient_profile': 'Patient is a 60-year-old with a history of myeloma. They have previously participated in the clinical trial NCT01391532, which was completed on January 19, 2023. Based on their medical history, they may be eligible for ongoing clinical trials for myeloma treatment.', 'revision_number': 6, 'max_revisions': 6, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n",
      "max revision reached\n",
      "{'policy_evaluator': {'patient_prompt': 'Is patient 20 eligible for any medical trial?', 'patient_id': 20, 'policy_eligible': True, 'rejection_reason': 'N/A', 'patient_data': {'patient_id': 20, 'name': 'Alice Doe', 'age': 60, 'medical_history': 'myeloma', 'previous_trials': 'NCT01391532', 'trial_status': 'Completed', 'trial_completion_date': '2023-01-19'}, 'patient_profile': 'Patient is a 60-year-old with a history of myeloma. They have previously participated in the clinical trial NCT01391532, which was completed on January 19, 2023. Based on their medical history, they may be eligible for ongoing clinical trials for myeloma treatment.', 'revision_number': 7, 'max_revisions': 6, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n"
     ]
    }
   ],
   "source": [
    "new_profile = \"\"\"\n",
    "'Patient is a 74-year-old with a history of Chronic Pain. \n",
    "They have previously participated in the clinical trial NCT07600953, which is currently completed. \n",
    "Based on their medical history, they may be eligible for trials focusing on pain management or chronic pain conditions.'\n",
    "\"\"\"\n",
    "\n",
    "# events = resume_from_state(graph, state_next, 'patient_profile', new_profile)\n",
    "events = resume_from_state(graph, state_next)\n",
    "\n",
    "# result = policy_checker(state_next.values)\n",
    "# result = policy_checker(state_next.values, [doc])\n",
    "# print(result['policy_eligible'])\n",
    "# if 'rejection_reason' in result:\n",
    "    # nprint(result['rejection_reason']) \n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Let's look at the trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "==== evaluaiton of trial NCT02366819\n",
      "explanation:\n",
      "('The patient has a history of esophagogastric adenocarcinoma, which is one of '\n",
      " \"the diseases included in the trial's inclusion criteria. Therefore, the \"\n",
      " \"trial is relevant to the patient's medical profile.\")\n",
      "Required information:\n",
      "(\"Additional information needed from the patient's medical history includes \"\n",
      " 'current ECOG performance status, recent blood test results for ANC, '\n",
      " 'hemoglobin, platelets, total bilirubin, SGOT, SGPT, and creatinine levels. '\n",
      " 'It would also be important to know if the patient has any concurrent medical '\n",
      " 'conditions or is taking any medications that may affect eligibility for the '\n",
      " 'trial.')\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>relevance_score</th>\n",
       "      <th>explanation</th>\n",
       "      <th>further_information</th>\n",
       "      <th>nctid</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Yes</td>\n",
       "      <td>The patient has a history of esophagogastric a...</td>\n",
       "      <td>Additional information needed from the patient...</td>\n",
       "      <td>NCT02366819</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  relevance_score                                        explanation  \\\n",
       "0             Yes  The patient has a history of esophagogastric a...   \n",
       "\n",
       "                                 further_information        nctid  \n",
       "0  Additional information needed from the patient...  NCT02366819  "
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# if event has the key grade_trials\n",
    "if \"grade_trials\" in event:\n",
    "    if len(event['grade_trials']['relevant_trials'])>0:\n",
    "        # convert to dataframe\n",
    "        df_trials_relevant = pd.DataFrame(event['grade_trials']['relevant_trials'])\n",
    "        for i, row in df_trials_relevant.iterrows():\n",
    "            print('==== evaluaiton of trial', row['nctid'])\n",
    "            print('explanation:')\n",
    "            nprint(row['explanation'])\n",
    "            print('Required information:')\n",
    "            nprint(row['further_information'])\n",
    "else:\n",
    "    print('The trial_grader was not reached!')\n",
    "\n",
    "df_trials_relevant\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed locally advanced gastric (primary endpoint includes proximal\\r\\n             and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral)\\r\\n             adenocarcinomas are eligible for enrolment but will not be included in the primary\\r\\n             analysis\\r\\n\\r\\n          -  Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary\\r\\n             tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)\\r\\n\\r\\n          -  All patients must have diagnostic laparoscopy with diagnostic washings for cytology;\\r\\n             both cytology positive and negative patients are eligible for enrolment, but only\\r\\n             cytology negative patients will be included in the primary analyses; gross peritoneal\\r\\n             disease is not eligible\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1\\r\\n\\r\\n          -  Eligible for surgery with curative intent\\r\\n\\r\\n          -  Absolute neutrophil count (ANC) >= 1250/ul\\r\\n\\r\\n          -  Hemoglobin >= 9 g/dL\\r\\n\\r\\n          -  Platelets >= 100,000/ul\\r\\n\\r\\n          -  Total bilirubin < 1.5 x upper limit of normal\\r\\n\\r\\n          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\\r\\n             transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver\\r\\n             metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver\\r\\n             metastases\\r\\n\\r\\n          -  Creatinine =< 1.5 x upper limit of normal\\r\\n\\r\\n          -  Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor\\r\\n             (RECIST) 1.1 will be allowed\\r\\n\\r\\n          -  Women of child-bearing potential and men must agree to use adequate contraception\\r\\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and for\\r\\n             the duration of study participation, up until 30 days after final study treatment;\\r\\n             should a woman become pregnant or suspect that she is pregnant while participating in\\r\\n             this study, she should inform her treating physician immediately\\r\\n\\r\\n          -  Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3,\\r\\n             subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative\\r\\n             drugs whenever possible, given the potential for drug-drug interactions with\\r\\n             irinotecan\\r\\n\\r\\n          -  Signed informed consent\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Previous or concurrent malignancy, except for adequately treated basal cell or\\r\\n             squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the\\r\\n             patient has been previously treated and the lifetime recurrence risk is less than 30%\\r\\n\\r\\n          -  Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's\\r\\n             disease, ulcerative colitis)\\r\\n\\r\\n          -  Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology\\r\\n             Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)\\r\\n\\r\\n          -  Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0\\r\\n\\r\\n          -  Serious underlying medical or psychiatric illnesses that would, in the opinion of the\\r\\n             treating physician, substantially increase the risk for complications related to\\r\\n             treatment\\r\\n\\r\\n          -  Active uncontrolled bleeding\\r\\n\\r\\n          -  Pregnancy or breastfeeding\\r\\n\\r\\n          -  Major surgery within 4 weeks\\r\\n\\r\\n          -  Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be\\r\\n             allowed and treated as in the *28/*28 dosing group\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['esophageal adenocarcinoma', 'gastric adenocarcinoma', 'stage iib gastric cancer', 'stage iiia esophageal adenocarcinoma', 'stage iiia gastric cancer', 'stage iiib esophageal adenocarcinoma', 'stage iiib gastric cancer', 'stage iiic esophageal adenocarcinoma', 'stage iiic gastric cancer']\", 'drugs': \"['oxaliplatin', 'leucovorin calcium', 'irinotecan hydrochloride', 'fluorouracil']\", 'nctid': 'NCT02366819', 'status': 'recruiting'})"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "states, state_next, state_last = fn_get_state(graph, thread, vernose = False, next = 'policy_checker')\n",
    "nctid = state_last.values['relevant_trials'][0]['nctid']\n",
    "df_trials[df_trials['nctid'] == nctid]['diseases'].values[0]\n",
    "df_trials[df_trials['nctid'] == nctid]['criteria'].values[0]\n",
    "doc = state_last.values['trials'][-1]\n",
    "doc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "----- CHECKING THE TRIALS RELEVANCE TO PATIENT PROFILE ----- \n",
      "---GRADER: TRIAL NCT02737787 NOT RELEVANT---\n",
      "---GRADER: TRIAL NCT01485861 NOT RELEVANT---\n",
      "---GRADER: TRIAL NCT03306264 NOT RELEVANT---\n",
      "---GRADER: TRIAL NCT02366819 NOT RELEVANT---\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'relevant_trials': []}"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# state = states[0].values\n",
    "state_next = states[1]\n",
    "# state_next = state_last\n",
    "state_next.values['patient_profile'] = \"\"\"\n",
    "Patient is a 74-year-old with a history of Chronic Pain in the chest. \n",
    "They have previously participated in the clinical trial NCT07600953, which is currently completed. \n",
    "Based on their medical history, they may be eligible for trials focusing on pain management or chronic chest pain conditions\"\n",
    "\"\"\"\n",
    "result = grade_trials(state_last.values)\n",
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--------- continue from modified state ---------\n",
      "Patient ID: 32\n",
      "Patient is a 77-year-old with a history of Chronic Pain. They have previously participated in the clinical trial NCT07600953, which is currently ongoing. Based on their medical history, they may be eligible for trials focusing on pain management or chronic pain treatments.\n",
      "{'patient_collector': {'patient_id': 32, 'patient_data': {'patient_id': 32, 'name': 'Michael Thomas', 'age': 77, 'medical_history': 'Chronic Pain', 'previous_trials': 'NCT07600953', 'trial_status': 'Ongoing', 'trial_completion_date': None}, 'patient_profile': 'Patient is a 77-year-old with a history of Chronic Pain. They have previously participated in the clinical trial NCT07600953, which is currently ongoing. Based on their medical history, they may be eligible for trials focusing on pain management or chronic pain treatments.', 'revision_number': 4}}\n",
      "max revision reached\n",
      "{'policy_checker': {'patient_prompt': 'Is patient 32 eligible for any medical trial?', 'patient_id': 32, 'policy_eligible': False, 'rejection_reason': 'Age exceeds the maximum limit of 75 years as per the eligibility criteria.', 'patient_data': {'patient_id': 32, 'name': 'Michael Thomas', 'age': 77, 'medical_history': 'Chronic Pain', 'previous_trials': 'NCT07600953', 'trial_status': 'Ongoing', 'trial_completion_date': None}, 'patient_profile': 'Patient is a 77-year-old with a history of Chronic Pain. They have previously participated in the clinical trial NCT07600953, which is currently ongoing. Based on their medical history, they may be eligible for trials focusing on pain management or chronic pain treatments.', 'revision_number': 5, 'max_revisions': 3, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the current year to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': [Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'drugs': \"['nivolumab']\", 'nctid': 'NCT02737787', 'status': 'recruiting'}), Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\\r\\n             previously treated with docetaxel-based therapy and has progressed during treatment of\\r\\n             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\\r\\n\\r\\n          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\\r\\n             or radiographic evidence of disease progression in soft tissue or bone\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\\r\\n\\r\\n          -  Adequate hematologic and organ function\\r\\n\\r\\n          -  Documented willingness to use an effective means of contraception\\r\\n\\r\\n          -  Safety cohort only: agreement to use CGM for first cycle of treatment\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\\r\\n             patients who are receiving any pharmacologic treatment for diabetes are not eligible\\r\\n\\r\\n          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\\r\\n             fraction < 50% or ventricular arrhythmia requiring medication\\r\\n\\r\\n          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\\r\\n             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\\r\\n             within 6 months prior to Day 1\\r\\n\\r\\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\\r\\n             drugs or active inflammatory disease which requires immunosuppressive therapy\\r\\n\\r\\n          -  Clinically significant history of liver disease\\r\\n\\r\\n          -  History of adrenal insufficiency or hyperaldosteronism\\r\\n\\r\\n          -  Phase II only: Previous therapy for prostate cancer with 17\\r\\n             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\\r\\n\\r\\n          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\\r\\n             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\\r\\n\\r\\n          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\\r\\n             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\\r\\n      ', metadata={'disease_category': 'cancer', 'diseases': \"['prostate cancer']\", 'drugs': \"['abiraterone', 'apitolisib', 'ipatasertib', 'placebo', 'prednisone', 'prednisolone']\", 'nctid': 'NCT01485861', 'status': 'recruiting'}), Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Able to understand and comply with the study procedures, understand the risks involved\\r\\n             in the study, and provide written informed consent before the first study-specific\\r\\n             procedure; specifically able to comply with the PK assessment schedule during the\\r\\n             first 2 treatment cycles.\\r\\n\\r\\n          2. Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or\\r\\n             European Medicines Agency (EMA) approved indications:\\r\\n\\r\\n               1. In North America: Participants with MDS previously treated or untreated with de\\r\\n                  novo or secondary MDS, including all French-American-British subtypes (refractory\\r\\n                  anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess\\r\\n                  blasts, refractory anemia with excess blasts in transformation, and chronic\\r\\n                  myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic\\r\\n                  Scoring System (IPSS) int-1, -2, or high-risk MDS.\\r\\n\\r\\n               2. In Europe: Participants with de novo or secondary AML, as defined by the World\\r\\n                  Health Organization (WHO) criteria, who are not candidates for standard induction\\r\\n                  chemotherapy.\\r\\n\\r\\n          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\\r\\n\\r\\n          4. Adequate organ function defined as follows:\\r\\n\\r\\n               1. Hepatic: Total or direct bilirubin ≤2 × upper limit of normal (ULN); aspartate\\r\\n                  transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine\\r\\n                  transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤2.5 × ULN.\\r\\n\\r\\n               2. Renal: serum creatinine ≤1.5 × ULN or calculated creatinine clearance or\\r\\n                  glomerular filtration rate >50 mL/min/1.73 m2 for subjects with creatinine levels\\r\\n                  above institutional normal.\\r\\n\\r\\n          5. No major surgery within 30 days of first study treatment.\\r\\n\\r\\n          6. Life expectancy of at least 3 months.\\r\\n\\r\\n          7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a\\r\\n             negative pregnancy test at screening. Women of non-childbearing potential are those\\r\\n             who have had a hysterectomy or bilateral oophorectomy, or who have completed\\r\\n             menopause, defined as no menses for at least 1 year AND either age ≥65 years or\\r\\n             follicle-stimulating hormone levels in the menopausal range.\\r\\n\\r\\n          8. Subjects and their partners with reproductive potential must agree to use effective\\r\\n             contraceptive measures during the study and for 3 months after the last dose of study\\r\\n             treatment. Effective contraception includes methods such as oral contraceptives or\\r\\n             double-barrier method (eg, use of a condom AND diaphragm, with spermicide).\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic\\r\\n             chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC)\\r\\n             counts.\\r\\n\\r\\n          2. Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia,\\r\\n             sepsis, or systemic infection in the 30 days before screening.\\r\\n\\r\\n          3. Treatment with any investigational drug or therapy within 2 weeks of study treatment,\\r\\n             or 5 half-lives, whichever is longer, before the first dose of study treatment, or\\r\\n             ongoing clinically significant adverse events (AEs) from previous treatment.\\r\\n\\r\\n          4. Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose\\r\\n             of study treatment.\\r\\n\\r\\n          5. Concurrent MDS therapies, including lenalidomide, erythropoietin,\\r\\n             cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF),\\r\\n             granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these\\r\\n             agents is permitted, provided that completion is at least 1 week before the first dose\\r\\n             of study treatment.)\\r\\n\\r\\n          6. Poor medical risk because of other conditions such as uncontrolled systemic diseases,\\r\\n             active uncontrolled infections, or comorbidities that may put the patient at risk of\\r\\n             not being able to complete at least 2 cycles of treatment.\\r\\n\\r\\n          7. Known significant mental illness or other condition, such as active alcohol or other\\r\\n             substance abuse or addiction, that in the opinion of the investigator predisposes the\\r\\n             subject to high risk of noncompliance with the protocol.\\r\\n\\r\\n          8. Rapidly progressive or highly proliferative disease (total white blood cell count of\\r\\n             >15 × 10^9/L) or other criteria that render the subject at high risk of requiring\\r\\n             intensive cytotoxic chemotherapy within the next 3 months.\\r\\n\\r\\n          9. Life-threatening illness or severe organ system dysfunction, such as uncontrolled\\r\\n             congestive heart failure or chronic obstructive pulmonary disease, or other reasons\\r\\n             including laboratory abnormalities, which, in the investigator's opinion, could\\r\\n             compromise the subject's safety, interfere with the absorption or metabolism of\\r\\n             ASTX727, or compromise completion of the study or integrity of the study outcomes.\\r\\n\\r\\n         10. Prior malignancy, except for adequately treated basal cell or squamous cell skin\\r\\n             cancer, in situ cervical cancer, prostate cancer or breast cancer under control with\\r\\n             hormone therapy, or other cancer from which the subject has been disease free for at\\r\\n             least 2 years.\\r\\n      \", metadata={'disease_category': 'leukemia', 'diseases': \"['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\", 'drugs': \"['astx727', 'dacogen']\", 'nctid': 'NCT03306264', 'status': 'recruiting'}), Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed locally advanced gastric (primary endpoint includes proximal\\r\\n             and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral)\\r\\n             adenocarcinomas are eligible for enrolment but will not be included in the primary\\r\\n             analysis\\r\\n\\r\\n          -  Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary\\r\\n             tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)\\r\\n\\r\\n          -  All patients must have diagnostic laparoscopy with diagnostic washings for cytology;\\r\\n             both cytology positive and negative patients are eligible for enrolment, but only\\r\\n             cytology negative patients will be included in the primary analyses; gross peritoneal\\r\\n             disease is not eligible\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1\\r\\n\\r\\n          -  Eligible for surgery with curative intent\\r\\n\\r\\n          -  Absolute neutrophil count (ANC) >= 1250/ul\\r\\n\\r\\n          -  Hemoglobin >= 9 g/dL\\r\\n\\r\\n          -  Platelets >= 100,000/ul\\r\\n\\r\\n          -  Total bilirubin < 1.5 x upper limit of normal\\r\\n\\r\\n          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\\r\\n             transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver\\r\\n             metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver\\r\\n             metastases\\r\\n\\r\\n          -  Creatinine =< 1.5 x upper limit of normal\\r\\n\\r\\n          -  Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor\\r\\n             (RECIST) 1.1 will be allowed\\r\\n\\r\\n          -  Women of child-bearing potential and men must agree to use adequate contraception\\r\\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and for\\r\\n             the duration of study participation, up until 30 days after final study treatment;\\r\\n             should a woman become pregnant or suspect that she is pregnant while participating in\\r\\n             this study, she should inform her treating physician immediately\\r\\n\\r\\n          -  Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3,\\r\\n             subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative\\r\\n             drugs whenever possible, given the potential for drug-drug interactions with\\r\\n             irinotecan\\r\\n\\r\\n          -  Signed informed consent\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Previous or concurrent malignancy, except for adequately treated basal cell or\\r\\n             squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the\\r\\n             patient has been previously treated and the lifetime recurrence risk is less than 30%\\r\\n\\r\\n          -  Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's\\r\\n             disease, ulcerative colitis)\\r\\n\\r\\n          -  Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology\\r\\n             Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)\\r\\n\\r\\n          -  Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0\\r\\n\\r\\n          -  Serious underlying medical or psychiatric illnesses that would, in the opinion of the\\r\\n             treating physician, substantially increase the risk for complications related to\\r\\n             treatment\\r\\n\\r\\n          -  Active uncontrolled bleeding\\r\\n\\r\\n          -  Pregnancy or breastfeeding\\r\\n\\r\\n          -  Major surgery within 4 weeks\\r\\n\\r\\n          -  Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be\\r\\n             allowed and treated as in the *28/*28 dosing group\\r\\n      \", metadata={'disease_category': 'cancer', 'diseases': \"['esophageal adenocarcinoma', 'gastric adenocarcinoma', 'stage iib gastric cancer', 'stage iiia esophageal adenocarcinoma', 'stage iiia gastric cancer', 'stage iiib esophageal adenocarcinoma', 'stage iiib gastric cancer', 'stage iiic esophageal adenocarcinoma', 'stage iiic gastric cancer']\", 'drugs': \"['oxaliplatin', 'leucovorin calcium', 'irinotecan hydrochloride', 'fluorouracil']\", 'nctid': 'NCT02366819', 'status': 'recruiting'})], 'relevant_trials': None, 'ask_expert': 'policy_checker'}}\n"
     ]
    }
   ],
   "source": [
    "branch_state = graph.update_state(state_next.config, state_next.values)\n",
    "print(\"--------- continue from modified state ---------\")\n",
    "events = []\n",
    "for event in graph.stream(None, branch_state):    \n",
    "    events.append(event)\n",
    "    print(event)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## HIL\n",
    "To correct Patient's data to pass the eligibility check."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "patient data found\n",
      "{'patient_id': 8, 'name': 'James Thomas', 'age': 49, 'medical_history': 'lymphoblastic leukemia', 'previous_trials': 'Trial 18', 'trial_status': 'Completed', 'trial_completion_date': '2023-11-06'}\n",
      "{'configurable': {'thread_id': '1', 'thread_ts': '1ef31789-5527-6dad-8002-b9d01aab14fd'}}\n",
      "--------- continue from modified state ---------\n",
      "today is: 2024-06-23\n",
      "binary_score='no' reason='The patient has participated in a previous trial (Trial 18) within the last 5 months, which violates the policy of not participating in any other clinical trial within the least 5 months prior to enrolling in a new trial.'\n",
      "Patient did not pass the general trials policies\n",
      "{'patient_prompt': 'Is patient 8 eligible for any medical trial?', 'patient_id': 8, 'policy_eligible': False, 'rejection_reason': 'The patient has participated in a previous trial (Trial 18) within the last 5 months, which violates the policy of not participating in any other clinical trial within the least 5 months prior to enrolling in a new trial.', 'patient_data': {'age': 49, 'medical_history': 'lymphoblastic leukemia', 'previous_trials': 'Trial 18', 'trial_status': 'Completed', 'trial_completion_date': '2023-11-06'}, 'patient_profile': 'Patient Profile:\\nThe patient is a 49-year-old with a history of lymphoblastic leukemia. They have previously participated in Trial 18, which was completed on November 6, 2023. Based on their medical history, they may be eligible for clinical trials focusing on leukemia treatments or immunotherapy.', 'revision_number': 2, 'max_revisions': 2, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the last 6 months are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the least 5 months prior to enrolling in a new trial to allow for proper assessment of any delayed adverse effects.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'trials': None, 'relevant_trials': None}\n"
     ]
    }
   ],
   "source": [
    "state = states[1]\n",
    "state.values\n",
    "# for k in state:\n",
    "#     print(k)\n",
    "\n",
    "\n",
    "# state.values[\"patient_data\"]['trial_status'] = None\n",
    "# state.values[\"patient_data\"]['previous_trials'] = None\n",
    "branch_state = graph.update_state(state.config, state.values)\n",
    "print(branch_state)\n",
    "# state\n",
    "\n",
    "\n",
    "print(\"--------- continue from modified state ---------\")\n",
    "for event in graph.stream(None, branch_state):\n",
    "    for k, v in event.items():\n",
    "        if k != \"__end__\":\n",
    "            print(v)\n",
    "\n",
    "# for event in graph.stream({\n",
    "#     'patient_prompt': f\"Is patient {sample_patient_id} eligible for any medical trial?\",\n",
    "#     # 'patient_prompt': \"Is patient Max eligible for any medical trial?\",\n",
    "#     \"max_revisions\": 2,\n",
    "#     \"revision_number\": 1,\n",
    "# }, thread):\n",
    "#     print(event)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Application GUI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "thread = {\"configurable\": {\"thread_id\": \"0\"}}\n",
    "states = list(graph.get_state_history(thread))\n",
    "# states[0].next\n",
    "policy_doc = states[0].values['policies'][0]\n",
    "# policy_header = policy_doc.page_content.split('\\n', 2)[:2]\n",
    "policy_doc.page_content.split('\\n', 2)[1]\n",
    "# print(f'Evaluating Policy: {policy_header}')\n",
    "# for s in states:\n",
    "    # print(s.values['last_node'],s.next )\n",
    "# states"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "ename": "OSError",
     "evalue": "Cannot find empty port in range: 7959-7959. You can specify a different port by setting the GRADIO_SERVER_PORT environment variable or passing the `server_port` parameter to `launch()`.",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mOSError\u001b[0m                                   Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[46], line 47\u001b[0m\n\u001b[0;32m     45\u001b[0m app \u001b[38;5;241m=\u001b[39m writer_gui(graph)\n\u001b[0;32m     46\u001b[0m \u001b[38;5;66;03m# app.demo.close()\u001b[39;00m\n\u001b[1;32m---> 47\u001b[0m \u001b[43mapp\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mdemo\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mlaunch\u001b[49m\u001b[43m(\u001b[49m\u001b[43mserver_name\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m127.0.0.1\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mserver_port\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;241;43m7959\u001b[39;49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32md:\\Portfolio\\LLMs Applications\\.llmenv\\Lib\\site-packages\\gradio\\blocks.py:2327\u001b[0m, in \u001b[0;36mBlocks.launch\u001b[1;34m(self, inline, inbrowser, share, debug, max_threads, auth, auth_message, prevent_thread_lock, show_error, server_name, server_port, height, width, favicon_path, ssl_keyfile, ssl_certfile, ssl_keyfile_password, ssl_verify, quiet, show_api, allowed_paths, blocked_paths, root_path, app_kwargs, state_session_capacity, share_server_address, share_server_protocol, auth_dependency, max_file_size, _frontend, enable_monitoring)\u001b[0m\n\u001b[0;32m   2319\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m   2320\u001b[0m     \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01mgradio\u001b[39;00m \u001b[38;5;28;01mimport\u001b[39;00m http_server\n\u001b[0;32m   2322\u001b[0m     (\n\u001b[0;32m   2323\u001b[0m         server_name,\n\u001b[0;32m   2324\u001b[0m         server_port,\n\u001b[0;32m   2325\u001b[0m         local_url,\n\u001b[0;32m   2326\u001b[0m         server,\n\u001b[1;32m-> 2327\u001b[0m     ) \u001b[38;5;241m=\u001b[39m \u001b[43mhttp_server\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mstart_server\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   2328\u001b[0m \u001b[43m        \u001b[49m\u001b[43mapp\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mapp\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   2329\u001b[0m \u001b[43m        \u001b[49m\u001b[43mserver_name\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mserver_name\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   2330\u001b[0m \u001b[43m        \u001b[49m\u001b[43mserver_port\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mserver_port\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   2331\u001b[0m \u001b[43m        \u001b[49m\u001b[43mssl_keyfile\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mssl_keyfile\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   2332\u001b[0m \u001b[43m        \u001b[49m\u001b[43mssl_certfile\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mssl_certfile\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   2333\u001b[0m \u001b[43m        \u001b[49m\u001b[43mssl_keyfile_password\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mssl_keyfile_password\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   2334\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   2335\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mserver_name \u001b[38;5;241m=\u001b[39m server_name\n\u001b[0;32m   2336\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mlocal_url \u001b[38;5;241m=\u001b[39m local_url\n",
      "File \u001b[1;32md:\\Portfolio\\LLMs Applications\\.llmenv\\Lib\\site-packages\\gradio\\http_server.py:154\u001b[0m, in \u001b[0;36mstart_server\u001b[1;34m(app, server_name, server_port, ssl_keyfile, ssl_certfile, ssl_keyfile_password)\u001b[0m\n\u001b[0;32m    152\u001b[0m         \u001b[38;5;28;01mpass\u001b[39;00m\n\u001b[0;32m    153\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m--> 154\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mOSError\u001b[39;00m(\n\u001b[0;32m    155\u001b[0m         \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mCannot find empty port in range: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mmin\u001b[39m(server_ports)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m-\u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mmax\u001b[39m(server_ports)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m. You can specify a different port by setting the GRADIO_SERVER_PORT environment variable or passing the `server_port` parameter to `launch()`.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    156\u001b[0m     )\n\u001b[0;32m    158\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m ssl_keyfile \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m    159\u001b[0m     path_to_local_server \u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mhttps://\u001b[39m\u001b[38;5;132;01m{\u001b[39;00murl_host_name\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m:\u001b[39m\u001b[38;5;132;01m{\u001b[39;00mport\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m/\u001b[39m\u001b[38;5;124m\"\u001b[39m\n",
      "\u001b[1;31mOSError\u001b[0m: Cannot find empty port in range: 7959-7959. You can specify a different port by setting the GRADIO_SERVER_PORT environment variable or passing the `server_port` parameter to `launch()`."
     ]
    }
   ],
   "source": [
    "import sys\n",
    "module_dir = os.path.abspath('../../temp/langgraph')  # Gets the absolute path to the src directory\n",
    "sys.path.append(module_dir)\n",
    "from helper_fns2 import writer_gui\n",
    "\n",
    "# class AgentState(TypedDict):\n",
    "#     task: str\n",
    "#     plan: str\n",
    "#     draft: str\n",
    "#     critique: str\n",
    "#     content: List[str]\n",
    "#     revision_number: int\n",
    "#     max_revisions: int\n",
    "\n",
    "# MultiAgent = ewriter()\n",
    "# app = writer_gui(MultiAgent.graph)\n",
    "memory = SqliteSaver.from_conn_string(\":memory:\")\n",
    "\n",
    "# memory.chat_memory.clear()\n",
    "graph = builder.compile(\n",
    "    checkpointer=memory\n",
    "    # ,interrupt_before=[\"__end__\"]\n",
    "    # , interrupt_after=['patient_collector', 'policy_search', 'policy_evaluator', 'trial_search', 'grade_trials']\n",
    "    , interrupt_after=[ 'trial_search', 'grade_trials']\n",
    ")\n",
    "# graph.clear()\n",
    "patient_prompt = f\"Is patient {16} eligible for any medical trial?\"\n",
    "thread = {\"configurable\": {\"thread_id\": \"0\"}}\n",
    "config = {'patient_prompt': patient_prompt,\"max_revisions\": 6,\"revision_number\": 0,\n",
    "                      'last_node': \"\", 'planner': \"no plan\", 'draft': \"no draft\", 'critique': \"no critique\", \n",
    "                      'content': [\"no content\",], 'queries': \"no queries\", 'revision_number':0}\n",
    "# state = list(graph.get_state_history(thread))\n",
    "if 1==2:\n",
    "    response = graph.invoke(config, thread)\n",
    "\n",
    "    current_states = list(graph.get_state_history(thread))\n",
    "    asnode = 'policy_search'\n",
    "    print(current_states)\n",
    "    current_values = current_states[0]\n",
    "    current_values.values['patient_profile'] = 'test value'\n",
    "    graph.update_state(thread, current_values.values, as_node = asnode)\n",
    "    current_state = list(graph.get_state_history(thread))[0]\n",
    "    print(current_state.next)\n",
    "else:\n",
    "    if app is not None:\n",
    "        app.demo.close()\n",
    "    app = writer_gui(graph)    \n",
    "    app.demo.launch(server_name=\"127.0.0.1\", server_port=7959)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "module_dir = os.path.abspath('../../temp/langgraph')  # Gets the absolute path to the src directory\n",
    "sys.path.append(module_dir)\n",
    "from helper_fns import ewriter, writer_gui\n",
    "\n",
    "MultiAgent = ewriter()\n",
    "app = writer_gui(MultiAgent.graph)\n",
    "app.launch()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 477,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient ID: 16\n",
      "{'patient_id': 16, 'name': 'Emma Smith', 'age': 80, 'medical_history': 'pancreatic cancer', 'previous_trials': 'NCT04589611', 'trial_status': 'Completed', 'trial_completion_date': '2023-05-27'}\n",
      "Patient is an 80-year-old with a history of pancreatic cancer. They have previously participated in the clinical trial NCT04589611, which has been completed as of May 27, 2023. Based on their medical history, they may be eligible for future pancreatic cancer clinical trials.\n",
      "Evaluating Policy: ['', '#### 1. **General Eligibility Criteria**']\n",
      "Patient did not pass this policy.\n",
      "\n",
      "\n",
      "#### 1. **General Eligibility Criteria**\n",
      "   - **Age Restrictions**: Patients must be between 18 and 75 years old.\n",
      "   - **Gender**: No restrictions unless specified by the trial protocol.\n",
      "   - **Informed Consent**: All patients must provide informed consent prior to participation.\n",
      "   - **Residency**: Patients must be residents of the country where the trial is conducted.\n",
      "   - **Health Insurance**: Patients must have valid health insurance coverage.\n",
      "\n",
      "Rejection Reason: \n",
      "'Age exceeds the limit specified in the policy document.'\n",
      "You can correct the patient's medical profile if required.\n"
     ]
    }
   ],
   "source": [
    "# Define the Gradio interface components\n",
    "patient_prompt = gr.Textbox(label=\"Patient ID\", placeholder=\"Specify the patient here, e.g., Is patient 32 eligible for any medical trial?\")\n",
    "last_node = gr.Textbox(label=\"Last Node\")\n",
    "next_node = gr.Textbox(label=\"Next Node\")\n",
    "thread = gr.Textbox(label=\"Thread\")\n",
    "draft_rev = gr.Textbox(label=\"Draft Rev\")\n",
    "count = gr.Textbox(label=\"Count\")\n",
    "start_evaluation_btn = gr.Button(\"Start Evaluation\")\n",
    "continue_evaluation_btn = gr.Button(\"Continue Evaluation\")\n",
    "\n",
    "live_agent_output = gr.Textbox(label=\"Live Agent Output\", lines=5, max_lines=5)\n",
    "\n",
    "# Create the Gradio interface\n",
    "def trial_management_agent():\n",
    "    with gr.Blocks() as demo:\n",
    "        with gr.TabItem(\"Main\"):\n",
    "            with gr.Row():\n",
    "                patient_prompt.render()\n",
    "                start_evaluation_btn.render()\n",
    "                continue_evaluation_btn.render()\n",
    "        \n",
    "            # with gr.Row():\n",
    "            #     last_node.render()\n",
    "            #     next_node.render()\n",
    "            #     thread.render()\n",
    "            #     draft_rev.render()\n",
    "            #     count.render()\n",
    "        \n",
    "            with gr.Row():\n",
    "                live_agent_output.render()\n",
    "        \n",
    "            start_evaluation_btn.click(start_evaluation, inputs=[patient_prompt], outputs=[live_agent_output], show_progress=True)\n",
    "            # continue_evaluation_btn.click(continue_evaluation, inputs=[patient_id, last_node, next_node, thread, draft_rev, count], outputs=live_agent_output)\n",
    "\n",
    "        # with gr.TabItem(\"Patient Profile\"):\n",
    "        #     patient_profile_output = gr.Textbox(label=\"Patient Profile\", interactive=False)\n",
    "        #     patient_profile_output.render()\n",
    "        #     patient_profile_output.update(show_patient_profile)\n",
    "\n",
    "        # with gr.TabItem(\"Policy Evaluator\"):\n",
    "        #     policy_evaluations_output = gr.Textbox(label=\"Policy Evaluations\", interactive=False)\n",
    "        #     policy_evaluations_output.render()\n",
    "        #     policy_evaluations_output.update(show_policy_evaluations)\n",
    "\n",
    "        # with gr.TabItem(\"Trial Grader\"):\n",
    "        #     trial_grading_output = gr.Textbox(label=\"Trial Grading\", interactive=False)\n",
    "        #     trial_grading_output.render()\n",
    "        #     trial_grading_output.update(show_trial_grading)\n",
    "\n",
    "    return demo\n",
    "\n",
    "def start_evaluation(patient_prompt):\n",
    "    print(patient_prompt)\n",
    "    initial_state = {\n",
    "        'patient_prompt': patient_prompt,    \n",
    "        \"max_revisions\": 10,\n",
    "        \"revision_number\": 1,\n",
    "    }\n",
    "    thread = {\"configurable\": {\"thread_id\": \"1\"}}\n",
    "    graph = builder.compile(\n",
    "        checkpointer=memory\n",
    "        # ,interrupt_before=[\"__end__\"]\n",
    "        # , interrupt_after=[\"expert\"]\n",
    "    )\n",
    "    print(graph)\n",
    "    thread = {\"configurable\": {\"thread_id\": \"1\"}}\n",
    "    result = graph.stream({\n",
    "        'patient_prompt': f\"Is patient 16 eligible for any medical trial?\",\n",
    "        # 'patient_prompt': \"Is patient Max eligible for any medical trial?\",\n",
    "        \"max_revisions\": 10,\n",
    "        \"revision_number\": 1,\n",
    "    }, thread)\n",
    "    # for event in events_gen:\n",
    "        # print(event)\n",
    "\n",
    "    # result = None\n",
    "    return result\n",
    "\n",
    "demo = trial_management_agent()\n",
    "# demo.launch()\n",
    "demo.close()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".llmenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
